Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS
Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS

A COMPENDIUM OF OUR RESEARCH

Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoeconomics in place for ready use across their customers and therapeutic areas.

For nearly three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through October 2017.

For more information on our research activities and health care consulting practice, please visit our website, www.analysisgroup.com.
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune/Inflammatory</td>
<td>4</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>17</td>
</tr>
<tr>
<td>Dermatology</td>
<td>36</td>
</tr>
<tr>
<td>Endocrine/Metabolic/Diabetes</td>
<td>50</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>65</td>
</tr>
<tr>
<td>Hematology</td>
<td>78</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>92</td>
</tr>
<tr>
<td>Neurology</td>
<td>99</td>
</tr>
<tr>
<td>Oncology</td>
<td>133</td>
</tr>
<tr>
<td>Renal</td>
<td>186</td>
</tr>
<tr>
<td>Respiratory</td>
<td>191</td>
</tr>
<tr>
<td>Substance Abuse</td>
<td>201</td>
</tr>
<tr>
<td>Other Diseases &amp; Conditions</td>
<td>205</td>
</tr>
<tr>
<td>Other (Health Policy, Market Access, and Methods)</td>
<td>216</td>
</tr>
</tbody>
</table>
Autoimmune/Inflammatory

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
**Publication:** Clinical and Experimental Rheumatology 2017 03; 35(5): 791-798
**Authors:** Yang M, Galebach PJ, Signorovitch JE, Garg V.

Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
**Publication:** Journal of Medical Economics 2017 09
**Authors:** Wang SX, Ganguli AX, Bodhani A, Medema JK, Reichmann WM, Macaulay D.

Economic burden of sarcoidosis in a commercially-insured population in the United States.
**Publication:** Journal of Medical Economics 2017 10; 20(10): 1048-1055
**Authors:** Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, Philbin M, Wan GJ.

Association between disease activity level improvement and reduction in healthcare resource utilization in patients with rheumatoid arthritis receiving targeted therapy.
**Abstract:** ISPOR 22nd Annual European Congress.
**Authors:** Lopez A, Priest J, Duh MS, McDonnell E, Bobbili PJ, Haider BA, Sundareshan D, Yood RA, Reed JI.

Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
**Publication:** Clinical Therapeutics 2017 03; 39(4): e849-e862
**Authors:** Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M.

Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.
**Publication:** Rheumatology International 2017 06:
**Authors:** Husni ME, Betts KA, Griffith J, Song Y, Ganguli A.

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.
**Publication:** Rheumatology Therapeutics 2017 07;
**Authors:** Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.

Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis after Etanercept Discontinuation in the United Kingdom, France, and Germany.
**Publication:** Clinical Therapeutics 2017 07; 39(8): 1618-1627
**Authors:** Li N, Betts KA, Messali AJ, Skup M, Garg V.

Drug Cost per Responder for the Treatment of Moderate-to-Severe Psoriasis and Active Psoriatic Arthritis.
**Abstract:** American Academy of Dermatology 75th Annual Meeting, Orlando, FL.
**Authors:** Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M, A G.

Economic Evaluation of Timely versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.
**Publication:** Rheumatology Therapeutics 2016 09;
**Authors:** Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Publication: Clinical Therapeutics 2016 05; 38(5): 1205-1216
Authors: Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.

Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Publication: Advances in Therapy 2016 05; 33(5): 807-823
Authors: Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.

Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: A matching-adjusted indirect comparison.
Abstract: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2016., United Kingdom.
Authors: Betts KA, Mittal M, Song J, Skup M, Joshi A.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.
Publication: Rheumatology Therapeutics 2016 07: 1-14
Authors: Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia and Mexico.
Publication: Journal of Medical Economics 2016 07: 1-49

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.
Publication: Journal of Medical Economics 2016 07; 19(7): 649-654

ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
Publication: Rheumatology 2016 01; 55(1): 80-88
Authors: van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, Bao Y.

An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis.
Publication: Current Medical Research and Opinion 2016 04; 32(4): 721-729
Authors: Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.

The economic burden of dermatomyositis and polymyositis in the us.

Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.
Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP, United States.
Authors: Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.
Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.

Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2016, United States.

Authors: Husni ME, Griffith J, Betts K, Song Y, Ganguli A.

Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.

Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP, United States.

Authors: Keystone EC, Betts KA, Schlacher CA, Song Y, Ganguli A, Griffith J.

Prediction of flaring in rheumatoid arthritis patients upon biologics dose tapering: a chart review study in Taiwan.


Real-world Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study.


Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons in psoriatic disease patients.

Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.

Authors: Lewwohl M, Skup M, Sundaram M, Yang H, Faust E, Kageleiry A, Chao J, Wolf D.

Effects of Adalimumab on Health-related Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Value of Reducing PASI Scores and Systemic Inflammation.

Abstract: the 74th Annual Meeting of the American Academy of Dermatology, Washington DC.

Authors: Okun M, Yang M, Koo V, Sundaram M, Signorovitch J.

Evaluation of timely versus delayed use of tumor necrosis factor inhibitors in the treatment of psoriatic arthritis: Economic and clinical results from a modeling study.

Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.

Authors: Strand V, Husni ME, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor, Interleukin, and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.

Abstract: Annual Meeting of the American Academy of Dermatology, Washington DC.

Authors: Strand V HM, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.

Abstract: 74th Annual Meeting of the American Academy of Dermatology United States., Washington, DC.

Authors: Betts K, Mittal M, Joshi A, Song J, Bao Y.

Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.

Publication: Arthritis Care Res (Hoboken) 2015 03; 67(5): 708-717

Authors: Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.
Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.

*Publication:* Journal of Medical Economics 2015 01; 18(1): 37-44
*Authors:* Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.

Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.

*Publication:* Current Medical Research and Opinion 2015 08; 31(8): 1611-1620
*Authors:* Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R.

Comorbidity burden and medication use among patients with psoriatic arthritis in the US.

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2015 San Francisco, CA United States.
*Authors:* Merola J, Han S, Xie J, Song H, Herrera V, Wei J, Wu EQ, Palmer JB.

Economic Burden and Treatment Patterns of Cycling between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) among Patients with Rheumatoid Arthritis (RA).

*Abstract:* ACR Annual Meeting, San Francisco, CA.
*Authors:* Li N, Betts KA, Griffith J, Ristovska L, Douglas K, Ganguli A.

Economic Impact of Expanded Use of Biologic Therapy for Crohn’s Disease In Latin American Countries.

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research.
*Authors:* Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.


*Abstract:* ACR/ARHP Annual Meeting, San Francisco, CA.
*Authors:* Strand V, Husni ME, Reichmann W, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.

*Abstract:* Arthritis and Rheumatology. Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP, San Francisco, CA
*Authors:* Betts KA, Mittal M, Joshi A, Song J, Bao Y.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.

*Abstract:* AMCP Nexus Orlando, FL.

Impact of Taiwan health policy for dose tapering and withdrawing biologics in rheumatoid arthritis patients: A real-world chart review study.

*Abstract:* 17th Congress of the Asia Pacific League of Associations for Rheumatology in Conjunction with IRA Annual Congress, Chennai India.

Projected economic impact of increased use of biologic treatments for rheumatoid arthritis in Argentina, Colombia, and Mexico over 10 years.

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile.
Short-term clinical outcomes and healthcare resource utilization in patients with rheumatoid arthritis tapering anti-TNF agents in Taiwan.

Abstract: 17th Asia Pacific League of Associations for Rheumatology Congress (APLAR), Chennai, India.

Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy.

Abstract: European League Against Rheumatism (EULAR) Congress, Rome, Italy.
Authors: Deodhar A, Mittal M, Joshi A, Signorovitch JE, Yang M, Bao Y.

Economic evaluation of timely versus delayed use of anti-tumor necrosis factor (TNF) biologics in the treatment of psoriatic arthritis (PSA) in the US.

Authors: Zhou Z, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A.

Indirect Treatment Comparison of Adalimumab, Etanercept, Certolizumab, Golimumab, and Infliximab for the Treatment of Ankylosing Spondylitis.

Authors: Betts KA, K. H.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.

Abstract: AMCP 27th annual conference, San Diego, CA.
Authors: Betts K, Reichmann W, Guo J.

Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.

Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.

Authors: Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons.

Authors: Wolf D, Skup M, Yang H, Faust E, Kageleiry A, Chao J, Lebwohl M.

Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Publication: Appl Health Econ Health Policy 2014 04; 12(2); 179-190
Authors: Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS.

Economic implications of flares among patients with early rheumatoid arthritis (RA).

Authors: Signorovitch J, Betts K, Garg V, Bao Y.

An indirect comparison and cost per responder analysis of adalimumab, methotrexate (MTX) and apremilast in the treatment of MTX-naive psoriatic arthritis (PSA) patients.

Authors: Strand V, Griffith J, Betts K, Friedman A, Signorovitch J, Ganguli A.
Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.

**Abstract:** International Congress of Drug Therapy in HIV Infection 2014 Glasgow United Kingdom.

**Authors:** Sweet D, Song J, Zhong Y, Signorovitch J.

ASAS40 and ASDAS responses are associated with improved physical function, HRQOL, and work productivity in patients with non-radiographic axial spondyloarthritis.

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Conference Paris France.

**Authors:** Van Der Heijde D, Joshi A, Mittal M, Pangan A, Chen N, Betts K, Qi C, Bao Y.

Claims database analysis of adherence to adalimumab therapy and health care costs for patients with rheumatoid arthritis.

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Conference Paris France.

**Authors:** Liu Y, Tundia N, Skup M, Ayyagari R, Du EX, Chao J, Mulani P, Bao Y.

A prediction model that identifies patients most likely to benefit from first-line therapy with adalimumab plus methotrexate in early rheumatoid arthritis.

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Conference Paris France.

**Authors:** Van Vollenhoven RF, Betts K, Signorovitch J, Bao C, Shaw JW, Ganguli A.

Real-world risk of fall-related injuries among rheumatoid arthritis (RA) patients treated with tumor necrosis factor inhibitors (anti-TNFs) or methotrexate (MTX).

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014, Paris France.

**Authors:** Bao Y, Ganguli A, De G, Kelkar S, Curtis JR.

Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.

**Abstract:** ISPOR 19th Annual International Meeting Montreal, QC Canada.

**Authors:** Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.


**Authors:** Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema JK, Cifaldi MA.

Real-world treatment patterns during and after an emergency room or acute care facility visit for gout.

**Abstract:** AMCP’s 27th Annual Meeting & Expo, San Diego, CA.

**Authors:** Krishnan E, Cloutier M, Guérin A, Héroux J.

Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.

**Abstract:** 72nd Annual Meeting of the American Academy of Dermatology Conference Denver, CO United States.

**Authors:** Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.

**Publication:** Arthritis Research & Therapy 2014 08; 16(4): 420

**Authors:** Zhang HF, Gauthier G, Hiscock R, Curtis JR.

Serum urate and incidence of kidney disease among veterans with gout.

**Publication:** Journal of Rheumatology 2013 07; 40(7): 1166-1172

**Authors:** Krishnan E, Akhras KS, Sharma H, Marynychko M, Wu E, Tawk RH, Liu J, Shi L.
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.

*Publication:* QJM 2013 08; 106(8): 721-729

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Cost-per-responder analysis of biological agents for the treatment of active ankylosing spondylitis in Germany.

*Abstract:* ISPOR 16th Annual European Congress Dublin Ireland.

*Authors:* Betts KA, Joshi AD, Yan SY, Zhou Z, Rao S, Wolff M, Cifaldi M.

Indirect comparison of joint damage prevention with adalimumab v. Abatacept, each in combination with methotrexate, in early rheumatoid arthritis.

*Abstract:* ISPOR 16th Annual European Congress Dublin Ireland.

*Authors:* Wu EQ, Cifaldi M, Diener M, Kaltenboeck A, Ganguli A, Bergman M.

Assessment of wage and salary growth in patients with rheumatoid arthritis (RA).

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2013 San Diego, CA United States.

*Authors:* Bergman MJ, De G, Ganguli A, Signorovitch J, Bao Y.

Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany.

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2013 San Diego, CA United States.

*Authors:* Wolff M, Zhou ZY, Signorovitch J, Shaw JW, Ganguli A.

The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2013 San Diego, CA United States.

*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema J, Cifaldi MA.

Spondyloarthritis epidemiology and burden phase 2 [speed 2] study: Disease progression in axial spondyloarthopathy (SpA).

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2013 San Diego, CA United States.

*Authors:* Ruderman E, Strand V, Joshi A, Bao Y, Betts K, Chopra P, McGuire MB, Rao SA.

Clinical outcomes and healthcare utilization following early versus late diagnosis of systemic lupus.

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012 Berlin Germany.

*Authors:* Korves C, Laliberte F, Suthoff E, Wei R, Oglesby A, Dennis G, Duh MS.

Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: Results from the ability-2 clinical trial.


*Authors:* Mease PJ, Rao S, Betts KA, Lu M, Fan L, Pangan AL, Van Der Heijde D, Cifaldi MA.

The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012 Berlin, Germany.

*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.
Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: Is USPA a proxy for non-radiographic axial SPA?

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012 Conference. Berlin Germany.

**Authors:** Boonen A, Kirson NY, Rao SA, Birnbaum HG, Swallow E, Yushkina Y, Jarvis J, Mease PJ, Cifaldi MA.

Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use.

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012, Berlin Germany.

**Authors:** Signorovitch J, Bao Y, Samuelsotn T, Mulani PM.

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on oral disease-modifying antirheumatic drugs (DMARDS).

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012., Berlin Germany.

**Authors:** Zhang F, Guerin A, Gauthier G, Curtis J.

Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012, Berlin Germany.

**Authors:** Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

Health care resource utilization (HRU) and costs associated with disease activity in systemic lupus erythematosus (SLE): A retrospective observational cohort analysis.

**Abstract:** ISPOR 18th Annual International Meeting New Orleans, LA United States.

**Authors:** Kan H, Guerin A, Kaminsky M, Yu AP, Wu EQ, Denio AE, Jhingran PM, Narayanan S, Molta C.

Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.

**Abstract:** ISPOR 18th Annual International Meeting. New Orleans, LA United States.

**Authors:** Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.

**Publication:** Journal of Medical Economics 2013 05; 16(6): 793-800

**Authors:** Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C.

Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.

**Publication:** Journal of Medical Economics 2013 02; 16(4): 479-489

**Authors:** Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.

Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.

**Publication:** Pain Medicine 2012 09; 13(9): 1110-1120

**Authors:** Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.

**Publication:** Pain Pract 2012 09; 12(7): 533-540

**Authors:** Reed C, Birnbaum HG, Ivanova JL, Schiller M, Waldman T, Mullen RE, Swindle R.
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.


*Authors:* Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M.

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).

*Publication:* Inflammatory Bowel Diseases 2012 11; 18(11): 2043-2055

*Authors:* Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells.

*Publication:* American Journal of Pathology 2012 03; 180(3): 1059-1067


Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.

*Publication:* Pharmacoeconomics 2012 04; 30(4): 323-336

*Authors:* Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M.


*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012. Conference Washington, DC United States.

*Authors:* Bergman MJ, Shaw JW, Cifaldi MA, Guerin A, Chopra P, Signorovitch J.

Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs etanercept.

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012 Washington, DC United States.

*Authors:* Xie J, Ganguli A, Yang H, Parikh K, Wu EQ, Cifaldi M.

Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC United States.

*Authors:* Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

Health care costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying anti-rheumatic drug (DMARDS) or methotrexate (MTX).

*Abstract:* ISPOR 15th Annual European Congress Berlin Germany.

*Authors:* Zhang F, Hiscock R, Curtis J.

Healthcare costs in psoriatic arthritis patients newly initiated on a biologic disease-modifying anti-rheumatic drug or methotrexate.

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012 Conference Washington, DC United States.

*Authors:* Zhang F, Hiscock R, Curtis J.

Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis.

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012 Washington, DC United States.

Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.


Authors: Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P.

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on non-biologic disease modifying anti-rheumatic drugs (DMARDS).


Authors: Curtis J, Gauthier G, Hiscock R, Zhang F.

Treatment patterns in psoriatic arthritis patients newly initiated on non-biologic disease-modifying anti-rheumatic drugs.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012., Washington, DC United States.

Authors: Curtis J, Gauthier G, Hiscock R, Zhang F.

Use of anti-tumor necrosis factor therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012 Washington, DC United States.

Authors: Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

Adherence to subcutaneous vs. Oral disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Abstract: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012, Berlin Germany.

Authors: Bergman M, Bao Y, Ayyagari R, Mulani PM.

Impact of early versus late systemic lupus erythematosus (SLE) diagnosis on clinical and economic outcomes.


Authors: Oglesby AK, Dennis GL, Korves C, Laliberte F, Suthoff ED, Wei R, Duh MS.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.


Authors: Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Variation in the use of biologics in the management of rheumatoid arthritis across the United Kingdom.

Abstract: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting 2012, Rheumatology 2012 Glasgow United Kingdom.

Authors: Choy E, McAuliffe S, Roberts K, Sargeant I.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.


Authors: Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.

Abstract: Inflammatory Bowel Diseases 2012, 7th Congress of ECCO European Crohn’s and Colitis Organisation, Barcelona, Spain.

Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.

**Publication:** Journal of Rheumatology 2011; 38(10); 2141-2149

**Authors:** McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA.

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.

**Abstract:** ACR/ARHP Annual Scientific Meeting, Chicago, IL.

**Authors:** Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

Economic burden of psoriatic arthritis and obesity in patients with psoriatic arthritis in the United States.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 Chicago, IL United States.

**Authors:** Zhang F, Guerin A, Latremouille-Viau D, Day RR, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriatic arthritis in the united states.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 Chicago, IL United States.

**Authors:** Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 SUPPL, Chicago, IL United States.

**Authors:** Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J.

Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 SUPPL, Chicago, IL United States.

**Authors:** Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

Economic model of workplace impacts of anti-TNF therapy for rheumatoid arthritis in Brazil.

**Abstract:** ISPOR 3rd Latin America Conference, Mexico City Mexico.

**Authors:** Teich V, Chaves L, Birnbaum H, Pike C, Waryas C, Cifaldi M.

Indirect comparison of adalimumab versus etanercept for the treatment of psoriatic arthritis.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Conference Baltimore, MD United States.

**Authors:** Kirson NR, S.; Birnbaum, H. G.; Kantor, E.; Wei, R.; Cifaldi, M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.

**Abstract:** 30th Annual Scientific Meeting of the American Pain Society Conference Austin, TX United States.

**Authors:** Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).

**Abstract:** Annual General Meeting of the British Society of Gastroenterology Conference Birmingham United Kingdom.

**Authors:** Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors.

**Publication:** Arthritis Research & Therapy 2011 02; 13(1): R25  
**Authors:** Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH.

Refractory gout brings economic pain.

**Publication:** PharmacoEconomics & Outcomes News 2011 03; 623: 5  
**Authors:** Wu E.

Societal cost of rheumatoid arthritis patients in the US.

**Publication:** Current Medical Research and Opinion 2010 01; 26(1): 77-90  
**Authors:** Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).

**Abstract:** 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX United States.  
**Authors:** Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

Direct and indirect costs of spondyloarthritis patients pre-and post-diagnosis.

**Abstract:** American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 10 Philadelphia, PA United States.  
**Authors:** Kirson N, Birnbaum H, Rao S, Swallow E, Waldman T, Dayoub E, Cifaldi M.

Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.

**Abstract:** 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton United Kingdom.  
**Authors:** Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoel-Streefland M, Jiang W, Zimetbaum PJ.

Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis.

**Abstract:** European League Against Rheumatism (EULAR) 2010 Congress, Rome, Italy.  
**Authors:** Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M.

Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD, Miami, FL United States.  
**Authors:** Kimball A, Signorovitch J, Mulani P, Bao Y.

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.

**Publication:** Dermatology 2010 11; 220(1): 1-7  
**Authors:** Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.

**Publication:** Journal of Occupational Environmental Medicine 2009 10; 51(10): 1167-1176  
**Authors:** Birnbaum H, Pike C, Kaufman R, Cifaldi M.

Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?

**Publication:** Journal of Rheumatology 2009 05; 36(5): 1032-1040  
**Authors:** Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E.
Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.
Publication: Expert Opinion on Pharmacotherapy 2009 02; 10(2): 255-269
Authors: Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M.

Changes in health care utilization and costs for employed patients with rheumatoid arthritis from 19972006.
Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09 Atlanta, GA United States.
Authors: Birnbaum H, Pike C, Banerjee R, Waldman T, Cifaldi M.

The costs of treatment failure gout: A claims-based analysis.
Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09 Atlanta, GA United States.
Authors: Wu EQ, Yu AP, Guerin A, Latremouille-Viau D, Tsaneva M, Forsythe A.

Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.
Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

Impact of adalimumab treatment in the workplace in patients with rheumatoid arthritis.
Abstract: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009, Rheumatology'09 Conference Glasgow United Kingdom.
Authors: Cifaldi MA, Birnbaum H, Pike C, Kaufman R, Schiller M, Shi L, Sun P, Ray S.

Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.
Authors: Menter A, Signorovitch J, Mulani P, Gupta S.

Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.
Authors: Mease P, Signorovitch J, Mulani P, Gupta S.

The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.
Authors: Mease P, Signorovitch J, Mulani P, Gupta S.

Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
Publication: Journal of Occupational Environmental Medicine 2008 09; 50(9): 998-1005
Authors: White AG, Birnbaum HG, Janagap C, Buteau S, Schein J.

Disease-related and all-cause health care costs of elderly patients with gout.
Publication: Journal of Managed Care Pharmacy 2008 03; 14(2): 164-175
Authors: Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Publication: Current Medical Research and Opinion 2008 08; 24(8): 2229-2240
Authors: Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.

Publication: Current Medical Research and Opinion 2007 08; 23(8): 1749-1759
Authors: Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?

Abstract: American Geriatrics Society Annual Scientific Meeting, Seattle, WA.
Authors: Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.


Abstract: American Geriatrics Society Annual Scientific Meeting, Seattle, WA.
Authors: Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.


Abstract: American Geriatrics Society Annual Scientific Meeting, Seattle, WA.
Authors: Wu EQ, Patel P, Krishnan E, Yu AP.

Authors: Greenberg PE, Birnbaum HG.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Publication: Rheumatology 2006 10; 45(10): 1238-1246

Tighter control of serum uric acid in gout is associated with lower morbidity and health care costs.

Publication: Arthritis and Rheumatism 2006 54(9): S332-S332
Authors: Wu EQ, Mody RR, Krishnan E, Yu AP, Cahill KE, Tang J, Patel PA.

Direct and indirect costs of rheumatoid arthritis to an employer.

Publication: Journal of Occupational Environmental Medicine 2000 06; 42(6): 588-596
Authors: Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC.

Cardiovascular

Age and Outcomes of Primary Prevention Implantable Cardioverter Defibrillators in Patients with Non-Ischemic Systolic Heart Failure.

Publication: Circulation 2017 09;

Impact of renal function on clinical outcomes among nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban.

Abstract: ISPOR 22nd Annual International Meeting. United States, Boston, MA.
Importance of balancing follow-up time and impact of oral-anticoagulant users’ selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.

**Publication:** Current Medical Research and Opinion 2017 06; 33(6): 1033-1043

**Authors:** Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson ED.

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.

**Publication:** Journal of the American Academy of Dermatology 2017 01; 76(1): 81-90

**Authors:** Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.

**Abstract:** 21st Annual Scientific Meeting of the Heart Failure Society of America, HFSA 2017, Gravevine, TX.

**Authors:** Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.

**Publication:** Journal of Medical Economics 2017 08; 20(8): 777-785

**Authors:** Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.

**Publication:** Current Medical Research and Opinion 2017 04; 33(4): 631-638

**Authors:** Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.

**Abstract:** 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.17, Washington, DC.

**Authors:** Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

**Publication:** Current Medical Research and Opinion 2017 10; 33(10): 1891-1900

**Authors:** Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

**Publication:** Clinical Therapeutics 2017 07; 39(7): 1396-1408


Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation.

**Abstract:** 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.17, Washington, DC.

**Authors:** McHorney C, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C, Schein J, Lefebvre P, Peterson E.

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.

**Publication:** PloS One 2016 11; 11(11): e0166103

**Authors:** Agus DB, Gaudette E, Goldman DP, Messali A.
Comparison of Adherence to Rivaroxaban versus Apixaban Among Patients with Atrial Fibrillation.
Publication: Clinical Therapeutics 2016 11; 38(11): 2477-2488
Authors: McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

Cost impact of switching from metoprolol to nebivolol for hypertension.
Authors: Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E.

Impact of a Telehealth and Care Management Program on All-Cause Mortality and Healthcare Utilization in Patients with Heart Failure.
Publication: Telemedicine Journal and e-Health 2016 07; 22(1): 2-11

Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Publication: Clinical Therapeutics 2016 08; 38(8): 1803-1816.e1803
Authors: Deitelzweig S, Laliberte F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.
Abstract: ISPOR 19th Annual European Congress, Austria.

Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.
Abstract: ISPOR 19th Annual European Congress, Austria.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.
Authors: Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

Cardiac resynchronization therapy and adherence to heart failure management regimens.
Abstract: 20th Annual Scientific Meeting of the Heart Failure Society of America United States.
Authors: Der Sarkissian M, Xiao Y, Shen Y, May D, Tsintzos SI, Lefebvre P, Duh MS.

Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: an analysis of electronic medical record data.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.
Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD, Germany.
Authors: Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.
Healthcare costs among patients diagnosed with deep vein thrombosis in the outpatient setting and treated with Rivaroxaban versus low-molecular-weight Heparin and Warfarin.

Authors: Laliberte F, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
Publication: Menopause 2016 06; 23(6): 600-610
Authors: Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
Publication: Journal of Medical Economics 2016 04; 19(1): 84-90

The Relationship between Local Economic Conditions and Acute Myocardial Infarction Hospital Utilization by Adults and Seniors in the United States, 1995-2011.
Publication: Health Services Research 2015 10; 50(5): 1688-1709
Authors: Carls GS, Henke RM, Karaca Z, Marder WD, Wong HS.

Response to comment on “is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database”.
Publication: Journal of Cardiac Failure 2015 05; 21(5): 435
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Duh MS, Ong SH.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Publication: Clinical Therapeutics 2015 03; 37(3): 554-562

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Publication: Advances in Therapy 2015 03; 32(3): 216-227

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.
Publication: Journal of the American Academy of Dermatology 2015 06; 72(6): 968-977 e962
Authors: Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.

The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.
Publication: Journal of Medical Economics 2015 07; 18(7): 483-491
Authors: Penn MS, Yenikomshian MA, Cummings AK, Klemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG.

Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis.
Publication: Current Medical Research and Opinion 2015 02: 1-30
Authors: Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E.
Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
Publication: Thrombosis Research 2015 02; 135(2): 303-310
Authors: Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.
Publication: Journal of Medical Economics 2015 12; 18(12): 1041-1049
Authors: Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
Publication: Journal of Acquired Immune Deficiency Syndromes 2015 08; 69(4): 413-421

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.
Authors: Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Olson WH, Pollack CV, Jr.

Development of a shared decision-making tool to assist patients and clinicians with assessing the individualized risks and benefits of oral anticoagulation therapy for atrial fibrillation.
Abstract: ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA.

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.
Abstract: SHMs Annual Meeting.
Authors: Merli; GJ, Hollander; JE, Lefebvre; P, Laliberté; F, Raut; MK, Olson; WH, Bookhart; B, Pollack; CV.

Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.
Publication: Journal of Medical Economics 2015 18(12): 1074-1084
Authors: Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberte F, Dea K, Germain G, Lynch SM.

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.
Publication: RMD Open 2015 11; 1(1): e000080
Authors: Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE.

Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients?
Real-world evidence from a retrospective analysis of a large United States hospital database.
Publication: Journal of Cardiac Failure 2014 11; 20(11): 853-863
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

Specialized adult congenital heart disease care: the impact of policy on mortality.
Publication: Circulation 2014 05; 129(18): 1804-1812
Authors: Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A.
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

Publication: Pharmacoepidemiology and Drug Safety 2014 03; 23(3): 268-277
Authors: Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.

Publication: Pharmacoconomics 2014 03; 32(3): 305-313
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

Publication: Current Medical Research and Opinion 2014 07; 30(7): 1317-1325
Authors: Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.

Publication: Journal of Medical Economics 2014 01; 17(1): 52-64
Authors: Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.

Risk factors associated with myocardial infarction in venous thromboembolism patients.

Publication: Current Medical Research and Opinion 2014 01; 30(1): 27-35
Authors: Laliberte F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S.

Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.

Publication: Journal of Clinical Pharmacy and Therapeutics 2014 09; 39(6): 663-672
Authors: Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

Pulse pressure and stroke risk: development and validation of a new stroke risk model.

Publication: Current Medical Research and Opinion 2014 12; 30(12): 2453-2460
Authors: Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.

Authors: Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?

Publication: Current Medical Research and Opinion 2014 08; 30(8): 1521-1528
Authors: Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.

Publication: Current Medical Research and Opinion 2014 08; 30(8): 1513-1520
Authors: Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.

Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension.

Publication: Current Medical Research and Opinion 2014 04; 30(4): 637-643
Authors: Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ.
Effects of rivaroxaban vs warfarin on hospitalization days, healthcare resource utilization, and costs in nonvalvular atrial fibrillation patients using rivaroxaban.

Abstract: American Heart Association (AHA) Scientific Sessions 2014, Chicago, IL.

Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.

Abstract: ISPOR 17th Annual European Congress Amsterdam Netherlands.
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers.

Abstract: ACMP 2014 Nexus Meeting, Boston, MA.
Authors: Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ.

Pulse pressure and stroke risk: Development and validation of a new stroke risk model.

Abstract: 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei Taiwan (Republic of China).
Authors: Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.

Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Anticoagulant options and inpatient costs for patients with non-valvular atrial fibrillation.

Abstract: Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2014, Baltimore, MD.
Authors: Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension.

Authors: Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ.

Costs of venous thromboembolism (VTE) among hospitalized patients in China.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Penn MS, Yenikomshian MA, Cummings AKG, Damron JM, Purvis S, Birnbaum HG.

Effect of prasugrel vs clopidogrel on hospital readmission among acute coronary syndrome patients treated with prasugrel.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada.

Hospital length of stay: Does rivaroxaban reduce impatient stay compared to warfarin among patients with non-valvular atrial fibrillation.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada.
Authors: Laliberté F, Pilon D, Raut M, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.
Real-World Comparative Effectiveness and Safety of Rivaroxaban and Warfarin in Nonvalvular Atrial Fibrillation Patients.

Authors: Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, P. L.

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alfa inhibitors versus methotrexate.


Authors: Wu JJ, Guerin A, Dea K, Wang K, Sundaram M, Mulani P.

Gastrointestinal comorbidities associated with atrial fibrillation.

Publication: Springerplus 2014 10; 3: 603

Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.

Publication: Circulation 2013 09; 128(13): 1412-1419

Authors: Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy.

Publication: International Journal of Cardiology 2013 07; 167(2): 564-569

Authors: Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS.

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.

Publication: Hypertension 2013 02; 61(2): 309-318

Authors: Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille M, Duh MS.

All-cause and disease-related health care costs associated with recurrent venous thromboembolism.

Publication: Thrombosis and Haemostasis 2013 12; 110(6): 1288-1297

Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S.

Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?


Authors: Laliberte F, Pilon D, Raut M, Nelson WW, Duh MS, Schein JR, Lefebvre P.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.


Authors: Laliberté F, Cloutier M, Nelson WW, Coleman CI, Sheng Duh M, Pilon D, Damaraju CV, Schein JR, Lefebvre P.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.

Abstract: 2013 Annual Meeting of the American College of Clinical Pharmacy, ACCP 2013 Albuquerque, NM United States.

Authors: Lefebvre P, Coleman CI, Bookhart B, Wang ST, Mody SH, Tran K, Zhuo D, Huynh L, Nutescu EA.
Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.

Abstract: 24th Annual Meeting of the North American Menopause Society, NAMS 2013, Dallas, TX United States.
Authors: Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Pulse pressure and stroke risk: Development and validation of a stroke risk equation.

Authors: Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.

Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Montreal, QC Canada.
Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.

Abstract: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2012 Berlin, Germany.
Authors: Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

All-cause and disease-related costs associated with recurrent venous thromboembolism.

Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart B, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA.
Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the united states.

Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Lacomte P, Ong SH, Duh MS.

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

Publication: Current Medical Research and Opinion 2013 30(4): 645-653
Authors: Laliberté F, Pilon D, Raat MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.

Publication: Patient 2013 07; 6(3): 213-224
Authors: Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.

Publication: Journal of Managed Care Pharmacy 2012 06; 18(5): 363-374
Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.

Publication: Advances in Therapy 2012 08; 29(8): 675-690
Authors: Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.

Publication: Current Medical Research and Opinion 2012 04; 28(4): 591-599
Authors: Signorovitch JE, Samuelsin TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S.

Integrated telehealth and care management program reduces all cause mortality in Medicare beneficiaries with heart failure.

Authors: Page RL, Kao DP, Macaulay D, Birnbaum HG, Jarvis J, Desai U, Lindenfeld J.

Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide.

Abstract: AMCP Educational Conference 2012, Cincinnati, OH.
Authors: Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J.

Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide.

Authors: Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, Wu EQ.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.

Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review.

Abstract: 2012 Canadian Hypertension Congress, Toronto, Canada.
Authors: Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S.

Are vasodilators of value in the care of patients hospitalized for acute heart failure?

Authors: Duh MS, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Gradman AH.

Chronic heart failure in the elderly: Clinical characteristics and resource utilization following initial hospitalization.

Authors: Korves C, Eldar-Lissai A, Wei R, Sharma H, Chen K, Ong SH, Duh MS.
Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Acute heart failure patients with and without renal impairment: A study of heart failure-related resource utilization and costs in the United States.
Authors: Eldar-lissai A, Eapen S, Ong SH, Rodermund D, Duh MS.

All-cause and disease-specific health care utilization and costs associated with venous thromboembolism in commercial, Medicare and Medicaid beneficiaries.
Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, Lamori JC, Bookhart B, Olson W, Dea K, Schein J, Kaatz S.

Are vasodilators of value in the care of patients hospitalized for acute heart failure?
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

Chronic heart failure in the elderly: Costs and resource utilization following initial hospitalizaton.
Authors: Eldar-lissai A, Korves C, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.
Abstract: American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY United States.
Authors: Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment.
Abstract: American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition New York, NY United States.
Authors: Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

Impact of once-daily vs. Twice-daily dosing frequency on adherence in chronic medications among patients with non-valvular atrial fibrillation.
Abstract: Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2012 Scientific Sessions, QCOR 2012 Atlanta, GA United States.
Authors: Laliberte F, Nelson WW, Schein JR, Rondeau-Leclerc J, Lefebvre P, Duh MS.
Risk of cardiovascular events associated with hypertension among Chinese and Caucasian stroke patients in the US.

Abstract: American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition., New York, NY United States.

Authors: Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

Are vasodilators of any value in the care of hospitalized acute heart failure patients?

Abstract: 61st Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.12 Chicago, IL United States.

Authors: Gradman A, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh M.

Gastrointestinal conditions among patients with atrial fibrillation.

Abstract: 61st Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.12 Chicago, IL United States.

Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.

Publication: Journal of Medical Economics 2012 02; 15(4): 644-653

Authors: Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.

Publication: Journal of Medical Economics 2012 05; 15(5): 925-937

Authors: Korves C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng Duh M.

A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery.

Publication: Current Orthopaedic Practice 2012 23(3): 221-228

Authors: Balcom WB, Mishol DN, Eapen S, Bookhart BK, Nutescu EA, Schein JR, Duh MS.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

Publication: Appl Health Econ Health Policy 2011 09; 9(5): 293-303

Authors: Kirson NY, Birnbaum HG, Ivanova Ji, Waldman T, Joish V, Williamson T.

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.

Publication: Current Medical Research and Opinion 2011 09; 27(9): 1763-1768

Authors: Kirson NY, Birnbaum HG, Ivanova Ji, Waldman T, Joish V, Williamson T.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.

Publication: Menopause 2011 10; 18(10): 1052-1059

Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.


Authors: Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.
Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February).

Publication: Annals of Pharmacotherapy 2011 02;
Authors: Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P.

Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.

Publication: European Journal of Heart Failure 2011 02; 13(2): 148-153

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.

Publication: Quality of Life Research 2011 12; 20(10): 1737-1744
Authors: Signorovitch J,Brainsky A, Grotzinger KM.

Comparison of bleeding rates between statin and statin-free patients on warfarin: A claims database approach.

Authors: Guerin A, Hylek EM, Frois C, Ponce De Leon Barido D, Marrone C, Bae JP, Zhao Z.

Factors associated with failing to achieve low density lipoprotein cholesterol goal with existing statin therapy: A chart extraction-based approach.

Abstract: ISPOR 14th Annual European Congress Madrid Spain.
Authors: Zhao Z, Ivanova J, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Frois C.

Risk of gastrointestinal conditions among patients with atrial fibrillation.

Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.

Authors: Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.

Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the US.

Abstract: 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Chicago, IL United States.
Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Antithrombotic treatment patterns, hospitalizations, and associated costs in acute coronary syndrome (ACS) patients.

Authors: Lefebvre P, Laliberte F, Dea K, Nelson W, Crivera C, Ellis L, Schein JR, Damaraju CV, Mody S, Duh MS.
Clinical characteristics, blood pressure (BP) control, and antihypertensive treatment (TRX) patterns among elderly patients (PTS) with hypertension (HTN).


Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States.

Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Hospitalization due to heart failure is associated with significant medical resource utilization and costs.


Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: A matched cohort study.


Authors: Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

Impact of initial combination therapy vs monotherapy on major cardiovascular (CV) events: A matched cohort study.


Authors: Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.


Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States.

Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

A single-center experience with low-dose warfarin in patients undergoing total hip or total knee replacement surgery.


Authors: Balcom WB, Bookhart BK, Mishol DN, Eapen S, Nutescu EA, Schein JR, Duh MS.

Treatment persistence among atrial fibrillation/flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting.


Authors: Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.
Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy.

*Abstract:* 60th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.11 New Orleans, LA United States.

*Authors:* Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

Long-term consequences and costs associated with venous thromboembolism.

*Abstract:* 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP 2011 Minneapolis, MN United States.

*Authors:* Mody S, Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy.

*Abstract:* 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP 2011 Minneapolis, MN United States.

*Authors:* Guerin A, Lin J, Jhaveri M, Wu E, Alpert J.

Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.

*Publication:* American Journal of Cardiovascular Drugs 2011 01; 11(1): 21-32

*Authors:* Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ.

Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.

*Publication:* Journal of Medical Economics 2011 03; 14(3): 267-278

*Authors:* Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

*Publication:* Journal of Medical Economics 2011 04; 14(3): 324-334

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.

*Publication:* Current Medical Research and Opinion 2010 09; 26(9): 2203-2212

*Authors:* Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives.

*Publication:* Current Medical Research and Opinion 2010 09; 26(9): 2065-2076

*Authors:* Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG.

Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease.


*Authors:* Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM.

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.

*Publication:* American Journal of Medicine 2010 04; 123(4): 350-357

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.
Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
Publication: Current Medical Research and Opinion 2010 04; 26(4): 849-860
Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

Persistence with nebivolol compared to other beta-blockers in the treatment of hypertension: A retrospective claims analysis.
Authors: Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure.
Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

Aliskiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis.
Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Conference Atlanta, GA United States.
Authors: Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ.

Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in South Central region.
Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA United States.
Authors: Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.

Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis.
Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA United States.
Authors: Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP.

Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBS) in patients with hypertension.
Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA United States.
Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH.
Incidence rate of venous thromboembolism and hemorrhage in patients undergoing total hip or knee arthroplasty: A managed care perspective.

**Abstract:** 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP, San Diego, CA United States.

**Authors:** Lefebvre P, Vekeman F, Nutescu E, Duh M, Bookhart B, Schein J, Dea K.

**Costs associated with cardiovascular events in patients with hypertension in US managed care settings.**

**Publication:** Journal of the American Society of Hypertension 2009 11; 3(6): 403-415

**Authors:** Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH.

Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.

**Publication:** Mayo Clinic Proceedings 2009 12; 84(12): 1065-1072

**Authors:** Simpson RJ, Jr., Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.

**Publication:** Biostatistics 2009 04; 10(2): 275-281

**Authors:** Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

Economic impact of switching from valsartan to other angiotensin II receptor blockers for nonmedical reasons in patients with hypertension.

**Abstract:** AMCP’s 2009 Educational Conference San Antonio, TX United States.

**Authors:** Wu EQ, Signorovitch J, Yu AP, Latremouille-Viau D, Dastani HB, Kahler K.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.

**Abstract:** ISPOR 12th Annual European Congress, Paris France.

**Authors:** Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Healthcare costs and resource utilization of patients receiving combination treatments of angiotensin receptor blocker with chlorthalidone or with hydrochlorothiazide.

**Abstract:** European Society of Cardiology, ESC Congress 2009 Barcelona Spain.

**Authors:** Sun S, Yu A, Chen K, Mattson M, Xu Y, Dabbous O.

The association of aspirin use on risk of hospitalization in CHF patients taking ace inhibitors: A retrospective analysis of a national cohort of veterans.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States.

**Authors:** Parikh NM, Shah DH, Deswal A, Ashton CM, Agarwal SJ, Chen H, Johnson M.

Cost trend associated with cardiovascular (CV) events in patients (pts) with hypertension (HTN) in US managed care settings.

**Abstract:** 24th Annual Scientific Meeting and Exposition of the American Society of Hypertension, ASH San Francisco, CA United States.

**Authors:** Jayawant SS, Fulcher N, Ramamurthy P, Moyneur E, Ong SH, Duh MS.

The risk of coronary heart disease and stroke among psoriasis patients.

**Abstract:** 67th Annual Meeting of the American Academy of Dermatology, AAD . San Francisco, CA United States.

**Authors:** Kimball A, Guerin A, Mulani P, Gupta S.


**Publication:** P T 2008 05; 33(5): 288-295

**Authors:** Shaya FT, Gu A, Yan X.
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).

*Publication:* Journal of Clinical Hypertension (Greenwich, Conn.) 2008; 10(6): 436-442

*Authors:* Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, Investigators TS.

Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences.

*Publication:* Circulation 2008; 118(5): 491-497

*Authors:* Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR.

Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.

*Publication:* Hypertension 2008; 51(1): 48-54


Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence.

*Publication:* Clinical Therapeutics 2008; 30(4): 761-774

*Authors:* Yu AP, Yu YF, Nichol MB, Gwadry-Sridhar F.

Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?

*Publication:* Journal of Heart Valve Disease 2007; 16(4): 362-369

*Authors:* Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG.

The value of antihypertensive drugs: a perspective on medical innovation.

*Publication:* Health Affairs 2007; 26(1): 97-110


Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.

*Publication:* Obesity (Silver Spring) 2007; 15(2): 511-521

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.

*Publication:* Value in Health 2007; 11(6): 443-450

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay.

*Abstract:* American Society of Nuclear Cardiology (ASNC), San Diego, CA.

*Authors:* Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ.

Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA.

*Publication:* European Heart Journal Supplements 2007 9(suppl B): B19-B22

*Authors:* Long G, Cutler DM, Berndt ER.

The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS).

*Publication:* Healthc Q 2007; 10(2): 38-46

*Authors:* Cremieux PY, Fortin P, Meilleur MC, Montague T, Royer J.
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.
Publication: Stroke 2006 10; 37(10): 2567-2572
Authors: Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands.
Publication: Journal of Medical Economics 2006 9(131): 121
Authors: Boersma C, Ivanova J, Koopmanschap MA, Voors AA, Postma MJ.

Assessing the economic impact of chronic conditions in postmenopausal women.
Authors: Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
Publication: Current Medical Research and Opinion 2005 10; 21(10): 1693-1699
Authors: Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.
Publication: Clinical Transplantation 2005 02; 19(1): 122-129
Authors: Radeva JI, Reed SD, Kalo Z, Kauf TL, Cantu E, 3rd, Cretin N, Schulman KA.

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Publication: American Heart Journal 2005 08; 150(2): 323-329
Authors: Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Valiant-Investigators.

Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J.

Publication: Journal of the American College of Cardiology 2004 07; 44(1): 192-198
Authors: Patel MR, Meine TJ, Radeva J, Curtis L, Rao SV, Schulman KA, Jollis JG.

Cost and Comorbidities Associated with Atrial Fibrillation.
Authors: Wu EQ, Howard BG, Mareva MN.

PCV22 Cost and comorbidities associated with atrial fibrillation in different age groups.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Birnbaum H, Milena M.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.
Publication: Women’s Health Issues 2003 11; 13(6): 204-213
Authors: Birnbaum H, Leong S, Kabra A.
Clinical and Economic Value of Cardiovascular Nuclear Medicine.
Publication: Meniscus Health Care Communications 1996
Authors: Mulhern C, Neels K.

Dermatology

Publication: Journal of the American Academy of Dermatology 2017 10;
Authors: Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM.

Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.
Publication: Journal of Dermatolog Treatments 2017 06; 28(4): 290-298
Authors: Wu JJ, Guerin A, Gauthier G, Sundaram M.

Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.
Authors: Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.
Publication: Journal of the American Academy of Dermatology 2017 01; 76(1): 81-90
Authors: Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
Publication: Journal of Dermatological Treatment 2017 06: 1-8
Authors: Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.

Drug Cost per Responder for the Treatment of Moderate-to-Severe Psoriasis and Active Psoriatic Arthritis.
Abstract: American Academy of Dermatology 75th Annual Meeting, Orlando, FL.
Authors: Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M, A G.

Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa.
Abstract: American Academy of Dermatology 75th Annual Meeting, Orlando, FL.
Authors: Kimball A, Yang M, Song Y, Valdecantos W, Ganguli.

High-Value Subpopulation for Skin Pain Improvement in Adalimumab-Treated Patients with Moderate to Severe Hidradenitis Suppurativa.
Abstract: American Academy of Dermatology 75th Annual Meeting, Orlando, FL.
Authors: Qureshi A, Yang M, Song Y, Zhang A, Sundaram M, Ganguli A.

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Publication: Value in Health. 2017 08;
Authors: Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis.
Publication: Journal of the American Academy of Dermatology 2016 10; 75(4): 740-746
Authors: Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.
Publication: Journal of Medical Economics 2016 07; 19(7): 649-654

What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis.
Publication: Journal of Medical Economics 2016 07; 19(7): 710-717
Authors: Jemec GB, Guerin A, Kaminsky M, Okun M, Sundaram M.

Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.
Publication: J Community Support Oncol 2016 01; 14(1): 21-28
Authors: Brown J, Su Y, Nellesson D, Shankar P, Mayo C.

Patients’ Willingness to Pay for a Subcutaneous Injection Device That Reduces Injection Site Pain in the Treatment of Psoriasis.
Abstract: 25th European Academy of Dermatology and Venereology (EADV), Vienna, Austria.
Authors: Cividino A, Mittal M, Yang M, Signorovitch JE, M. S.

Adalimumab Is Associated with Reduced Risk of Joint-related Signs and Symptoms Compared with Methotrexate in Patients with Moderate to Severe Psoriasis.
Authors: Merola J, Sundaram M, Yang M, Li J, Galebach P, Okun M.

Cardiovascular (CV) event risk assessment in psoriasis (PS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) versus phototherapy.
Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Wu J, Cloutier M, Gauthier-Loiselle M, Guerin A, Sundaram M.

Cardiovascular Event Risk Assessment in Patients with Psoriasis Treated with Tumor Necrosis Factor-alpha Inhibitors versus Phototherapy.
Authors: Cloutier M, Gauthier-Loiselle M, Guerin A.

Comparison of Outcomes between Psoriasis Patients who Switched from Etanercept to Adalimumab versus to Ustekinumab.
Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Jashin J, Wu J, Sundaram M, Guérin A, Gauthier, Thompson-Leduc P.

How is the severity of hidradenitis suppurativa measured in clinical practice?
Abstract: 74th Annual Meeting of the American Academy of Dermatology Washington, DC.
Authors: Sundaram M, Lin P, Thomason D, Signorovitch J.

Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis.
Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Armstrong A, Betts K, Li J, Sundaram M, Wu E, Signorovitch J.
Predicting PASI90 Response Among Adalimumab-Treated Patients with Moderate to Severe Psoriasis.
Authors: Ryan C, Sundaram M, Yang M, Goyal R, Zhou Z, Signorovitch J.

Progression from a Milder to a More Severe Form of Hidradenitis Suppurativa is Associated with a Substantial Economic Burden.
Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

Progression from mild hidradenitis suppurativa (HS) to moderate-to-severe (m<s>2</s>) HS is associated with a substantial economic burden.
Abstract: 74th Annual Meeting of the American Academy of Dermatology Washington, DC.
Authors: Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

Psoriasis Plaque Resolution by Body Region and Plaque Signs with Adalimumab and Etanercept: an Indirect Comparison.
Authors: Papp K, Sundaram M, Yang M, Jarvis J, Signorovitch J.

Relative efficacy and costs per responder for adalimumab versus secukinumab in the treatment of moderate to severe psoriasis.
Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Armstrong A, Betts K, Sundaram M, Li J, Wu E.

Risk and economic burden of antibiotic failure in patients with moderate to severe hidradenitis suppurativa.
Abstract: 74th Annual Meeting of the American Academy of Dermatology Washington, DC.
Authors: Kimball A, Sundaram M, Gauthier G, Pivneva I, Nitulescu R, Guerin A.

Psoriasis Treatment Patterns: Phototherapy, Oral Nonbiologic, and Biologic Therapies.
Publication: American Journal of Pharmacy Benefits 2015 05;
Authors: Kimball AB GG, Hiscock R, Zhang HF.

Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.
Publication: Arthritis Care Res (Hoboken) 2015 03; 67(5): 708-717
Authors: Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.
Publication: Journal of the American Academy of Dermatology 2015 06; 72(6): 968-977 e962
Authors: Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.

Publication: British Journal of Dermatology 2015 02; 172(2): 504-512
Authors: Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.
Abstract: AMCP Nexus Orlando, FL.
Cost per Responder Associated with Biologic Therapies for Psoriasis.

Abstract: AMCP 27th annual conference, San Diego, CA.
Authors: Liu Y, Reichmann W, Macaulay D.

Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.

Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

Comparative efficacy of methotrexate versus apremilast for methotrexatenaive psoriasis patients: An indirect comparison.

Authors: Armstrong AW, Betts K, Sundaram M, Thomason D, Signorovitch J.

Health care resource utilization, health care costs, and dose escalation in biologic-naive psoriasis patients initiated on ustekinumab versus adalimumab.

Authors: Guerin A, Sundaram M, Gauthier G.

Long-term Effect of Achieving PASI90 Compared with PASI75 Response on Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis.

Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Ryan C, Sundaram M, Yang M, Goyal R, Signorovitch J.

A practical model for early identification of response with methotrexate for moderate to severe psoriasis.

Authors: Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.

Authors: Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

Starting-dose trends over time in biologic-naive and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab.

Authors: Guerin A, Sundaram M, Gauthier G.

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.

Publication: Journal of the European Academy of Dermatology and Venereology 2014 06; 28(6): 790-798
Authors: Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.

Publication: British Journal of Dermatology 2014 12; 171(6): 1434-1442
Authors: Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.
Early identification of response with methotrexate for moderate-to-severe psoriasis.
Authors: Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

Health care costs in psoriasis patients newly initiated on a biologic therapy or methotrexate.
Authors: Zhang F, Hiscock R.

Abstract: AMCP’s 26th Annual Meeting & Expo, Tampa, FL.
Authors: Sundaram M, Guérin A, Styles A, M K.

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alfa inhibitors versus methotrexate.
Authors: Wu JJ, Guerin A, Dea K, Wang K, Sundaram M, Mulani P.

Higher health care costs and dose escalation rates in psoriasis patients treated with ustekinumab compared to adalimumab.
Authors: Guerin A, Wang K, Sundaram M.

Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.
Authors: Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

Nail psoriasis significantly impairs health-related quality of life among patients with chronic plaque psoriasis.
Authors: Okun M, Kageleiry A, Signorovitch J, Yang M, Sundaram M.

Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis.
Abstract: 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO United States.
Authors: Langley RG, Signorovitch J, Wang K, KA. B, Sundaram M, Mulani P, Yan S.

Patient preferences and willingness to pay for enhancements to subcutaneous injection devices used to treat psoriasis.
Authors: Cividino A, Signorovitch JE, Skup M, Tundia N, Mulani P, Arulmani U, Bao Y.

Economic and comorbidity burden of moderate-to-severe psoriasis.
Abstract: Annual Maui Dermatology Conference, Maui, HI.
Authors: Feldman S, Zhao Y, Tran MH, Shi L.

Abstract: ISPOR 16th Annual European Congress Dublin Ireland.
Authors: Betts KA, Sundaram M, Mughal F, Yan SY, Signorovitch J, Wang K, Wu EQ.
Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.
Abstract: 71st Annual Meeting of the American Academy of Dermatology Conference Miami Beach, FL United States.
Authors: Kimball AB, Signorovitch JE, Sundaram M, Samuelson T.

Abstract: American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL.
Authors: Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

Economic burden of hidradenitis suppurativa after a single surgical intervention: Assessment of unmet needs using a retrospective claims-based analysis.
Abstract: 71st Annual Meeting of the American Academy of Dermatology Conference Miami Beach, FL United States.
Authors: Jemec G, Guerin A, Okun M, Kaminsky M, Sundaram M.

Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.
Abstract: 71st Annual Meeting of the American Academy of Dermatology Conference Miami Beach, FL United States.
Authors: Sundaram M,Styles A, Guerin A, Aberki C, Okun M, Hayes O, Mulani P.

Validation of the hidradenitis suppurativa clinical response as a clinical endpoint for hidradenitis suppurativa treatment evaluation.
Abstract: 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States.
Authors: Okun M, Yang M, Sundaram M, Gu Y.

Validation of the physician’s global assessment of psoriasis of the hands and/or feet as a clinical endpoint.
Abstract: American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL.
Authors: Goldblum O, Sundaram M, Yang M, Thomason D.

Risks of developing psychiatric disorders in pediatric patients with psoriasis.
Publication: Journal of the American Academy of Dermatology 2012 10; 67(4): 651-657 e651-652
Authors: Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
Publication: Journal of the American Academy of Dermatology 2012 02; 66(2): e67-76
Authors: Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Publication: British Journal of Dermatology 2012 12; 167(6): 1374-1381
Authors: Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM.

Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in Germany.
Authors: Betts K, Yan Y, Sundaram M, Hengst N, Wolff M, Bensimon AG.
Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Kimball AB, Sundaram M, Samuelson TM, Signorovitch JE.

Economic burden of hidradenitis suppurativa following a single surgical intervention: Assessment of unmet need using a retrospective claims-based analysis.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Jemec G, Guérin A, Sundaram M, Kaminsky MS, Okun MM.

Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event-free response versus etanercept.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Reich K, Signorovitch JE, Sundaram M, Mulani PM.

Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM.

Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Sundaram M, Okun MM, Guérin A, Styles A, Hayes OA, Aberki C, Mulani PM.

Psoriasis is significantly associated with lower rates of pregnancy and live births.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Cather JC, Horn EJ, Sundaram M, Latremouille-Viau D, Guérin A.

Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.
Authors: Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

Treatment Patterns in Psoriasis Patients Newly Initiated on an Oral Conventional Systemic Therapy or on Phototherapy.

Abstract: 21st European Academy of Dermatology and Venereology Congress 2012, Prague, Czech Republic.
Authors: Zhang F, Guérin A, Hiscock R, Kimball A.

Economic burden associated with workplace productivity losses (WPL) in patients with psoriasis in a population in the United States.


Economic burden of psoriasis (PSO) and obesity in patients with psoriasis in the United States.

Authors: Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.

Authors: Zhang F, Guerin A, Gauthier G, Day R, Khan Z.
Quality-of-life effects of psoriasis skin symptoms affecting different body regions.


Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Mulani PM.

Sex differences in health-related quality of life in patients with moderate to severe psoriasis.


Authors: Cather JC, Horn EJ, Sundaram M, Yang M, Farooqui S, Mulani PM.


Authors: Zhang F, Guerin A, Latremouille-Viau D, Day R, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.


Authors: Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

Psoriasis is significantly associated with lower rates of pregnancy and live births.


Authors: Cather JC, Latremouille-Viau D, Horn EJ, Bao Y.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.


Authors: Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Economic burden of comorbidities in patients with psoriasis is substantial.

Publication: Journal of the European Academy of Dermatology and Venereology 2011 02; 25(2): 157-163

Authors: Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Treatment patterns of psoriasis patients and trends over time.

Abstract: ISPOR 14th Annual European Congress Madrid Spain.

Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z.

ABT-874 versus methotrexate in moderate to severe psoriasis: Effects on health-related quality-of-life outcomes.


Authors: Reich K, Tsaneva M, Sundaram M, Bao Y.

Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with ABT-874.


Authors: Papp K, Yu A, Sundaram M, Bao Y.

Adalimumab provides health-related quality of life benefits for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.


Authors: Duffin K, Menter A, Yang H, Gupta S.
Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept.


*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

Effects of ABT-874 treatment on health-related quality of life and Work Productivity and Activity Impairment in patients with psoriasis.


*Authors:* Papp K, Signorovitch J, Sundaram M, Bao Y.

Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis.


*Authors:* Papp K, Wu E, Goldblum O, Gupta S.

Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis.


*Authors:* Papp K, Latremouille-Viau D, Mulani P, Gupta S.

Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo.


*Authors:* Crowley J, Yang H, Sundaram M, Mulani P.

Health-related quality of life outcomes in patients with moderate to severe psoriasis treated with ABT-874 versus etanercept or placebo.


*Authors:* Menter A, Signorovitch J, Sundaram M, Bao Y.

Persistent impairment of work productivity and activity in patients with longer disease duration of psoriasis with hand/foot involvement.


*Authors:* Kimball A, Mulani P, Gupta S, Signorovitch J.

Resource utilization and costs associated with adalimumab or etanercept for moderate to severe psoriasis in a real-world setting.


*Authors:* Papp K, Guerin A, Gupta S, Bao Y.

Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis.


*Authors:* Papp K, Guerin A, Mulani P, Gupta S.
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Publication: Clinical Drug Investigation 2011 01; 31(1): 51-60
Authors: Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
Publication: Journal of the American Academy of Dermatology 2010 05; 62(5): 812-818
Authors: Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Publication: Journal of the American Academy of Dermatology 2010 12; 63(6): 1011-1018
Authors: Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

 Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.
Publication: American Journal of Medicine 2010 04; 123(4): 350-357
Authors: Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life.
Abstract: Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.

Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.
Abstract: Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.

Adalimumab provides health-related quality-of-life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy.
Abstract: Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.
Authors: Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM.

Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.
Abstract: Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.

Effects of ABT-874 versus etanercept or placebo health-related quality of life in patients with moderate to severe psoriasis.
Abstract: Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.
Authors: Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P.

Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity.
Abstract: Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.
Authors: Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.
Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment.

**Abstract:** Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.

**Authors:** Papp K, Signorovitch J, Yang H, Yu AP, Wu EQ, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P.

Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting.

**Abstract:** Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden.

**Authors:** Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM.

Burden of illness in patients with hidradenitis suppurativa.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD Conference Miami, FL United States.

**Authors:** Guerin A, Mulani P, Gupta S.

Adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy: Effects on patient-reported outcomes in patients with psoriasis.

**Abstract:** American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, FL.

**Authors:** Thaçi D, Xie J, Gupta S, Mulani P.

Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder.

**Abstract:** American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, FL.

**Authors:** Wu EQ, Signorovitch JE, Bao Y, Mulani PM.

Comorbidity prevalence in psoriasis patients: A meta-analysis.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD Conference Miami, FL United States.

**Authors:** Mrowietz U, Guerin A, Mulani P, Gupta S.

Comorbidity risks increase over time in patients with psoriasis.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD, Miami, FL United States.

**Authors:** Kimball A, Yu A, Mulani P, Bao Y.

Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety, and cost per responder.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States.

**Authors:** Wu E, Signorovitch J, Mulani P, Bao Y.

Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD Conference Miami, FL United States.

**Authors:** Papp K, Signorovitch J, Mulani P, Bao Y.

Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis.

**Abstract:** 68th Annual Meeting of the American Academy of Dermatology, AAD Conference Miami, FL United States.

**Authors:** Signorovitch J, Kantor E, Mulani P, Bao Y.
Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparisons of adalimumab with etanercept, infliximab, and ustekinumab.

Authors: Signorovitch J, Mulani P, Gupta S, Bao Y.

Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis.

Abstract: American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, FL.
Authors: Signorovitch J, Gupta SR, Bao Y, Mulan PM.

Direct and indirect economic burden of employees with moderate to severe psoriasis.

Authors: Reich K, Wu E, Mulani P, Gupta S.

Economic burden of comorbidities in patients with psoriasis.

Authors: Kimball A, Wu E, Mulani P, Bao Y.

Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy on patient-reported outcomes in psoriasis patients.

Authors: Thaci D, Xie J, Mulani P, Gupta S.

Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol on patient-reported outcomes in patients with palmo-plantar, nail, or scalp psoriasis.

Authors: Thaci D, Xie J, Mulani P, Gupta S.

Increased cancer risks among patients with psoriasis.

Authors: Kimball A, Guerin A, Mulani P, Bao Y.

Increased economic burden associated with moderate to severe psoriasis compared with mild psoriasis.

Authors: Kimball A, Yu A, Mulani P, Bao Y.

Increased risk of psychiatric disorders in a pediatric population with psoriasis.

Authors: Kimball A, Yu A, Mulani P, Gupta S.

Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.

Authors: Kimball A, Signorovitch J, Mulani P, Bao Y.
Potential drug interactions of oral systemic therapies for psoriasis have adverse outcomes in a real-world setting.

Authors: Saurat JH, Guerin A, Mulani P, Gupta S.

Psoriasis is associated with increased mortality risk.

Authors: Kimball A, Guerin A, Mulani P, Bao Y.

Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept.

Abstract: American Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA.
Authors: Wu EQ GA, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y.

Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis.

Abstract: American Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA.
Authors: Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y.

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.

Publication: Pharmacoeconomics 2010 09; 28(10): 935-945
Authors: Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM.

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.

Publication: Dermatology 2010 02; 220(2): 128-137
Authors: Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.

Publication: Dermatology 2010 11; 220(1); 1-7
Authors: Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Economic burden of psoriasis compared to the general population and stratified by disease severity.

Publication: Current Medical Research and Opinion 2009 10; 25(10): 2429-2438
Authors: Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial.

Authors: Reich K, Signorovitch J, Ramakrishnan K, Gupta S, Mulani P.

Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.

Authors: Menter A, Signorovitch J, Mulani P, Gupta S.

Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.

Authors: Mease P, Signorovitch J, Mulani P, Gupta S.
**Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis.**


*Authors:* Papp K, Signorovitch J, Mulani P, Gupta S.

**Adalimumab’s benefits for patient-reported outcomes in psoriasis patients are consistent across subgroups with different disease histories.**


*Authors:* Kimball AB, Wu EQ, Mulani P, Gupta S.

**The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities.**


*Authors:* Kimball A, Chen L, Mulani P, Gupta S.

**Comorbidities of psoriasis have an independent effect on impairing patient health-related quality of life and work productivity.**


*Authors:* Strober B, Guerin A, Mulani P, Gupta S.

**Discontinuation of adalimumab treatment for psoriasis following sustained response: Effects on health-related quality of life.**


*Authors:* Menter A, Wu EQ, Mulani P.

**The effect of adalimumab on improving work productivity among moderate to severe psoriasis patients.**


*Authors:* Kimball AB, Yu AP, Mulani P, Gupta S.

**The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.**


*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Health-related quality of life and work productivity among psoriasis patients by disease severity.**


*Authors:* Kimball A, Chen L, Mulani P, Gupta S.

**Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial.**


*Authors:* Reich K, Yu AP, Mulani P, Gupta S.

**The impact of psoriasis on healthcare costs and patient work loss.**


*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.
Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.
Publication: Current Medical Research and Opinion 2008 12; 24(12): 3493-3501
Authors: Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.
Publication: Managed Care Interface 2007 10; 20(10): 26-32
Authors: Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes.
Abstract: American College of Gastroenterology (ACG), Philadelphia, PA.
Authors: Loftus EV, Wu EQ, Yu AP.

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs.
Publication: Journal of the American Academy of Dermatology 2006 03; 54(3): 448-457
Authors: Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS.

A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization.
Publication: Cutis 2006 06; 77(6): 385-392
Authors: Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Emani S.

Endocrine/Metabolic/Diabetes

Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on canagliflozin or sitagliptin: A real-world analysis.

Real-world persistence and HbA1c goal attainment in type 2 diabetes patients initiated on canagliflozin or a glucagon-like peptide-1.
Abstract: 53rd Annual Meeting of the European Association for the Study of Diabetes, EASD, Lisbon, Portugal.

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonyureas for type 2 diabetes and the influence of medication adherence.
Publication: Obesity Science and Practice 2017 09; 3(3): 342-351
Authors: Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH.

Renal outcomes with DPP-4 inhibitors compared with sulfonylurea as add-on to metformin among patients with type 2 diabetes.
Authors: Teh HH, Desai U, Kirson NY, Hellstern M, Leigh PS, Mukherjee J, Khunti K.

Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients’ Treatment Persistence Behavior: Real-World Data from Germany.
Publication: Experimental and Clinical Endocrinology and Diabetes 2017 09;
Authors: Moennig E, Perez-Nieves M, Hadjiyianni I, Cao D, Ivanova J, Klask R.
Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.
Publication: Current Medical Research and Opinion 2017 10; 33(10): 1833-1842
Authors: Perez-Nieves M, Ivanova JI, Hadjiyianni I, Zhao C, Cao D, Schmerold I, Kalirai S, King S, DeLozier AM, Birnbaum HG, Peyrot M.

Correlates of basal insulin persistence among insulin-naive people with type 2 diabetes: results from a multinational survey.
Publication: Current Medical Research and Opinion 2017 10; 33(10): 1843-1851

Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.
Publication: Diabetic Medicine 2017 03; 34: 189
Authors: Hassan SW, Hadjiyianni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.

Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin: Data from UK patients.
Publication: Diabetic Medicine 2017 03; 34: 189-190
Authors: Hassan SW, Gulati K, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Publication: BMC Endocrine Disorders 2017 06; 17(1): 32

Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.
Publication: Diabetes Therapy 2017 03; 8(3): 555-571

Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.
Publication: Current Medical Research and Opinion 2017 03; 33(6): 1105-1110
Authors: DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS.

Basal Insulin Persistence, Associated Factors, and Outcomes after Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.
Publication: Diabetes Therapy 2017 02; 8(1): 149-166
Authors: Hadjiyianni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M.

Clinical and economic burden associated with chronic hypoparathyroidism: A retrospective chart review in the United States, Canada, United Kingdom, France, Germany, Italy, and Spain.
Abstract: 99th Annual Meeting of the Endocrine Society, ENDO, Orlando, FL.
Authors: Chen K, Krasner A, Li N, Xiang CQ, Souroutzidis A, Xie J.

Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk.
Publication: American Journal of Epidemiology 2017 09; 186(6): 736-744
Authors: Aroner SA, Yang M, Li J, Furtado JD, Sacks FM, Tjonneland A, Overvad K, Cai T, Jensen MK.
Systematic literature review of clinical, humanistic, and economic burden in Cushing's disease.

**Abstract:** 99th Annual Meeting of the Endocrine Society, ENDO 2017.

**Authors:** Watchko S, Nellesen D, Neary MP.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.

**Publication:** Diabetes Therapy 2016 09; 7(3): 439-454

**Authors:** Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.


**Publication:** Current Medical Research and Opinion 2016 06; 32(6): 1151-1159

**Authors:** Lefebvre P, Pilon D, Robitaille MN, Lafuenteille MH, Chow W, Pfeifer M, Duh MS.

Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.

**Publication:** Journal of Endocrinological Investigation 2016 12; 39(12): 1391-1399

**Authors:** Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.

Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.

**Publication:** Journal of Medical Economics 2016 04; 19(4): 374-385

**Authors:** Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany.

**Authors:** Kallenbach L, Pesuit J, Fan T, Hu W, Shui A, Cheng W, Duh M, Zichlin M, Levin P.

Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.

**Publication:** Current Medical Research and Opinion 2016 04; 32(4): 669-680

**Authors:** Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.

**Abstract:** AMCP Nexus 2016 Conference, National Harbor, Maryland.

**Authors:** Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhana A, Wu E.

The Prevalence of Hyperkalemia in the United States.

**Abstract:** AMCP Nexus 2016 Conference, National Harbor, Maryland.

**Authors:** Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhana A, Pham H, Hollenack K, Wu EQ.

Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany.

**Authors:** Zhou Z, Yang H, Fang A, Zhao J, Wu E, Chaudhari P, Seifeldin R.

The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany.

**Authors:** Yang H, Zhou Z, Zhao J, Fang A, Wu E, Chaudhari P, Seifeldin R.
Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.

Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany.
Authors: Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.

Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany.
Authors: Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Maintenance of weight loss or stable weight in subjects with obesity: A retrospective longitudinal analysis of electronic medical record data.

Authors: Der Sarkissian M, Bhak R, Huang J, Buchs S, Vekeman F, Ganguly R, Duh MS.


Abstract: ISPOR 21st Annual International Meeting Research, Washington, DC.
Authors: Lefebvre P, Chow W, Pilone D, Emond B, Lafeuille M, Pfeifer M, Rupnow MF, Duh MS.

Patterns of Weight Loss, Maintenance, and Gain in Patients with Obesity.

Abstract: ENDO, Boston, MA.
Authors: Huang; J, Buchs; S, DerSarkissian; M, Bhak; R, Vekeman; F, Ganguly; R, Duh; MS.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
Publication: Menopause 2016 06; 23(6): 600-610
Authors: Simon JA, Laliberte F, Duh MS, Pilone D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.
Publication: BMJ Open 2016 02; 6(2): e009421

Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.
Publication: Diabetes Therapy 2015 09; 6(3): 339-355

Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated with Topical Testosterone.
Publication: Am J Mens Health 2015 11; 9(6): 496-505
Authors: Muram D, Kaltenboeck A, Boytsov N, Hayes-Larson E, Ivanova J, Birnbaum HG, Swindle R.

Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
Publication: Value in Health 2015 03; 18(2): 198-205
Authors: Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.

For a Step Change to Curb the Obesity Epidemic.
Publication: Pharmacoeconomics 2015 07; 33(7): 613-617
Authors: Frois C, Cremieux PY.
Policy Makers' Views of Obesity-Related Challenges Around the World: An interview between Pierre Cremieux (of Analysis Group, Inc., and Guest Editor of this Special Issue) and policy makers from Brazil (Patricia Constante Jaime), Canada (Kimberly Elmslie), China (Bin Wang), France (Francois Cremieux), and the USA (Mark McClellan).

Publication: Pharmacoeconomics 2015 07; 33(7): 619-628
Authors: Cremieux P.

Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.

Publication: Journal of Medical Economics 2015 02; 18(2): 113-125
Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.

Publication: Journal of Medical Economics 2015 04; 18(8): 586-595
Authors: Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons NB.

Real-world evaluation of weight loss in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA) - an electronic health-record (EHR)-based study.

Abstract: Obesity Week, Los Angeles, CA.
Authors: P; L, W; C; D; P; B; E; MH; L; M; P; MFT; R; MS; D.


Publication: Pharmacoeconomics 2015 07; 33(7): 629-641
Authors: Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

Economic outcomes among Medicare patients receiving skin substitutes for treatment of diabetic foot ulcers.

Authors: Rice JB, Desai U, Ristovska L, Cummings AG, Birnbaum HG, Skornicki M, Margolis D, Parsons N.

Glycated hemoglobin (Hba1c) control in patients with Type 2 Diabetes Mellitus (T2DM) treated with canagliflozin in a realworld setting.

Authors: Lefebvre P, Pilon D, Robitaille M, Lefeuille M, Chow W, Pfeifer M, Duh MS.

Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.

Publication: Journal of Medical Economics 2014 09; 17(9): 646-657

Costs after initiating saxagliptin, sulfonylurea, or sitagliptin in patients with T2DM.

Publication: American Journal of Pharmacy Benefits 2014 05; 6(3): e60-e69
Authors: Kaltenboeck A, Ivanova J, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.

Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.

Publication: Postgraduate Medicine 2014 05; 126(3): 47-55
Authors: Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E.
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

**Publication:** Pharmacoepidemiology and Drug Safety 2014 03; 23(3): 268-277

**Authors:** Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease.

**Publication:** European Journal of Endocrinology of the European Federation of Endocrine Societies 2014 07; 171(1): 89-98

**Authors:** Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.

Opportunities for Improving Attainment of Quality Measures in Patients with Type 2 Diabetes Mellitus.

**Publication:** American Journal of Managed Care 2014 01; 20(1)

**Authors:** Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M.

Quality measure attainment in patients with type 2 diabetes mellitus.

**Publication:** American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15

**Authors:** Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P.

Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities.

**Publication:** Journal of Medical Economics 2014 04; 17(4): 288-295

**Authors:** Truong HL, Nellesen D, Ludlam WH, Neary MP.

Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.

**Abstract:** ISPOR 17th Annual European Congress Amsterdam Netherlands.

**Authors:** Kaltenboeck A, Boytsov N, Hayes-Larson E, San Roman A, Ivanova J, Birnbaum H, Foster S, Vazquez J, Muram D, Swindle R.

Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data.

**Abstract:** ISPOR 17th Annual European Congress Amsterdam Netherlands.

**Authors:** Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L.

The burden of “serial non-adherence” in type 2 diabetic patients.

**Abstract:** 50th Annual Meeting of the European Association for the Study of Diabetes, EASD 2014 Vienna Austria.

**Authors:** Frois C, Dea K, Ling D, Dunn J, Baron M.

Systematic Review of real-world evidence on treatment of Acromegaly.

**Authors:** Guérin A, Xu Y, Hiscock R, Begelman SM, Mu Y, Alaghband R, Wu EQ.

Units and costs per day per claim of comparable insulins supplied to Medicaid patients.

**Abstract:** ISPOR 19th Annual International Meeting, Montreal, QC Canada.

**Authors:** Ivanova JI, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R.

Burden of diabetic foot ulcers for Medicare and private insurers.

**Publication:** Diabetes Care 2014 11; 37(3): 651-658

**Authors:** Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.
Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes.

*Publication:* J Diabetes Sci Technol 2013 09; 7(5): 1229-1242
*Authors:* Virdi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R.

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.

*Publication:* Diabetes Care 2013 10; 36(10): 3297-3304
*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.

*Publication:* QJM 2013 08; 106(8): 721-729
*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.

*Publication:* Diabetes Obes Metab 2013 04; 15(4): 335-341
*Authors:* Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.

*Abstract:* 24th Annual Meeting of the North American Menopause Society, NAMS 2013, Dallas, TX United States.
*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis.

*Authors:* Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E.

Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis.


Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in patients with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Montreal, QC Canada.
*Authors:* Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).

*Abstract:* 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL.
*Authors:* Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in elderly versus overall people living with type-2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA United States.
*Authors:* Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.
Economic Outcomes Associated with Hba1c and Ldl-C Goal Achievement In Patients with Type 2 Diabetes Mellitus.
**Abstract:** International Society for Pharmacoeconomics and Outcomes Research.
**Authors:** Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin.
**Abstract:** ISPOR 18th Annual International Meeting New Orleans, LA United States.
**Authors:** Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep FA, Birnbaum H.

Medical, drug, and work-loss costs of diabetic foot ulcers.
**Abstract:** ISPOR 18th Annual International Meeting New Orleans, LA United States.
**Authors:** Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Trend in economic burden of diabetes in urban china from 2009 to 2011.
**Abstract:** International Society for Pharmacoeconomics and Outcomes Research.
**Authors:** Wu E, Xie J, Du E, Liu M, Liu G.

Improved clinical outcomes associated with dual-goal (HBA1C and LDL-C) achievement in newly diagnosed type 2 diabetes mellitus.
**Abstract:** American Heart Association’s Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism 2013 Scientific Sessions New Orleans, LA United States.
**Authors:** Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Kang AL, Fonseca VA.

Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.
**Publication:** Endocrine Practice 2012 09; 18(5): 651-659
**Authors:** Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

The direct and indirect costs among U.S. privately insured employees with hypogonadism.
**Publication:** Journal of Sexual Medicine 2012 09; 9(9): 2438-2447
**Authors:** Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.

Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.
**Authors:** Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
**Publication:** Postgraduate Medicine 2012 01; 124(1): 124-132
**Authors:** Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus.
**Abstract:** 1st American Diabetes Association Middle East Congress, Dubai, UAE.
**Authors:** Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB.

Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens versus vials.
**Abstract:** ISPOR 15th Annual European Congress Berlin Germany.
**Authors:** Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.
HbA1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM).

**Abstract:** ISPOR 15th Annual European Congress Berlin Germany.

**Authors:** Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ.

Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients.

**Abstract:** ISPOR 15th Annual European Congress Berlin Germany.

**Authors:** Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus.

**Abstract:** 48th Annual Meeting of the European Association for the Study of Diabetes, EASD 2012 Berlin Germany.

**Authors:** Chen K, Wu E, Cheng D, Bensimon A, Bron M.

Glycemic control and quality of life for patients with type 2 diabetes mellitus in China.

**Abstract:** ISPOR 5th Asia-Pacific Conference Taipei Taiwan (Republic of China).

**Authors:** Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ.

PDB17 Comparison of Clinical and Economic Outcomes Associated with Dpp4 Inhibitors (DPP4I) versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research.

**Authors:** Bron M, Chen K, Cheng D, Bensimon A, Wu E.

Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis.

**Abstract:** ISPOR 5th Asia-Pacific Conference. Taipei Taiwan (Republic of China).

**Authors:** Chen K, Bron M, Cheng D, Sharma H, Wu EQ.

Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.

**Abstract:** 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic.

**Authors:** Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

Economic burden of type 2 diabetes mellitus in China.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC United States.

**Authors:** Zheng Y, Wu EQ, Xie K, Zheng B, Yang HY, Xie J, Wu J.

Effect of diabetes patient characteristics on the willingness-to-pay for a new basal insulin-a discrete choice experiment.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC United States.

**Authors:** Yang M, Lin P, Wintfeld N, Frois C.

Health utility for patients with type 2 diabetes mellitus in China.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC United States.

**Authors:** Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ.
Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.

**Abstract:** Diabetes UK Professional Conference 2012 Glasgow United Kingdom.

**Authors:** Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM.

---

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.

**Publication:** Menopause 2011 10; 18(10): 1052-1059

**Authors:** Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

---

Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity.

**Publication:** European Journal of Endocrinology of the European Federation of Endocrine Societies 2011 06; 164(6): 905-910

**Authors:** Li K, Li L, Yang M, Liu H, Liu D, Yang H, Boden G, Yang G.

---

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.

**Publication:** Current Medical Research and Opinion 2011 01; 27(1): 189-195

**Authors:** Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

---

Prevalence rates and costs of metabolic syndrome and associated risk factors using employees’ integrated laboratory data and health care claims.

**Publication:** Journal of Occupational Environmental Medicine 2011 01; 53(1): 27-33

**Authors:** Birnbaum HG, Mattson ME, Kashima S, Williamson TE.

---

Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.

**Abstract:** IDF World Diabetes Congress, Dubai, United Arab Emirates.

**Authors:** Bron M, Yang HY, Yu AP, Marynchenko M, Fan L.

---

Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM).

**Abstract:** ISPOR 14th Annual European Congress Madrid Spain.

**Authors:** Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ.

---


**Abstract:** ISPOR 14th Annual European Congress, Madrid Spain.

**Authors:** Wu EQ, Guerin A, Latremouille-Viau D, Day R, Khan Z, Zhang F.

---

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.

**Abstract:** ACR/ARHP Annual Scientific Meeting, Chicago, IL.

**Authors:** Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

---

Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.

**Abstract:** ISPOR 14th Annual European Congress Madrid Spain.

**Authors:** Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

---

Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 SUPPL, Chicago, IL United States.

**Authors:** Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J.
Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population.

**Abstract:** 47th Annual Meeting of the European Association for the Study of Diabetes, EASD 2011 Lisbon Portugal.

**Authors:** Yang H, Marynchenko M, Bron M, Wu E, Yu AP.

Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.

**Abstract:** 22nd Annual Meeting of the North American Menopause Society Washington, DC United States.

**Authors:** Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population.

**Abstract:** 47th Annual Meeting of the European Association for the Study of Diabetes, EASD 2011 Lisbon Portugal.

**Authors:** Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP.

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation.

**Abstract:** 47th Annual Meeting of the European Association for the Study of Diabetes, EASD 2011 Lisbon Portugal.

**Authors:** Zhou S, Wu E, Peng Yu A, Lu M, Sharma H, Graf T.

Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.

**Abstract:** 47th Annual Meeting of the European Association for the Study of Diabetes, EASD 2011 Lisbon Portugal.

**Authors:** Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.

**Abstract:** 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Chicago, IL United States.

**Authors:** Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus.

**Abstract:** ADA 71st Scientific Session, San diego, CA.

**Authors:** Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP.

Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization.

**Abstract:** 93rd Annual Meeting and Expo of the Endocrine Society, ENDO 2011 Boston, MA United States.

**Authors:** Wu E, Zhou S, AP, Y, Lu M, Graf TR.

Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence.

**Abstract:** ADA 71st Scientific Session, San diego, CA.

**Authors:** Bron M, Marynchenko M, Yang Y, Wu EQ, Yu AP.

Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs.

**Abstract:** ADA 71st Scientific Session, San diego, CA.

**Authors:** Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ.
Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization.


Authors: Wu E, Zhou S, Yu AP, Lu M, Graf TR.

Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes.

Abstract: ADA 71st Scientific Session, San Diego, CA.

Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients.

Abstract: ADA 71st Scientific Session, San Diego, CA.

Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

The direct and indirect costs associated with hypogonadism among privately-insured employees in the United States.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD United States.

Authors: Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R.

Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET).

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD United States.

Authors: Lefebvre P, Sarda SP, Laliberte F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD United States.

Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

Publication: Clinical Drug Investigation 2011 08; 31(9): 665-674

Authors: Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.


Authors: Cremieux PY, Eapen S, Trask SW, Ghosh A.

The impact of bariatric surgery on comorbidities and medication use among obese patients.

Publication: Obesity Surgery 2010 07; 20(7): 861-870

Authors: Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M.

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.

Publication: Diabetes Research and Clinical Practice 2010 01; 87(1): 108-116

Authors: Lee L, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.
Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Yu AP, Yu YF, Nichol MB.

PD5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large US managed care cohort.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.

Authors: Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes.

Abstract: American Society for Healthcare Engineering (ASHE) 47th Annual Conference, Tampa, FL.
Authors: Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T.

Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients.

Abstract: American Diabetes Association, 70th Scientific Sessions, Orlando, FL.
Authors: Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O.

Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs.

Abstract: 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP, San Diego, CA United States.
Authors: Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Publication: Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322
Authors: Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Pech CT, Lefebvre P.

Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbA1c<7.0.

Abstract: 45th EASD Annual Meeting of the European Association for the Study of Diabetes Vienna Austria.
Authors: Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S.

Anti-hypertensive drug use and risk of dementia in patients with diabetes mellitus (DM).

Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Johnson ML, Parikh NM, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Morgan R.

Risk factors for dementia in elderly patients with diabetes mellitus.

Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Parikh NM, Morgan R, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Johnson M.

A study on the economic impact of bariatric surgery.

Publication: American Journal of Managed Care 2008 09; 14(9): 589-596
Authors: Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buesing M.
Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.

*Publication:* Bariatric Times 2008 11
*Authors:* Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.

Direct and indirect costs among employees with diabetic retinopathy in the United States.

*Publication:* Current Medical Research and Opinion 2008 05; 24(5): 1549-1559
*Authors:* Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.

Achieving Glycemic Goal with Initial Combination Therapy versus Sequential Augmentation Therapy using Metformin and Pioglitazone.

*Abstract:* 44th EASD meeting, Rome, Italy.

Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies.

*Abstract:* American Diabetes Association’s 68th Scientific Sessions, San Francisco, CA.
*Authors:* Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2035-2042
*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2157-2169
*Authors:* Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.

*Publication:* Obesity (Silver Spring) 2007 02; 15(2): 511-521
*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.

*Publication:* Value in Health 2007 11; 10(6): 443-450
*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.


*Authors:* Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

Prevalence of diabetic peripheral neuropathy and associated pain in French adults.

*Abstract:* Journal of Neurology.

Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients.

*Abstract:* American Diabetes Association (ADA).


*Abstract:* International Society for Pharmacoeconomics and Outcomes Research.
*Authors:* Wu E, Xie J, Crémieux P, Sullivan P.
Obesity’s Impact on Diabetes Patients’ Health-Related Quality Of Life In The U.S.
Authors: Cremieux P, Xie J, Greenberg P, Wu EQ, Castor A.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Xie J, Sullivan P.

Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes.

Employment and Income Associated with Obesity and Overweight in the US.
Authors: Wu EQ, Xie J, Sullivan PW.

Employment and Income Associated with Obesity and Overweight in the US.
Abstract: Academy of Managed Care Pharmacy (AMCP).

Quality of Life of Obese Adults in the US.
Abstract: International Society for Quality of Life Research (ISOQOL).
Authors: Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW.

Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Prospective.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.
Publication: Women’s Health Issues 2003 11; 13(6): 204-213
Authors: Birnbaum H, Leong S, Kabra A.

PDB6: Factors associated with high-risk diabetic patients in the California Medicaid populations (medi-cal).
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Chaikledkaew U, Wu E, Johnson K.

PDB10: A Methodology to identify high-risk patients with diabetes in the California Medicaid population (MEDI-CAL).
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Chaikledkaew U, Wu E, Johnson K.

Productivity and medical costs of diabetes in a large employer population.
Publication: Diabetes Care 2002 01; 25(1): 23-29
Authors: Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.

Identification of Diabetes Patients Using Claims Data: An Economic Analysis.
Authors: Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.
Gastrointestinal

**Public health impact of Rotarix vaccination among commercially insured children in the United States.**
*Publication:* Vaccine 2017 08; 35(37): 5065-5072  
*Authors:* Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS.

**Association of clinical complications and surgery treatment on recurrence of acute diverticulitis.**
*Abstract:* ISPOR 22nd Annual European Congress, Boston, MA.  
*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Association of socio-demographics and clinical complications with future medical expenditures in diverticulitis.**
*Abstract:* ISPOR 22nd Annual European Congress, Boston, MA.  
*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Evaluation of age, multimorbidity and clinical complications as risk factors for urgent surgical treatment for diverticulitis.**
*Abstract:* ISPOR 22nd Annual European Congress, United States, Boston, MA.  
*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Incremental expenditures associated with recurrence of diverticulitis.**
*Abstract:* ISPOR 22nd Annual European Congress, Boston, MA.  
*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Trajectories of expenditures associated with acute gastrointestinal diseases.**
*Abstract:* ISPOR 22nd Annual European Congress, Boston, MA.  
*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.**
*Publication:* Current Medical Research and Opinion 2017 03; 33(3): 529-536  
*Authors:* Rubin DT, Patel H, Shi S, Mody R.

**Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.**
*Publication:* Cancer Research and Treatment 2017 07; 49(3): 578-587  

**P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.**
*Publication:* J Crohns Colitis 2017 02; 11(suppl_1): S426  

**Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC). Add to Collection.**
*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO., Chicago, IL.  
*Authors:* Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.**
*Publication:* Digestive Diseases and Sciences 2016 07; 61(10): 2823-2830  
*Authors:* Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M.
Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.
Publication: Human Vaccines & Immunotherapeutics 2016 05; 12(5): 1235-1243
Authors: Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia and Mexico.
Publication: Journal of Medical Economics 2016 07: 1-49

Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Publication: Current Medical Research and Opinion 2016 03; 32(7): 1233-1241

Cost-analysis model of colonoscopy preparation using split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).
Publication: Journal of Medical Economics 2016 04; 19(4): 356-363
Authors: Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

Identifying higher-value subpopulations for treatment in heterogenous rare diseases: An example study of early responders to teduglutide for short bowel syndrome.
Abstract: ISPOR 19th Annual European Congress. Austria., Austria.
Authors: Chen K, Xie J, Tang C, Zhao J, Olivier C, Jeppesen PB, Signorovitch J.

Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.
Abstract: 81st Annual Scientific Meeting of the American College of Gastroenterology., United States.
Authors: Seidner DL, Joly F, Gabe SM, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

Assessment of the real-world safety profile of vedolizumab using the united states food and drug administration adverse event reporting system (FAERS).
Abstract: Digestive Disease Week 2016, DDW 2016, San Diego, CA.
Authors: Cross R, Vekeman F, Xiao Y, Wu EQ, Chao J, Wang A.

Diagnostic testing in IBS patients: Which factors are most strongly associated with more frequent diagnostic tests and procedures?
Authors: Luo M, Guerin A, Ayyagari R, Shi S, Lopez A, Lacy B.

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.
Publication: PloS One 2016 01; 11(1): e0145504

Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.
Publication: PloS One 2016 01; 11(1): e0145977
Authors: Krishnarajah G, Duh MS, Korves C, Demissie K.
Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Publication: PloS One 2016 04; 11(4): e0154258
Authors: Lacy BE, Patel H, Guerin A, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R.

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Publication: Journal of Medical Economics 2015 06; 18(6): 447-456
Authors: Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

Cost-Utility Analysis of Adalimumab for The Treatment of Moderate-To-Severe Ulcerative Colitis In Patients In Spain.
Abstract: International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Congress (ISPOR), Milan, Italy.
Authors: Wang S, Yang H, Yang M, Bao Y.

Economic Impact of Expanded Use of Biologic Therapy for Crohn’s Disease In Latin American Countries.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.

Comparison of real-world outcomes of adalimumab and infliximab for patients with moderate or severe ulcerative colitis in the United States.
Abstract: ACG 2015 Annual Scientific Meeting & Post Graduate Course, Honolulu, Hawaii.
Authors: Sakuraba A, Sandborn W, Skup M, Macaulay D, Reichmann W, Chao J.

Effect of adalimumab dose escalation on hospitalization risk in patients with moderately to severely active ulcerative colitis.

A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).
Abstract: ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA.
Authors: Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

Direct costs in patients with celiac disease-a retrospective claims analysis.
Abstract: 16th International Celiac Disease Symposium (ICDS), Prague, Czech Republic.
Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

Prevalence of comorbidities in patients with celiac disease.
Abstract: 16th International Celiac Disease Symposium (ICDS), Prague, Czech Republic.
Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).
Authors: Cleveland M, Yermakov S, Davis M, Campbell R, Huynh L, Farraye F, Yenikomshian M.

Direct costs in patients with celiac disease-a retrospective claims analysis.
Abstract: Digestive Disease Week (DDW), Washington, D.C.
Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.
Prevalence of comorbidities in patients with celiac disease.

Abstract: Digestive Disease Week (DDW), Washington D.C.
Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies.

Authors: Wang S, Yang H, Faust E, Bao Y.

The impact of moderate-to-severe Crohn's Disease on employees' salary growth.

Publication: Inflammatory Bowel Diseases 2014 10; 20(10): 1734-1738
Authors: Loftus EV, Jr., Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P.

Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.


Prevalence and risk of developing comorbid conditions in patients with chronic constipation.

Publication: Current Medical Research and Opinion 2014 12; 30(12): 2505-2513

The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.

Publication: Journal of Medical Economics 2014 08; 17(8): 577-586
Authors: Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E.

Age-related health care disparities in patients with irritable bowel syndrome: Findings from a sample of commercially insured patients.


Comparison of cost per responder and remitter in patients with inflammatory bowel disease in the united states: An indirect comparison of adalimumab and vedolizumab.

Authors: Liu Y, Ozbay AB, Skup M, Reichmann W, Diener M, Chao J.

Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis (sub-acute) in the UK.

Abstract: 22nd United European Gastroenterology Week, Vienna, Austria.

Indirect comparison of adalimumab and vedolizumab in inflammatory bowel disease in the United Kingdom: cost per responder/remitter analysis.

Abstract: 22nd Annual United European Gastroenterology Week, Vienna, Austria.

Regional variation of care for irritable bowel syndrome in the United States.

Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.

Authors: Ghosh S, Desjardins O, Skup M, Wang S, Yang M, Yang H, Qi C, Bao Y, Chao J.

Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.

Publication: Human Vaccines & Immunotherapeutics 2014; 10(8): 2255-2266

Authors: Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

Gastrointestinal comorbidities associated with atrial fibrillation.

Publication: Springerplus 2014; 10: 3: 603

Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.

Publication: Journal of Managed Care Pharmacy 2013; 11(9): 755-764

Authors: Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT.

Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.

Publication: Postgraduate Medicine 2013; 125(2): 40-50

Authors: Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW.

A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy.


Authors: Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

Association between adherence to adalimumab therapy and health care costs for patients with crohn's disease: Claims database analysis.

Abstract: 78th Annual Scientific Meeting of the American College of Gastroenterology Conference San Diego, CA United States.

Authors: Schifrien B, Yen E, Liu Y, Skup M, Tundia N, Ayyagari R, Yang H, Bao Y, Mulani P, Chao J.

Impact of the FDA safety communication on prescription trends of clopidogrel in combination with proton pump inhibitors.

Abstract: 78th Annual Scientific Meeting of the American College of Gastroenterology Conference San Diego, CA United States.

Authors: Guerin A, Mody R, Carter V, Wu E.

Indirect comparison of adalimumab and infliximab in ulcerative colitis: Cost per remitter analysis.

Abstract: 78th Annual Scientific Meeting of the American College of Gastroenterology Conference San Diego, CA United States.

Authors: Liu Y, Reichmann B, Yan S, Macaulay D, Skup M, Mulani P, Chao J.

Quality of life and life enjoyment: An analysis of end colostomy patients.


Authors: Yan S, Yang M, Hoch J, van den Broek N, Xie J, Warusavitarne J.
Budgetary impact of linaclotide in the treatment of US adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC).

Abstract: ISPOR 18th Annual International Meeting New Orleans, LA United States.
Authors: Taylor DCA, Carson RT, Xie J, Dean J, Du EX, Sarocco P, Blum SI.

Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.

Abstract: Digestive Disease Week, Orlando, FL.
Authors: Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.

Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population.

Authors: Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, Wu EQ.

High risk of leaving the workforce in US employees with ulcerative colitis.

Abstract: 8th Congress of the European Crohn's and Colitis Organisation, ECCO 2013 Vienna Austria.
Authors: Cohen R, Rizzo J, Yang M, Skup M, Macaulay D, Behrer C, Fok B, Mulani PM, Chao J.

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).

Publication: Inflammatory Bowel Diseases 2012 11; 18(11): 2043-2055
Authors: Sussman DA, Kubiluun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis.

Publication: Advances in Therapy 2012 07; 29(7): 620-634
Authors: Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Direct and indirect utilization and costs associated with ulcerative colitis.

Authors: Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

Cost-effectiveness of adalimumab for treatment of CROHN’s disease in Germany.

Abstract: ISPOR 15th Annual European Congress., Berlin Germany.
Authors: Yang M, Skup M, Zhou ZY, Hengst N, Wolff M, Mulani PM, Chao J.

Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy.

Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology Conference Las Vegas, NV United States.
Authors: Colombel JF, Thakkar R, Robinson A, Yang M, Skup M, Swallow E, Betts K, Chao J, Mulani P.

Cost-effectiveness model of adalimumab for the treatment of moderate to severe ulcerative colitis in the United Kingdom.

Abstract: 20th United European Gastroenterology Week, Amsterdam, the Netherlands.
Authors: Ali T, Yang M, Skup M, Yang M, Wu EQ, Chao J, Mulani PM.

Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis in the US.

Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology Las Vegas, NV United States.
Authors: Ali T, Skup M, Yang M, Wu E, Mulani P, Chao J.
Direct and indirect utilization and costs associated with ulcerative colitis.
Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology Conference Las Vegas, NV United States.
Authors: Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

Prevalence and risk of developing gastrointestinal conditions in patients with chronic constipation.
Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology Las Vegas, NV United States.

Prevalence and risk of developing non-gastrointestinal physical and mental comorbidities in patients with chronic constipation.
Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV United States.

Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.
Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology Las Vegas, NV United States.

Risk of malignancy, infection, serious infection, and acute health care use in patients with Crohn’s disease treated with adalimumab vs. immunosuppressants.
Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV United States.
Authors: Colombel JF, Thakkar R, Castillo M, Robinson A, Skup M, Yang M, Swallow E, Sorg R, Chao J, Mulani P.

Treatment benefit-risk preferences of patients with early Crohn’s disease.
Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology Las Vegas, NV United States.
Authors: Loftus E, Yang M, Skup M, Ivanova J, Sorg R, Chao J, Mulani P.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

The economic burden of unmet treatment needs in Medicaid patients with chronic constipation.
Authors: Carson RT, Guerin A, Lewis B, Yin D, Kaminsky M, Ramakrishnan K, Wu EQ.

Impact of induction dosing on maintenance outcome with adalimumab in Crohn’s disease.
Abstract: Digestive Disorders Federation Meeting 2012 Liverpool United Kingdom.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.
Treatment patterns and indicators of unmet needs in Medicaid patients with irritable bowel syndrome with constipation and chronic constipation.

*Abstract:* Digestive Disease Week, San Diego, CA.
*Authors:* Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

The economic burden of treatment failure in Medicaid patients with irritable bowel syndrome with constipation.

*Abstract:* AMCP 24th Annual Meeting & Expo, San Francisco, California.
*Authors:* Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

Gastrointestinal conditions among patients with atrial fibrillation.

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.12 Chicago, IL United States.
*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.

*Abstract:* Inflammatory Bowel Diseases 2012, 7th Congress of ECCO European Crohn’s and Colitis Organisation, Barcelona, Spain.

Assessing preference for deep remission in patients with Crohn’s disease.

*Abstract:* 7th Congress of the European Crohn’s and Colitis Organisation, ECCO Barcelona Spain.

Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s disease.

*Abstract:* Inflammatory Bowel Diseases 2012, 7th Congress of ECCO-European Crohn’s and Colitis Organisation, Barcelona, Spain.

Increased risks of developing anxiety and depression in young patients with Crohn’s disease.

*Publication:* American Journal of Gastroenterology 2011 09; 106(9): 1670-1677
*Authors:* Loftus EV, Jr., Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM.

Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn’s disease.

*Publication:* Inflammatory Bowel Diseases 2011 01; 17(1): 127-140
*Authors:* Loftus EV, Jr., Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J.

Markov model projection of remission status for early vs. delayed step-up adalimumab use in moderate to severe Crohn’s disease.

*Abstract:* 2010 Advances in Inflammatory Bowel Diseases Crohn’s and Colitis Foundation’s National Clinical and Research Conference Hollywood, FL United States.
*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

C-reactive protein levels in moderate to severe crohn’s disease patients decreased rapidly and significantly during adalimumab therapy.

*Abstract:* 76th Annual Scientific Meeting of the American College of Gastroenterology Washington, DC United States.
*Authors:* Ghosh S, Wu E, Bensimon A, Mulani P, Yang M, Chao J.
A retrospective comparison of health care outcomes in Crohn’s disease patients with and without prolonged steroid monotherapy.

Authors: Siegel CA, Yang HY, Yu AP, Yang M, Mulani PM, Chao J.

The economic and quality of life burden of illness in chronic constipation (CC) and irritable bowel syndrome (IBS): A systematic review.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States.
Authors: Yee K, Nellesen D, Chawla A, Carson R, Lewis B.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).

Authors: Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn’s disease.

Authors: Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

Racial differences in use of biologics for crohn’s disease in a Medicaid population.

Authors: Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

Impact of induction dosing on maintenance outcome with adalimumab in Crohn’s disease.


The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy.

Publication: Alimentary Pharmacology and Therapeutics 2010 11; 32(10): 1228-1239
Authors: Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD.

Systematic review: the costs of ulcerative colitis in Western countries.

Publication: Alimentary Pharmacology and Therapeutics 2010 04; 31(7): 693-707
Authors: Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).

Abstract: 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX United States.
Authors: Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.
Markov model projection of remission status for early vs. delayed step-Up Adalimumab use in moderate to severe crohn’s disease.

Abstract: 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX United States.
Authors: Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

Racial differences in use of biologics for crohn’s disease in a Medicaid population.

Abstract: 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX United States.
Authors: Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

T1065 Impact of Nighttime Symptoms (NTS) on Treatment Patterns and Healthcare Costs Among Gastroesophageal Reflux Disease (GERD) Patients.

Abstract: Digestive Disease Week, New Orleans, LA.
Authors: Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, Chey WD.

M1047 Quality-of-Life Benefits for Adalimumab-Treated Patients with Moderate to Severe Crohn’s Disease are Predicted by Early Mucosal Healing Status.

Abstract: Digestive Disease Week, New Orleans, Louisiana.
Authors: Rutgeerts PJ, Thakkar R, Wu EQ, Kaltenboeck A, Yang M, Mulani P, Chao J.

Impact of compliance with proton pump inhibitors on NSAID treatment.

Publication: American Journal of Managed Care 2009 10; 15(10): 681-688
Authors: Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA.

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease.

Publication: European Journal of Gastroenterology and Hepatology 2009 11; 21(11): 1302-1309
Authors: Loftus EV, Jr., Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.

Publication: Current Medical Research and Opinion 2009 11; 25(11): 2703-2709
Authors: Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial.

Publication: American Journal of Gastroenterology 2009 05; 104(5): 1170-1179

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.

Abstract: International Society for pharmacoconomics and Outcomes Research.
Authors: Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.


Publication: Current Medical Research and Opinion 2009 08; 25(8): 1869-1878
Authors: Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M.

Adalimumab Therapy is Associated with Improvements in Clinical Laboratory Parameters in Patients with Moderately to Severely Active Crohn’s Disease.

Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.

**Publication:** Journal of Medical Economics 2009 10; 12(4): 348-355

**Authors:** Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Cost-effectiveness analysis of adalimumab vs. certolizumab maintenance therapies for moderate to severe Crohn's disease.

**Abstract:** ISPOR 14th Annual International Meeting, Orlando, FL United States.

**Authors:** Jonasson S, Kaltenboeck A, Horn C, Mulani P, Majethia S, Chao J.

Number-needed-to-treat (NNT) analysis: Remission rates for adalimumab vs. Infliximab in Crohn’s disease.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States.

**Authors:** Jonasson S, Kaltenboeck A, Horn C, Wu E, Majethia S, Mulani P, Chao J.

S1030 Increased Risk of Psychiatric Disorders in Young Patients with Crohn’s Disease.

**Abstract:** Digestive Disease Week Annual Conference, Chicago, IL.

**Authors:** Loftus EV, Guérin A, Yu AP, Wu E, Chao J, Mulani P.

S1136 Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn’s Disease.

**Abstract:** Digestive Disease Week Annual Conference, Chicago, IL.

**Authors:** Rubin DT, Bensimon AG, Yu AP, Wu E, Chao J, Mulani P.

P246-Young patients with Crohn’s disease are at increased risk for psychiatric disorders.

**Abstract:** European Crohn’s & Colitis Organisation 4th Congress, Hamburg, Germany.

**Authors:** Loftus E, Guérin A, Yu A, Wu E, Chao J, Mulani P.

Rate of dosage escalation in patients with crohn’s disease treated with infliximab.

**Abstract:** Canadian Digestive Diseases Week 2009, Banff, AB Canada.

**Authors:** Plevy S, Wu E, Yu A, Chao J, Mulani P.

Corrigendum: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn’s Disease: Patient-Reported Outcomes of the CHARM Trial.

**Publication:** The American journal of gastroenterology 2009 104(7)

**Authors:** Loftus EV, Feagan BG, Colombel J-F, Rubin DT, Wu EQ, Yu AP, Pollack PF, JINGDONG C, Mulani P.

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease.

**Publication:** Pharmacoeconomics 2009 08; 27(7): 609-621

**Authors:** Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM.

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study.

**Publication:** Gastroenterology 2008 11; 135(5): 1493-1499


The costs of Crohn’s disease in the United States and other Western countries: a systematic review.

**Publication:** Current Medical Research and Opinion 2008 02; 24(2): 319-328

**Authors:** Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J.
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial.
Publication: American Journal of Gastroenterology 2008 12; 103(12): 3132-3141
Authors: Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Adalimumab maintenance therapy for patients with Crohn’s Disease is cost effective compared with nonbiologic maintenance therapy: P-0074.

Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist–Naïve Patients with Crohn’s Disease.
Abstract: American College of Gastroenterology 2008 Annual meeting, Orlando, FL.
Authors: Loftus E, Feagan B, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

Health-Related Quality Of Life in TNF-Antagonist–Naïve Patients with Crohn’s Disease during Short- and Long-Term Adalimumab Treatment.
Abstract: American College of Gastroenterology 2008 Annual meeting, Orlando, FL.
Authors: Rubin D, Rutgeerts P, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

Infliximab Dosage-Increase Rate in Patients with Crohn’s Disease.
Abstract: American College of Gastroenterology 2008 Annual meeting, Orlando, FL.
Authors: Plevy S, Wu EQ, Yu A, Chao J, Mulani P.

Loss of treatment response to infliximab maintenance therapy in Crohn’s disease: a payor perspective.
Publication: Value in Health 2008 09; 11(5): 820-829
Authors: Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF.

Adalimumab maintenance therapy is cost effective for maintaining remission in patients with Crohn’s disease.

Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn’s Disease.
Authors: Kane S, Wu EQ, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

M1033 Nighttime Symptoms and Sleep Impairment Among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs).
Abstract: Digestive Week, San Francisco, CA.
Authors: Chey WD, Mody R, Chen L, Kothari S, Persson B, Wu E, Lu M.

M1041 Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)?: A Community-Based US Survey Study.
Abstract: Digestive Week, San Diego, CA.
Authors: Chey WD, Mody R, Kothari S, Wu E, Chen L, Persson B, Beaulieu N, Lu M.

T1061 Improvement in short inflammatory bowel disease questionnaire scores in adalimumab-treated Crohn’s disease patients who failed infliximab (CHOICE trial).
Abstract: Digestive Disease Week, San Diego, CA.
Authors: Lichtiger S, Present DH, Wu E, Beaulieu N, Kent JD, Lomax KG, Chao J, Mulani P.
T1062 Improvement in Work Productivity with Adalimumab in Crohn’s Disease Patients Who Failed Prior Infliximab: An Analysis of the CHOICE Trial.
Abstract: Digestive Disease Week, San Diego, CA.
Authors: Lichtiger S, Present DH, Persson B, Wu E, Kent JD, Lomax KG, Chao J, Mulani P.

T1197 A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn’s Disease.
Abstract: Digestive Disease Week, San Diego, CA.
Authors: Loftus EV, Colombel J-F, Johnson SJ, Wu E, Chao J, Mulani P.

Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn’s disease.
Publication: Managed Care Interface 2008 21: 20-23
Authors: Wu E, Yu A, Tang J, Atanasov P, Chao J, Mulani P.

An evaluation of adalimumab on the risk of hospitalization in patients with Crohn’s disease, data from CHARM: O-007.
Publication: Inflammatory Bowel Diseases 2008 01; 14: S2-S3

PGI17 Adherence to infliximab maintenance therapy and its impact on hospitalization of patients with crohn’s disease.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Kane S, Wu E, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study.
Abstract: American College of Gastroenterology (ACG), Philadelphia, PA.
Authors: Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H.

Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens.
Abstract: American College of Gastroenterology (ACG), Philadelphia, PA.
Authors: Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Lu M.

Impact of adalimumab (HUMIRA (R)) on Patient-Reported Outcomes among Patients with Fistulizing Crohn’s Disease in the CHARM Trial.
Abstract: American College of Gastroenterology (ACG), Philadelphia, PA.
Authors: Colombel JF, Wu EQ, Yu AP.

Lower Disease Activity And Clinical Remission Are Associated with Reduced Hospitalization Risk In Crohn’s Disease.
Abstract: ISPOR 12th International Meeting, Arlington, VA.
Authors: Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM.

PGI13 Lower disease activity and clinical remission are associated with reduced hospitalization risk in crohn’s disease.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.

**Publication:** Pharmacoepidemiology and Drug Safety 2006 01; 15(1): 47-56

**Authors:** Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM.

Loss of Treatment Response among Crohn’s Disease Patients Receiving Infliximab Maintenance Therapy.

**Abstract:** Academy of Managed Care Pharmacy, 2006.

**Authors:** Wu EQ, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P.

The economic consequences of irritable bowel syndrome: a US employer perspective.

**Publication:** Archives of Internal Medicine 2003 04; 163(8): 929-935

**Authors:** Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ.

Productivity Loss Due to Irritable Bowel Syndrome—Reply

**Publication:** 2003

**Authors:** Greenberg P, Birnbaum H, Leong S, Pike C, Ben-Hamadi R, Barghout V, Frech F, Ofman J.

Alternative Management Strategies for Dyspepsia.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research.

**Authors:** Wu E, Hay J.

---

**Hematology**

Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.

**Publication:** Leukemia and Lymphoma 2017 09: 1-10

**Authors:** Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L.

Disease-stratified adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.

**Publication:** Value in Health 2017 20 (5): A232

**Authors:** Cheng WY, Duh MS, Xiao Y, Cole A, Hao Y, Vekeman F, Bobbili PJ, Blinder M.

A Risk Score for Fluconazole Failure among Patients with Candidemia.

**Publication:** Antimicrobial Agents and Chemotherapy 2017 05; 61(5)

**Authors:** Ostrosky-Zeichner L, Harrington R, Aziz N, Yang H, Li N, Zhao J, Koo V, Wu EQ.

Value of transfusion independence in severe aplastic anemia from patients’ perspectives—a discrete choice experiment.

**Abstract:** ISPOR 22nd Annual European Congress, Boston, MA.

**Authors:** Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Muhlacher AC, Roy A, Duh MS.

Impact of U.S. FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous hematopoietic stem cell transplant on total healthcare costs.

**Abstract:** 22th Congress of the European Hematology Association. Spain, Madrid, Spain.

**Authors:** Parikh K, Xie J, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

Mediation by patient-reported outcomes on the association between film-coated versus dispersible formulations of deferasirox and serum ferritin reduction: A post hoc analysis of the eclipse trial.

**Publication:** Haematologica 2017 07; 102: 87

**Authors:** Taher AT, Origa R, Perrotta S, Kourakis A, Belhoul K, Huang V, Han J, Bruderer A, Bobbili P, Duh MS, Porter JB.
Real-world adherence to iron chelation therapy: Comparing a film-coated tablet versus dispersible tablet of deferasirox.


Authors: Cheng W, Xiao Y, Bobbili P, Coe A, Hao Y, Paley C, Said Q, Huang V, Duh MS, Blinder M.

Achievement of Glycated Hemoglobin Goals in the US REMAINS UNCHANGED THROUGH 2014.

Publication: Diabetes Therapy 2017 06;

Authors: Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia A patients treated with BAY 81-8973.

Publication: Haemophilia 2017 04; 23: 34-36


Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia A patients treated with BAY 81-8973.

Abstract: 69th Annual National Hemophilia Foundation meeting (NHF) Meeting Chicago, IL


Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.

Publication: Journal of Medical Economics 2017 20(4): 337-344

Authors: Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.

Publication: Haemophilia. 2017

Authors: Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.

Publication: Journal of Medical Economics 2016 03; 19(3): 292-303

Authors: Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.

Publication: J Comp Eff Res 2016 03; 5(2): 129-139


Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

Publication: Leukemia 2016 04; 30(4): 995-998

Authors: Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lefevre MH, Lefevre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.

Epidemiologic and clinical characteristics of thalassemia (THAL) intermedia (TI) in the US.


Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 (Date of Publication: May 2016), United States.


Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Abstract: European Association for the Study of the Liver, (EASL) 50th International Liver Congress, Vienna, Austria.


Daclatasvir and Sofosbuvir versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Publication: Clinical Therapeutics 2016 38(2): 404-412


Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.

Publication: Journal of Blood Medicine 2016 07; 7: 129-137

Authors: Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.

Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.

Publication: Journal of Emergency Medicine 2015 10; 49(4): 513-522 e511

Authors: Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.

Publication: Leukemia and Lymphoma 2015 03; 56(10): 2803-2811

Authors: Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.

Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII FC fusion protein and conventional recombinant factor VIII.

Abstract: ISPOR 18th Annual European Congress. Milan Italy., Milan, Italy.

Authors: Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.

Publication: Current Medical Research and Opinion 2015 03; 31(3): 513-523


Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.

Publication: Clinical Therapeutics 2015 06;

Authors: Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.
Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318

*Authors:* Le TK, Kalsekar A, Macauley D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

Epidemiologic and clinical characteristics of thalassemia intermedia in the United States.

*Abstract:* 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL.


The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.

*Abstract:* 57th ASH Annual Meeting and Exposition.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanava M, Wu E.

Patterns of prior treatment and bleeds among patients with severe hemophilia a: Impact on frequency of dosing with bay 81-8973 in the leopold I trial.

*Abstract:* 57th Annual Meeting of the American Society of Hematology, ASH 2015, San Diego, CA

*Authors:* Church N, Ayyagari R, Pocoski J, Sajeev G, Kelkar SS, Du EX, Mass-Enriquez M, Xie J.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfected with HIV: A matching-adjusted indirect comparison.


Factor consumption for prophylaxis and treatment of bleeding: Recombinant factor IX FC fusion protein compared with conventional recombinant factor IX.

*Abstract:* ISPOR 18th Annual European Congress., Milan, Italy.

*Authors:* Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products.

*Abstract:* 25th Congress of the International Society on Thrombosis and Haemostasis, ISTH 2015., Toronto, ON Canada.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products.

*Abstract:* 25th Congress of the International Society on Thrombosis and Haemostasis, ISTH 2015, Toronto, ON Canada.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with thalassemia.


*Authors:* Vekeman F, Sasane M, Cheng WY, Agnihotram RV, Fortier J, Duh MS, Paley C, Adams-Graves P.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.

*Abstract:* ISPOR 20th Annual International Meeting, Philadellphia, PA.

*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.
Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.


A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV) - and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.


Authors: Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Comparative efficacies and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.


Authors: Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

Economic consequences of cytomegalovirus disease among stem cell transplant recipients.

Abstract: 2015 BMT Tandem Meetings San Diego, CA United States.

Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snydman DR.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Publication: Clinical Lymphoma, Myeloma & Leukemia 2014 10; 14(5): 380-388

Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

A cost-analysis model for anticoagulant treatment in the hospital setting.

Publication: Journal of Medical Economics 2014 07; 17(7): 492-498

Authors: Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.

Publication: Journal of Medical Economics 2014 12; 17(12): 862-871

Authors: Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease.


Authors: Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Duh MS, Paley C, Adams-Graves P.

Associations between joint damage and quality of life among patients with severe hemophilia a in the 3-year spinart trial.


Authors: Pocoski J, Lin PL, Hong W, Kelkar SS, Jiao T, Du EX, Humphries TJ, Xie J.

Subcutaneous (SQ) bortezomib (BTZ) in patients (PTS) with relapsed mantle cell lymphoma (MCL): Retrospective, observational study of treatment patterns and outcomes in US community oncology practices.


Authors: Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, Ng Y, Van De Velde H, Dow E, Niculescu L, Bonthapally V, Goy A.
Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.

Authors: Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Associations between clinical outcomes, health care resources utilization, and quality of life among patients with severe hemophilia A.

Abstract: World Federation of Hemophilia, WFH 2014 World Congress Melbourne, VIC Australia.
Authors: Lin PL, Pocoski J, Du EX, Kelkar SS, Silberman C, Xie J.

High cost patients and cost patterns from pediatric to adult care in a Medicaid population with sickle cell disease.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

High utilizers of health care resources: Results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.

Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

An indirect comparison of the efficacy of prophylactic use of rF VIII Fc and other rFVIII products and model of the effect of compliance.

Abstract: World Federation of Hemophilia, WFH 2014 World Congress Melbourne, VIC Australia.
Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness.

Abstract: World Federation of Hemophilia, WFH 2014 World Congress Melbourne, VIC Australia.
Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: Simulating the effect of compliance on real-world effectiveness.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis modeling the effect of compliance.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R.
Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Publication: Pediatric Blood & Cancer 2013 05; 60(5): 828-835
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM).


Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
Authors: Tandon N, Balart L, Laliberté F, Pilone D, Lefebvre P, Prabhakar A.

Medical complications in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
Authors: Vekeman F, Cheng WY, Sasane M, Huynh L, Kaminsky M, Duh MS, Paley C, Mesa RA.

Transition from pediatric to adult care of high cost patients in a Medicaid population with sickle cell disease.
Authors: Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

Age-related emergency department reliance (EDR) and healthcare resource utilization in patients with sickle cell disease (SCD).
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Montreal, QC Canada.
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Final results from the multicenter compact study of complications in patients with sickle cell disease (SCD) and utilization of iron chelation therapy: A retrospective medical records review.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference, Montreal, QC Canada.

Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.
Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD).

Authors: Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Direct and indirect cost burden of chronic hepatitis C infection in privately-insured patients, stratified by liver disease severity.

Abstract: ISPOR 18th Annual International Meeting New Orleans, LA

Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.

Abstract: Digestive Disease Week (DDW) 2013, Orlando, FL.

Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders.

Authors: Jordan L, Duh MS, Vekeman F, Matter S, Bieri C, Sasane M.

Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.

Publication: Current Medical Research and Opinion 2012 01; 28(1): 79-87
Authors: Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.

Publication: Journal of Clinical Pharmacy and Therapeutics 2012 04; 37(2): 173-181
Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Age-related emergency department reliance and healthcare resource utilization in patients with sickle cell disease.

Abstract: 54th Annual Meeting of the American Society of Hematology, ASH 2012 Atlanta, GA United States.
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Dynamics of improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP) in EXTEND.

Abstract: 54th Annual Meeting of the American Society of Hematology, ASH 2012 Atlanta, GA United States.
Authors: Grotzinger KM, Bussel JB, Saleh MN, Bieri C, Orlova Y, Brainsky A.

Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.


Development and validation of a classification algorithm for prophylactic vs. on-demand factor VIII therapy in patients with hemophilia a.

Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.


Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.


Authors: Vekeman F, Pocoski J, Cheng W, Trahey A, Sarda SP, Valluri S, Preblick R, Duh MS.

Improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP): Results of extend from june 2006 to february 2011.

Abstract: 17th Congress of the European Hematology Association Conference Amsterdam Netherlands.

Authors: Grotzinger K, Bieri C, Olney H, Saleh M, Sheng Duh M, Brainsky A.

Interim results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.

Abstract: 17th Congress of the European Hematology Association Amsterdam Netherlands.


Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

Publication: Journal of Medical Economics 2012 01; 15(2): 352-360

Authors: Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.

Age-related blood transfusion patterns in patients with Sickle Cell Disease (SCD) and the association with sickle cell complications.


Authors: Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

Age-related iron chelation utilization and healthcare costs in patients with Sickle Cell Disease (SCD).


Authors: Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

Preoperative hemoglobin levels, characteristics, and resource utilization in total hip replacement patients with an anemia diagnosis versus without an anemia diagnosis: An electronic medical record analysis.


Authors: Forlenza JB, Ellis L, Parise H, Lafeuille MH, Lefebvre P.

Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD.

Authors: Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

Transfusional iron overload (TIO) monitoring and treatment: Findings from an electronic medical records review study at the moffitt cancer center and research institute.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD United States.

Authors: Duh MS, Wetzstein G, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray L.
Risk of venous thromboembolism complications.

Authors: Lefebvre P, Laliberte F, Nutescu E, Duh MS, Lamori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

The economics of the hematopoietic growth factors.

Publication: Cancer Treatment and Research 2011 11; 157: 403-418
Authors: Eldar-Lissai A, Lyman GH.

Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.

Publication: Annals of Pharmacotherapy 2010 03; 44(3): 595; author reply 595-596
Authors: Lefebvre P, Vekeman F, Cremieux PY.

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.

Publication: Journal of Cancer Research and Therapeutics 2010 01; 6(1): 31-35
Authors: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

Publication: Transfusion 2010 01; 50(1): 190-199
Authors: Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.

Publication: Consultant Pharmacist 2010 08; 25(8): 493-500
Authors: Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

Monitoring and treatment of transfusional iron overload: Findings from an electronic medical records review study at the Moffitt cancer center and research institute.

Abstract: 52nd Annual Meeting of the American Society of Hematology, ASH 2010 Orlando, FL United States.

Monitoring and treatment among patients with transfusional iron overload: Preliminary findings from an electronic medical records review study at H. Lee moffitt cancer center and research institute.

Abstract: 2010 Annual Meeting of the American College of Clinical Pharmacy, ACCP 2010., Austin, TX United States.
Authors: Ray LA, Wetzstein GA, Korves C, Wang ST, Clinton B, Wei R, Corral M, Duh MS.

Persistence and compliance of deferoxamine (DFO) versus deferasirox (DFX) in Medicaid patients with sickle-cell disease (SCD).

Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD).

Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
Publication: Transfusion 2009 05; 49(5): 895-902
Authors: Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Publication: Journal of Medical Economics 2009 03; 12(1): 1-8
Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Publication: Cancer 2009 02; 115(4): 706-715
Authors: Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

The cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.
Authors: Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Kakara A, Van De Velde H, Esseltine DL, Garrison L.

Persistence and compliance of deferoxamine versus deferasirox in medicaid patients with sickle-cell disease.
Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Authors: Duh MS, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Baraghout V, Hanea ML.

Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.
Authors: Skarin AT, Vekeman F, Laliberté F, Afonja O, Lafeuille MH, Baraghout V, Duh MS.

Association of health-related quality of life (HRQoL), bleeding, and platelet levels in chronic idiopathic thrombocytopenic purpura (itp): Results from RAISE and EXTEND.
Abstract: 14th Congress of the European Hematology Association Berlin Germany.
Authors: Bussel J, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Brainsky A.

Improvement in fatigue and health-related quality of life (HRQoL) with long-term Eltrombopag therapy in chronic idiopathic thrombocytopenic purpura: results of phase 3, double-blind study (raise).
Abstract: 14th Congress of the European Hematology Association Conference Berlin Germany.
Authors: Provan D, Bussel JB, Cheng G, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

Improvement in fatigue and health-related quality of life with long-term Eltrombopag treatment in adults with chronic idiopathic thrombocytopenic purpura: The EXTEND study.
Abstract: 14th Congress of the European Hematology Association Conference Berlin Germany.
Authors: Bussel J, Saleh M, Salama A, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.
Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.

Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Duh MS, Toy EL, Vekeman F, Laliberte F, Dorlante BL, Perlman D, Barghout V, Heaney ML.

Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Vekeman F, Laliberte F, Afonja O, Laffaille MH, Barghout V, Duh MS, Skarin AT.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: Data from multi-center clinical practices.

Abstract: ISPOR 14th Annual International Meeting Orlando, FL United States.
Authors: Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.


Publication: Annals of Hematology 2008 07; 87(7): 527-536
Authors: Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S.

Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.

Publication: Annals of Pharmacotherapy 2008 01; 42(1): 16-23
Authors: Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.

Anaemia and the risk of injurious falls in a community-dwelling elderly population.

Publication: Drugs and Aging 2008 04; 25(4): 325-334
Authors: Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT.


Publication: Pharmacoeconomics 2008 01; 26(2): 99-120
Authors: Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE.

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.

Publication: American Journal of Health-System Pharmacy 2007 09; 64(18): 1943-1949
Authors: Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer’s perspective.

Publication: Journal of Health & Productivity 2007 10: 309
Authors: Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?

Publication: Hepatology 2007 07; 46(1): 283; author reply 283-284
Authors: Wu WK, Duh MS, Lefebvre P.
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.
*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.
*Authors:* Cremieux P, Vekeman F, Lefebvre P.

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
*Publication:* Clinical Therapeutics 2006 09; 28(9): 1443-1450
*Authors:* Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
*Publication:* Current Medical Research and Opinion 2006 09; 22(9): 1623-1631
*Authors:* Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.
*Publication:* Clinical Therapeutics 2006 10; 28(10): 1701-1708
*Authors:* Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives.
*Authors:* Duh MS, Latypova A, Greenberg P.

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
*Publication:* Current Medical Research and Opinion 2006 10; 22(10): 1929-1937
*Authors:* Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
*Publication:* Journal of Supportive Oncology 2006 05; 4(5): 243-250
*Authors:* Chu E, Einhorn LH, Lefebvre P.

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
*Publication:* Journal of the American Society of Nephrology 2006 12; 17(12): 3497-3502
*Authors:* Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.
*Publication:* P AND T 2006 31(10); 594
*Authors:* Gosselin A, McKenzie R, Lifebvre P, Mody S, Piech C, Duh M.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
*Publication:* Drugs and Aging 2006 12; 23(12): 969-976
*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.
Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.

*Publication:* Pharmacoeconomics 2006 05; 24(5): 479-494  
*Authors:* Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.

**Health-Related Quality Of Life of Anemia Patients in the U.S.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific.  
*Authors:* Cremieux P, Xie J, Wu EQ, Castor A.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1677-1682  
*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1527-1533  
*Authors:* Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.

*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J.

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.

*Publication:* Oncologist 2005 06; 10(6): 438-448  
*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.

*Authors:* Duh MS, L Mark T.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis.

*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.

*Publication:* Journal of Managed Care Pharmacy 2004 11; 10(6): 531-537  
*Authors:* Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?

*Publication:* Critical Care Medicine 2004 32(3): 666-674  
*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH.

The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.

*Publication:* Critical Care Medicine 2004 01; 32(1): 39-52  
*Authors:* Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ.
PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.
Publication: Journal of Clinical Oncology 2002 06; 20(11): 2757-2758
Authors: Gabrilove JL, Sarokhan B, Cremieux P.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
Publication: Cancer 2002 08; 95(4): 888-895
Authors: Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Anemia-related costs for cancer patients.
Publication: Journal of Managed Care Medicine 2002 6(1); 20-28
Authors: Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

Cost Effectiveness of rHuEPO in Oncology.
Publication: Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer 2002
Authors: Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

Costs Associated with Anemia and Cancer.
Authors: Cremieux PY GM, Holland M, Slavin MB.

Publication: Pharmacoeconomics 1999 11; 16(5 Pt 1); 459-472
Authors: Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

Infectious Diseases

A claims-based analysis of hepatitis a, b, and a/b vaccination series completion and compliance among US adults.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.
Authors: Patterson BJ, Cheng WY, Trofa AF, Duchesneau ED, Macheca M, Masseria C, Duh MS.

Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.
Publication: PLoS Medicine 2017 07; 14 (7) (no pagination)(e1002357)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Publication: Advances in Therapy 2017 01; 34(1); 207-220
Authors: Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.
The Impact of a Community-Based Intervention Including a Monthly Food Ration on Food Insecurity Among HIV-Positive Adults During the First Year of Antiretroviral Therapy.
Publication: AIDS and Behavior 2017 08;
Authors: Rothman J, Kayigamba F, Hills V, Gupta N, Machara F, Niyigena P, Franke MF.

Assessing Patient Preferences for and Relative Importance of Features of New Direct Acting Antiviral (DAA) Treatments for Chronic Hepatitis C Virus (HCV) Infections.
Abstract: American Association for the Study of Liver Disease 68th Annual Meeting, Washington, DC.
Authors: Welzel TM, Yang M, Sajeev G, Pinsky B, Mehta D, Bao Y, Wu E, Chen YJ.

Real-world burden of care for patients with chronic hepatitis C before, during and after treatment with novel direct-acting antiviral agents (DAAs).
Abstract: Academy of Managed Care Pharmacy (AMCP) Nexus 2017, Dallas, TX.
Authors: Yang M, Mu F, Macaulay D, Kort JJ, Chen YJ.

Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.
Publication: Human Vaccines & Immunotherapeutics 2016 05; 12(5): 1235-1243
Authors: Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
Publication: J Comp Eff Res 2016 05; 5(3): 273-279
Authors: Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Publication: J Comp Eff Res 2016 03; 5(2): 129-139

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.
Publication: Antimicrobial Agents and Chemotherapy 2016 06; 60(6): 3398-3406

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.
Publication: BMC Infectious Diseases 2016 12; 16(1): 730

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for the treatment of chronic hepatitis c genotype 1 in Japanese patients: A matching-adjusted indirect comparison.
Abstract: 18th European Congress of the International Society for Pharmacoconomics and Outcomes Research, Milan, Italy.
Authors: Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G.

Comparative hepatotoxicity of echinocandins in hospitalized patients (pts): A retrospective cohort study.
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Abstract: European Association for the Study of the Liver, (EASL) 50th International Liver Congress, Vienna, Austria.


Indirect comparison of daclatasvir+asunaprevir vs sofosbuvir/ledipasvir for HCV in Japanese patients.

Abstract: 25th APASL Conference, Tokyo, Japan.

Authors: Swallow E, Kelley C, Signorovitch J, McPhee F, Wygant G.

Predictors of CD4 count recovery in the CIPRA HT-001 trial of early ART.

Abstract: 23rd Conference on Retroviruses and Opportunistic Infections, CROI 2016, United States.

Authors: Collins SE, Calnan M, Juste MAJ, Severe P, Secours R, Bernard D, Batavia A, Fitzgerald DW, Koenig SP, Pape JW.

Daclatasvir and Sofosbuvir versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Publication: Clinical Therapeutics 2016 38(2): 404-412


Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.

Publication: PloS One 2016 01; 11(1): e0145977

Authors: Krishnarajah G, Duh MS, Korves C, Demissie K.

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.

Publication: J Comp Eff Res 2015 11; 4(6): 593-605

Authors: Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.

Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.

Publication: Clinical Therapeutics 2015 06;

Authors: Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

Simulations Show Diagnostic Testing For Malaria In Young African Children Can Be Cost-Saving Or Cost-Effective

Publication: Health Affairs 2015 07; 34(7): 1196-1203

Authors: Phillips V, Njau J, Li S, Kachur P.

CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.


The epidemiology of herpes zoster and its complications in Medicare cancer patients.

Publication: BMC Infectious Diseases 2015 02; 15: 106

Authors: Yenikomshian MA, Guignard AP, Haguinet F, LaCasse AS, Skarin AT, Trahey A, Karner P, Duh MS.
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.

*Publication:* Journal of Acquired Immune Deficiency Syndromes 2015 08; 69(4): 413-421


Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318

*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfected with HIV: A matching-adjusted indirect comparison.


Association of Obesity with 30-day readmission rates among patients Hospitalized with Acute Bacterial Skin and Skin-Structure Infections (ABSSI).

*Abstract:* ISPOR 20th Annual International Meeting Research Philadelphia, PA.

*Authors:* Ayyagari R, Revol C, Tang W, Faust E, Tuttle EG.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA.

*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2015 Vienna Austria.


Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection.

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2015, Vienna Austria.


A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)-and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.

*Abstract:* ISPOR.20th Annual International Meeting, Philadelphia, PA.

*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.


*Authors:* Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.
Economic consequences of cytomegalovirus disease among stem cell transplant recipients.

Abstract: 2015 BMT Tandem Meetings San Diego, CA United States.
Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snydman DR.

A second look at the association between gender and mortality on antiretroviral therapy.
Publication: PloS One 2015 11; 10 (11) (no pagination)(e0142101)
Authors: Koenig SP, Bornstein A, Severe K, Fox E, Devieux JG, Severe P, Joseph P, Marcelin A, Bright DA, Pham N, Cremieux P, Pape JW.

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Publication: Appl Health Econ Health Policy 2014 02; 12(1): 85-93
Authors: Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Publication: Journal of Medical Economics 2014 12; 17(12): 862-871
Authors: Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

Demographics and clinical characteristics associated with high healthcare resource utilization (hru) and costs among chronic hepatitis c (chc) patients.
Abstract: American Association for the Study of Liver Diseases (AASLD) Annual Meeting Boston, MA.
Authors: LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

The pharmacoeconomics review of 7-valent pneumococcal conjugate vaccination in Asian-pacific region.
Authors: Zhu L.

Cost burden of cytomegalovirus (CMV) disease among solid organ transplant recipients.

Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.
Authors: Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C.
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada.
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection.
Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J.

Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
Authors: Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.
Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.
Treatment patterns, health care resource utilization and costs in United States patients diagnosed with chronic hepatitis C infection.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ.

Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.
Publication: Human Vaccines & Immunotherapeutics 2014 11; 10(8): 2255-2266
Authors: Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.
Publication: Circulation 2013 09; 128(13): 1412-1419
Authors: Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
Authors: Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

The epidemiology of herpes zoster (HZ) and its complications in Medicare cancer patients.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, QC Canada.
Authors: Yenikomshian MA, La Casce AS, AT. S, Trahey A, Guignard A, Haguinet FF, Karner PE, Duh MS.

Budget impact analysis of liposomal amphotericin b and amphotericin b lipid complex for treating invasive fungal infections in hospitalized patients.
Abstract: ISPOR 18th Annual International Meeting New Orleans, LA United States.
Authors: Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ.

Direct and indirect cost burden of chronic hepatitis C infection in privately-insured patients, stratified by liver disease severity.
Abstract: ISPOR 18th Annual International Meeting New Orleans, LA

Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.
Abstract: Digestive Disease Week (DDW) 2013, Orlando, FL.

Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.
Abstract: ISPOR 18th Annual International Meeting New Orleans, LA United States.
Authors: Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.
Direct and indirect cost burden is higher in HCV infection compared with a matched nonHCV infected cohort in a privately-insured population.


Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials.


Authors: Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States.


Authors: Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D.

PIH14 Rates and Predictors of Chlamydia re-Screening among Privately insured Patients with Chlamydia in 2007-2009.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.

Authors: Shi L, Liu J, Kissinger P, Khan M, Wu E.

Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.


Authors: Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.


Abstract: ISPOR 14th Annual European Congress Madrid Spain.

Authors: Shi L, Liu J, Kissinger P, Khan M, Wu EQ.

Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications.

Publication: Pain Medicine 2010 03; 11(3): 369-378

Authors: Michna E, Duh MS, Korves C, Dahl JL.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?

Publication: Hepatology 2007 07; 46(1): 283; author reply 283-284

Authors: Wu WK, Duh MS, Lefebvre P.

Lower respiratory tract infections: impact on the workplace.

Publication: Pharmacoeconomics 2003 06; 21(10): 749-759

Authors: Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

Economic burden of respiratory infections in an employed population.

Publication: Chest 2002 08; 122(2): 603-611

Authors: Birnbaum HG, Morley M, Greenberg PE, Colice GL.
Neurology

The economic burden of bipolar I disorder in the United States in 2015.
Publication: Journal of Affective Disorders 2017 Accepted for publication Sept, 2017; 226: 45-51
Authors: Cloutier M, Greene M, Guerin A, Touya M, Wu E.

Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Publication: Journal of Medical Economics 2017 09; 1-19

Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
Authors: Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ.

Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
Publication: Current Medical Research and Opinion 2017 08; 33(10): 1763-1772

Publication: Journal of Medical Economics 2017 10; 20(10): 1056-1065
Authors: Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP.

Healthcare costs among patients with Lennox-Gastaut syndrome treated with clobazam.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.
Authors: Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Duh MS, Chatamra K, Kymes SM.

Healthcare resource utilization and costs among adult schizophrenia patients using once-monthly versus twice-monthly long-acting antipsychotics.
Abstract: ISPOR 22nd Annual International Meeting, Boston, MA.
Authors: Benson C, Alcusky M, Pilon D, Durkin M, Xiao Y, Thompson-Leduc P, Lafeuille M, Lefebvre P.

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
Publication: BMC Psychiatry 2017 06; 17(1): 222

Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.
Publication: Epilepsy & Behavior 2017 06; 73: 46-50
Authors: Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguerre-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J.

A systematic literature review and metaanalysis of epidemiologic studies in chronic and episodic migraine.
Abstract: 3rd Congress of the European Academy of Neurology, Netherlands.
Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.

**Publication:** Epilepsia 2017 In Press


**Publication:** Clinical Therapeutics 2017 07; 39(7): 1380-1395 e1384

**Authors:** Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y.

Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.

**Publication:** J Manag Care Spec Pharm 2017 07; 23(7): 771-780

**Authors:** Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S.

Real-world costs of ischemic stroke by discharge status.

**Publication:** Current Medical Research and Opinion 2017 02; 33(2): 371-378

**Authors:** Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ.

Health care resource utilization before and after perampanel initiation for the treatment of epilepsy in the united states.

**Abstract:** 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Canada.

**Authors:** Faught E, Laliberte F, Wang Z, Barghout V, Choi J, Haider B, Lejeune D, Germain G, Duh MS.

Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.

**Abstract:** 21st Annual Scientific Meeting of the Heart Failure Society of America, HFSA 2017, Gravevine, TX.

**Authors:** Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.

**Publication:** European Child and Adolescent Psychiatry 2017 03; 26(8): 875-897

**Authors:** Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.

**Publication:** Current Medical Research and Opinion 2017 04; 33(4): 631-638

**Authors:** Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.

**Publication:** Current Medical Research and Opinion 2017 04; 33(4): 713-721

**Authors:** Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ.

Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study.

**Abstract:** American Academy of Neurology 69th Annual Meeting, Boston, MA.

**Authors:** Ye X, Kantor D, Barbato LM, Wakeford C, Yang M, Macaulay D, Marshall T.
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

**Publication:** Cns Drugs 2017 08; 1-12  
**Authors:** Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.

**Publication:** Patient Preference and Adherence 2017 03; 11: 619-629  
**Authors:** Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P.

Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.

**Abstract:** 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.17., Washington, DC.  
**Authors:** Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

**Publication:** European Journal of Health Economics 2017 01; 1-15  
**Authors:** Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

**Publication:** Current Medical Research and Opinion 2017 10; 33(10): 1891-1900  
**Authors:** Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

Adherence and Persistence on Long-acting Monotherapy and Combination Therapy in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) in the US.

**Abstract:** AMCP Nexus 201, Dallas, TX.  
**Authors:** Zhou Z, ZY Zhou, Kelkar SS, Xie J, Grebla R.

Economic burden of illness for patients with traumatic brain injury resulting in chronic motor impairment.

**Abstract:** 12th World Congress on Brain Injury of the International Brain Injury Association, New Orleans, LA.  
**Authors:** Swallow E, Liu WJ, Wen J, Fang A, Kirson N, Birnbaum H, Bates D.

Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey.

**Publication:** Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring 2017 02; 6: 65-74  
**Authors:** Desai U, Kirson NY, Enloe CJ, Ristovska L, King S, Birnbaum HG.

Healthcare resource utilization among patients with lennox-gastaut syndrome treated with clobazam.

**Abstract:** 69th American Academy of Neurology Annual Meeting, AAN.  
**Authors:** Pina-Garza JE, Montours GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Sheng Duh M, Isojarvi J, Kymes S, Saurer TB.

Impact of ocrelizumab vs. Interferon beta-1a in delaying the deterioration of patients’ daily functions and associated costs in relapsing-remitting multiple sclerosis.

**Abstract:** ISPOR 20th Annual European Congress, Glasgow, Scotland.  
**Authors:** Yang H, Duchesneau E, Guerin A, Ma E, Thomas NP.

Publication: Clinical Therapeutics. 2017 09;
Authors: Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.

Publication: Neuromuscular Disorders 2016 05; 26(9): 576-583
Authors: Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, Trajectory Analysis P.

Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

Publication: Am Health Drug Benefits 2016 10; 9(7): 399-410
Authors: Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pes J, Clancy Z, Fastenau J, Durkin M.


Publication: Journal of Clinical Psychiatry 2016 10; 77(10): e1332-e1341
Authors: Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population.

Publication: Journal of Alzheimer’s disease : JAD 2016 05;
Authors: Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.

Publication: Patient Prefer Adherence 2016 03; 10: 391-405
Authors: Joseph A, Cloutier M, Guerin A, Nitulescu R, Sikirica V.

Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.

Publication: Current Medical Research and Opinion 2016 03; 32(3): 405-416


Publication: Journal of Clinical Psychiatry 2016 06; 77(6): 764-771

Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists.

Publication: BMC Geriatrics 2016 07; 16: 138
Authors: Kirson NY, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Ye W, Andrews JS, Ball D, Kahle-Wrobleski K.

Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.

Publication: Neurological Sciences 2016 02; 37(2): 165-179
Authors: Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R.
Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.

*Publication:* Pharmacoepidemiology and Drug Safety 2016 25(4): 413-421  
*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the first-HD and tetra-HD trials.

*Authors:* Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.


*Abstract:* AMCP Nexus 2016 Annual Meeting, National Harbor, MD.  
*Authors:* Kantor D, Johnson K, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V.

Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare resource use and costs in veterans with schizophrenia with limited antipsychotic exposure in the prior 12 months.

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Ireland.  
*Authors:* Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak R, Kageleiry A, Duh MS, Shiner B, Young-Xu Y.

Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis.

*Abstract:* 20th International Congress of Parkinson’s Disease and Movement Disorders, Germany.  

Can indirect comparison methods mitigate evolving trial populations in adjunctive antiepileptic drug trials? A propensity score matched indirect comparison of brivaracetam and levetiracetam.

*Abstract:* ISPOR 21st Annual International Meeting Research Washington, DC  
*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

A life-course assessment of medication use and medical costs of lennox-gastaut syndrome (LGS).

*Abstract:* ISPOR 21st Annual International Meeting Research, Washington, DC  
*Authors:* Montouris G, Pina-Garza JE, Vekeman F, Cheng WY, Tuttle EG, Giguere-Duval P, Duh MS, Isojarvi J.

Real-world costs of ischemic stroke by discharge status.

*Abstract:* ISPOR 21st Annual International Meeting Research, Washington, DC  
*Authors:* Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ.

Association of Rescue Medication Use with Clinical Outcomes and Health Care Costs in Patients with Seizure Clusters.

*Abstract:* 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA.  

Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.

*Authors:* Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.
Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.

**Publication:** Neurology, 2016 06; 86(SUPPL. 1)

**Authors:** Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.


**Authors:** Fox E, Johnson K, Lin F, Signorovitch J, Li N, Peeples M, Ristovska L, Souroutzidis A, Hong W, Herrera V.

Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.

**Publication:** Current Medical Research and Opinion 2016 02; 32(4): 759-769

**Authors:** Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.

**Publication:** PloS One 2016 10; 11(10): e0164684

**Authors:** Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P.

Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research.

**Authors:** Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.

Patient and Caregiver Burden Associated with Fragile X Syndrome in the United States.

**Publication:** Am J Intellect Dev Disabil 2015 09; 120(5): 444-459

**Authors:** Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.

**Publication:** Journal of the Neurological Sciences 2015 10; 357(1-2): 8-18

**Authors:** Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R.

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.

**Publication:** Pharmacoeconomics 2015 10; 33(10): 1049-1067

**Authors:** Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM.

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.

**Publication:** Journal of Neurology 2015 07; 262(11): 2425-2432


Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.

**Publication:** J Comp Eff Res 2015 07; 4(6): 579-592

**Authors:** Xiao Y, Muser E, Lafeuille MH, Pes J, Fastenau J, Duh MS, Lefebvre P.
Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.

*Publication:* American Journal of Health-System Pharmacy 2015 03; 72(5): 378-389
*Authors:* Lafeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P.

Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.

*Publication:* Journal of Medical Economics 2015 06; 18(11): 919-929
*Authors:* Zhou ZY, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J.

Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.

*Publication:* Journal of Medical Economics 2015 06; 18(9): 711-720
*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Cox-Buckley B, Sarda S, Duh MS, Iyer R.

Medical costs of Alzheimer’s disease misdiagnosis among US Medicare beneficiaries.

*Publication:* Alzheimers Dement 2015 07;
*Authors:* Hunter CA, Kirson NY, Desai U, Cummings AK, Faries DE, Birnbaum HG.

The Growing Economic Burden of Depression in the U.S.

*Publication:* Scientific American MIND Guest Blog 2015 02;
*Authors:* Greenberg P.

The economic burden of adults with major depressive disorder in the United States (2005 and 2010).

*Publication:* Journal of Clinical Psychiatry 2015 02; 76(2): 155-162
*Authors:* Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC.

Development of a classifier to identify patients with Lennox–Gastaut syndrome in health insurance claims databases via the random forest methodology.

*Abstract:* 69th Annual Meeting of the American Epilepsy Society, Philadelphia, PA.
*Authors:* Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

A life-course assessment of treatment patterns and healthcare costs of Lennox-Gastaut syndrome.

*Authors:* Montouris GD, Piña-Garza JE, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Isojarvi J.

Predicting factors for reaching stabilized maintenance with once-monthly paliperidone almitate in Medicaid patients with schizophrenia.

*Authors:* Muser E, Pilon D, Emond B, Xiao Y, Amos T, Lefebvre P, Benson C.

Treatment patterns in schizophrenia patients reaching stabilized maintenance therapy with once-monthly paliperidone palmitate.

*Authors:* Amos T, Pilon D, Muser E, Emond B, Xiao Y, Lefebvre P, Benson C.

Functional limitations and healthcare resource utilization for individuals with cognitive impairment without dementia: Findings from a U.S. population-based survey.

Development of a risk score to guide individualized treatment selection in attention-deficit/hyperactivity disorder.

**Abstract:**

**Authors:**

Systematic literature review and mixed treatment comparison of guanfacine extended release (GXR) versus other pharmacotherapies in children and adolescents with attention deficit/hyperactivity disorder (ADHD).

**Abstract:**

**Authors:**
Joseph A, Xie J, Bischof M, Zhanabekova Z, Cai S, Zhuo Y, Huss M, Sikirica V.

Bone pain, skeletal related events and opioid use in patients with prostate cancer and bone metastases.

**Abstract:**
ISPOR 20th Annual International Meeting Research Philadelphia, PA.

**Authors:**
Valderrama A, Eapen S, Hennessey KA, Jones C, Wen L, Germino J, Duh MS.

The burden of treatment switch in patients with major depression: A US retrospective administrative claims analysis.

**Abstract:**
ISPOR 20th Annual International Meeting Research Conference, Philadelphia, PA.

**Authors:**
Perez V, Gauthier G, Guerin A, Francois C, Merikle E.

Description of prophylactic drug utilization patterns in migraine patients.

**Abstract:**
ISPOR 20th Annual International Meeting Research Philadelphia, PA.

**Authors:**
Shei A, Woolley JM, Desai PR, Enloe CJ, Kirson NY, Birnbaum HG, Corey-Lisle PK, Sapra S.

Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: A retrospective chart review.

**Abstract:**
ISPOR 20th Annual International Meeting, Philadelphia, PA.

**Authors:**

Healthcare Utilization and costs among Adults with Major depressive Disorder treated with Vilazodone vs. Other selective Serotonin Reuptake Inhibitors.

**Abstract:**
ISPOR 20th Annual International Meeting Research Philadelphia, PA.

**Authors:**
Zhou Z, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE.

Predictors of receiving at least 5 claims for once monthly paliperidone palmitate among Medicaid patients with schizophrenia.

**Abstract:**

**Authors:**
Lafeuille MH, Xiao Y, Muser E, Pesaj Fastenau J, Duh MS, Lefebvre P.

Real-world treatment outcomes in adults with attention deficit/hyperactivity disorder treated with lisdexamfetamine versus atomoxetine following methylphenidate treatment.

**Abstract:**
World Congress of ADHD, Glasgow, Scotland.

**Authors:**

Relative efficacy and tolerability of vortioxetine versus approved antidepressants for major depressive disorder: A meta-regression of clinical trials.

**Abstract:**
ISPOR 20th Annual International Meeting Research Philadelphia, PA.

**Authors:**
Diamand F, Danchenko N, Brignone M, Rive B, Perez V, Ereshefsky L, Francois C, Merikle E.
Treatment patterns among chronic users of immediate-release oxycodone initiating treatment with extended-release opioids.

Authors: Pergolizzi JV, Kirson NY, Bell J, Jones C, Mantovanelli F, Cummings AG, Birnbaum HG, Ben-Jospeh R.

Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.

Abstract: AMCP 27th Annual Meeting & Expo, San Diego, CA.
Authors: Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Development of a claims-based classifier to identify Lennox-Gastaut Syndrome.

Authors: Pina-Garza EJ, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

A systematic review and network meta-analysis of eslicarbazepine acetate and other recently-approved antiepileptic drugs for adjunctive treatment of partial-onset seizures in adults.

Abstract: 68th Annual Meeting of the American Epilepsy Society, AES 2014 Seattle, WA.
Authors: Betts K, Bollu V, De G, Blum D, Velez F.

Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in Quebec.


Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.

Publication: American Journal of Managed Care 2014 09; 20(9): 711-721
Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelsion TM, Xie J, Erder MH, Damermerman RS, Robertson B, Wu EQ.

Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit/hyperactivity disorder in Quebec.


Implications of early treatment among Medicaid patients with Alzheimer's disease.

Publication: Alzheimers Dement 2014 03; 10(2): 214-224
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.

Publication: Journal of Child and Adolescent Psychopharmacology 2014 06; 24(5): 260-268
Authors: Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ.

Pulse pressure and stroke risk: development and validation of a new stroke risk model.

Publication: Current Medical Research and Opinion 2014 12; 30(12): 2453-2460
Authors: Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.

Publication: Current Medical Research and Opinion 2014 08; 30(8): 1643-1655
Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.
Burden of schizophrenia on selected comorbidity costs.
Authors: Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P.

Clinical characteristics and treatment pattern in cluster seizures: A preliminary chart review analysis.
Abstract: 68th Annual Meeting of the American Epilepsy Society, AES 2014, Seattle, WA.
Authors: Vazquez B, Wu E, Macaulay D, Sidowar M, Roberts H, Squillacote D, Rabinowicz AL, Guo A.

The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs.

Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: A longitudinal analysis.

Systematic literature review and mixed treatment comparison of GXR versus other treatments in children and adolescents with attention deficit hyperactivity disorder (ADHD).
Abstract: ISPOR 17th Annual European Congress Amsterdam Netherlands.
Authors: Joseph A, Ayyagari R, Bischof M, Cai S, Xie M, Zhanabekova Z, Sikirica V.

Comparison of re-hospitalization and emergency room visit patterns among patients with schizophrenia receiving paliperidone palmitate or oral atypical antipsychotics in an inpatient setting.
Abstract: 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Taipei Taiwan (Republic of China).
Authors: Lafeuille MH, Grittner A, Muser E, Fastenau J, Duh MS, Lefebvre P.

Healthcare resource utilization preceeding first diagnosis for fragile X syndrome (fxs).
Abstract: ANA 2014 Annual Meeting, Baltimore, MD.

Medical specialists involved in caring for patients with fragile X syndrome (FXS): a Medicaid perspective.

Pulse pressure and stroke risk: Development and validation of a new stroke risk model.
Abstract: 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei Taiwan (Republic of China).
Authors: Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Assessing the impact of time-dependent treatment with once-monthly paliperidone palmitate or oral atypical antipsychotics on healthcare resource utilization and Medicaid spending among patients with schizophrenia using marginal structural models.
Authors: Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesat J, Fastenau J, Duh MS.
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.

Abstract: 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA.


Comparison of healthcare resource utilization and Medicaid spending among patients with schizophrenia treated with once monthly paliperidone palmitate or oral atypical antipsychotics using the inverse probability of treatment weighting approach.


Authors: Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.

Impact of improved adherence to disease-modifying therapies on healthcare resource utilization and medical costs for patients with multiple sclerosis.

Abstract: 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA.

Authors: Yermakov S, Davis M, Calnan M, Fay M, Buckley B, Sarda S, Duh MS, Iyer R.

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.

Abstract: 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA.


Abstract: 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA.

Authors: Nazareth T, Marvel J, Sikirica S, Xie J, Reichmann W, Zhao C, Sasane R.

Assessing the economic burden of Alzheimer’s disease patients treated by specialists within three months of preliminary diagnosis of cognitive decline.

Abstract: Alzheimer’s Association International Conference 2014 Copenhagen Denmark.


Excess costs associated with possible misdiagnosis of Alzheimer’s disease among patients with vascular dementia in a UK CPRD population.

Abstract: Alzheimer’s Association International Conference 2014 Copenhagen Denmark.

Authors: Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Price D, Belger M, Hunter CA, Lenox-Smith AJ, Reed CC.

Comparison of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics in an inpatient setting.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.

Authors: Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

Effect of improving adherence to disease-modifying agents on health care resource utilization and medical costs in patients with multiple sclerosis.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.

Authors: Yermakov S, Davis M, Calnan M, Fay M, Duh M, Iyer R.
Factors associated with performance on the Medicaid HEDIS measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.

Authors: Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa JA, Clancy Z, Fastenau J, Durkin M.

Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective.

Abstract: APA 167th Annual Meeting, New York City, NY.

Authors: Signorovitch J, Wu E, Li N, Chopra P.

Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective.

Abstract: APA 167th Annual Meeting, New York City, NY.

Authors: Signorovitch J, Wu E, Li N, Chopra P.

Systematic review of long-acting injectables (LAI) versus oral atypical antipsychotics (OA) on hospitalization in schizophrenia.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.

Authors: Lafeuille MH, Cloutier M, Fortier J, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Treatment patterns of patients receiving paliperidone palmitate in an inpatient setting.

Abstract: ISPOR 19th Annual International Meeting Montreal, QC Canada.

Authors: Lafeuille MH, Fortier J, Grittner AM, Muser E, Fastenau J, Duh MS, Lefebvre P.

Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review.

Publication: Neuropsychiatric Disease Treatments 2014 08; 10: 1543-1569

Authors: Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J.


Publication: J Multidiscip Healthc 2014 02; 7: 93-104

Authors: Mortimer R, Privopoulos M, Kumar S.

HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington’s Disease.

Publication: Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 223


Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.

Publication: Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 224


Costs of Parkinson’s disease in a privately insured population.

Publication: Pharmacoeconomics 2013 09; 31(9): 799-806

Authors: Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.

Publication: Journal of Medical Economics 2013 10; 16(10): 1203-1215
Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.


Publication: Cns Drugs 2013 11; 27(11): 943-953
Authors: Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.

Publication: Journal of Medical Economics 2013 11; 16(11): 1290-1299
Authors: Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.

Publication: Journal of Medical Economics 2013 11; 16(11): 1275-1289
Authors: Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

An economic model of Parkinson’s disease: implications for slowing progression in the United States.

Publication: Movement Disorders 2013 03; 28(3): 319-326
Authors: Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD.

Authors’ reply to Alatorre et al.: ”cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison”.

Publication: Appl Health Econ Health Policy 2013 06; 11(3): 307
Authors: Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

Publication: Journal of Clinical Psychiatry 2013 06; 74(6): 568-575
Authors: Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.

Publication: Journal of the Neurological Sciences 2013 07; 330(1-2): 71-77
Authors: Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.

Publication: Journal of Medical Economics 2013 07; 16(7): 962-975
Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals’ perspectives.

Publication: Circulation: Cardiovascular Quality and Outcomes 2013 01; 6(1): 18-26
Authors: Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ.
Pre-diagnosis excess acute care costs in Alzheimer’s patients among a US Medicaid population.
Publication: Appl Health Econ Health Policy 2013 08; 11(4): 407-413
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

Glioblastoma treatment patterns and outcomes and resource use in the united states.
Abstract: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology Conference San Francisco, CA.

Health care resource use and direct costs associated with fragile x syndrome (FXS) in the United States.
Abstract: ISPOR 16th Annual European Congress Dublin Ireland.
Authors: Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada.
Abstract: ISPOR 16th Annual European Congress, Dublin Ireland.

Pulse pressure and stroke risk: Development and validation of a stroke risk equation.
Authors: Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Montreal, QC Canada.
Authors: Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Montreal, QC Canada.
Authors: Betts KA, Sikirica V, Hodgkins P, Du E, Zhou Z, Erder HM, Wu EQ.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Montreal, QC Canada.
Authors: Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Duh MS.

Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Montreal, QC Canada.

Excess costs associated with misdiagnosis of Alzheimer’s disease among u.s. Medicare beneficiaries with vascular dementia or parkinson’s disease.
Abstract: Alzheimer’s Association International Conference 2013 Boston, MA.
Authors: Kirson N, Hunter C, Desai U, Cummings A, San Roman A, Faries D, Hardwick C, Birnbaum H.
Therapy combination: a prevalent pattern among children and adolescents with attention-deficit/hyperactivity disorder treated with stimulants in the Canadian province of Quebec.

Abstract: World Congress on ADHD, Milan, Italy.

Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression.

Abstract: ISPOR 18th Annual International Meeting New Orleans, LA.
Authors: Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R.

Burden of schizophrenia on selected comorbidities costs.

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA.
Authors: Lafeuille MH, Dean J, Fastenau J, Panish JM, Olson WH, Markowitz M, Duh MS, Lefebvre P.

A meta-analysis of efficacy and safety of prescription opioids, including formulations with tamper-resistant technologies, in non-cancer pain management.

Abstract: ISPOR 18th Annual International Meeting, LA United States.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.

Authors: Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Dug MS.

Guanfacine immediate release vs. Guanfacine extended release: Comparative medication adherence, resource utilization, and healthcare costs among children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Authors: Sikirica V, Xie J, He TL, Erder MH, Hodgkins P, Yang H.


Abstract: American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL.
Authors: Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

An economic model of improved acute stroke care in the management of acute ischemic stroke from a state Medicaid perspective.

Abstract: 2013 International Stroke Conference and Nursing Symposium of the American Heart Association/American Stroke Association, Honolulu, HI.
Authors: Zhou ZY, Fan L, Chen E, Xie J, Wu EQ.

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.

Publication: BMC Psychiatry 2013 09; 13: 221
Authors: Lafeuille MH, Laliberte-Augé F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.

Authors: Helmers SI, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.
Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Publication: Pain Pract 2012 09; 12(7): 533-540
Authors: Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Publication: Neurology 2012 10; 79(18): 1908-1916
Authors: Manjunath R, Paradis PE, Parise H, Lafaille MH, Bowers B, Duh MS, Lefebvre P, Faught E.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Publication: Journal of Managed Care Pharmacy 2012 11; 18(9): 676-689
Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

Publication: Appl Health Econ Health Policy 2012 11; 10(6): 381-395
Authors: Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Publication: Pharmacoeconomics and Drug Safety 2012 05; 21 Suppl 2: 130-137
Authors: Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ.

Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson’s disease.
Publication: Parkinsonism & Related Disorders 2012 05; 18(4): 321-326
Authors: Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
Publication: Cns Drugs 2012 07; 26(7): 581-600
Authors: Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a Medicaid population.
Publication: Managed Care 2012 01; 21(1): 49-58
Authors: Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Publication: Pharmacoeconomics 2012 08; 30(8): e1-15
Authors: Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Characteristics, clinical and economic outcomes in Medicaid pediatric vagus nerve stimulation (VNS) therapy patients for the treatment of refractory epilepsy.
Abstract: 65th Annual Meeting of the American Epilepsy Society, AES, Baltimore, MD.
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.
Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC.

Authors: Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

Economic value of screening for early parkinson's disease in a european setting.


Authors: Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

Economic value of slowing Parkinson's disease in Germany: Modeling progression through Hoehn and Yahr stages.


Authors: Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.

Abstract: Institute of Psychiatric Services Meeting, New York, NY.

Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers.

Abstract: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Conference, Lyon France.

Authors: Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

Period prevalence of stimulant augmentation among pediatric attention deficit/hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population.


Authors: Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, EQ W.

Economic value of screening for early parkinson's disease in a european setting.

Abstract: 16th Congress of the European Federation of Neurological Societies, EFNS., Stockholm Sweden.

Authors: Johnson S, Siderowf AD.

Economic value of slowing parkinson's disease in germany: Modelling progression through hoehn and yahr stages.


Authors: Johnson SJ, Birnbaum HG, Siderowf AD.

The impact of long-acting injectable vs oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.


Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Impact of long-acting injectable vs. oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.


Authors: Lafeuille MH, Laliberte-Augier F, Lefebvre P, Frois C, Fastenau J, Duh MS.
Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis.

**Abstract:** 20th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, IACAPAP 2012 Conference Paris France.

**Authors:** Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

Prevalence, comorbidity burden and treatment of alzheimer's disease among the elderly in the united states.

**Abstract:** Alzheimer's Association International Conference 2012 Vancouver, BC Canada.

**Authors:** Ivanova J, Birnbaum H, Desai U, Kirson N, Cummings A, San Roman A, Rao S, Andrews R, Doan Q, Zachry W.

An application of group-based modeling approach for trajectory recognition: The developmental courses of hyperactivity and inattentive symptoms.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC.

**Authors:** Cheng W, Goodwin R, Wu P, Vitaro F, Tremblay R.

Economic value of screening for early parkinson’s disease.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.

**Authors:** Johnson S, Siderowf A.

Economic value of slowing parkinson’s disease to payers and patients: Modeling progression through hoehn and Yahr stages.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC.

**Authors:** Johnson S, Diener M, Kaltenboeck A, Birnbaum H, Grubb E, Siderowf A.

The impact of long-acting injectable versus oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC.

**Authors:** Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Impact of long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Washington, DC.

**Authors:** Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Incremental clinical and economic burden of uncontrolled partial-onset seizures in a privately-insured population.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012 Conference Washington, DC.

**Authors:** Paradis PE, Parise H, Duh MS, Bowers BW, Faught E.

Model of rasagiline versus standard of care for parkinson’s disease: Comparison of progression effects.

**Abstract:** 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.

**Authors:** Johnson S, Wang ST, Birnbaum H, Grubb E.
Treatment patterns, resource utilization and costs associated with guanfacine immediate release versus guanfacine extended release among children and adolescents with attention deficit/hyperactivity disorder (ADHD).

Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.

Authors: DiBello J, Sikirica V, Samuelson T, Xie J, He T, Erder MH.

Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.

Abstract: American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY.

Authors: Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

Characteristics and use patterns of chronic hydrocodone users.

Abstract: 31st Annual Scientific Meeting of the American Pain Society Honolulu, HI.

Authors: Rice J, Samuelson T, Birnbaum H, Katz N.

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. non-antipsychotics.


Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US.

Abstract: American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY United States.

Authors: Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

Urgent care utilization for adolescents treated with atypical antipsychotics or nonantipsychotics: A comparison of rates and reasons.


Authors: Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH.

Cost implications of early treatment among patients with alzheimer’s disease - A Medicaid perspective.

Abstract: 64th American Academy of Neurology Annual Meeting New Orleans, LA.

Authors: Geldmacher D, Kirson N, Birnbaum H, Eapen S, Cummings K, A, Joish V.


Abstract: 64th American Academy of Neurology Annual Meeting, New Orleans, LA.

Authors: Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E.

Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective.

Abstract: 64th American Academy of Neurology Annual Meeting New Orleans, LA.

Authors: Demaerschalk B, Switzer J, Xie J, Fan L, Villa K, Wu E.

Atypical antipsychotics versus non-antipsychotics: Comparative treatment patterns, resource utilization, and costs in stimulant-treated adolescents with ADHD who require subsequent pharmacotherapy.

Abstract: AMCP’s 24th Annual Meeting & Expo, San Francisco, CA.

Authors: Sikirica V, Pliszka SR, Betts K, Hodgkins P, Samuelson T, Xie J, Dammerman R.
Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.

Publication: Journal of Medical Economics 2012 10; 15(1): 87-95
Authors: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.

Publication: Journal of Medical Economics 2012 03; 15(3): 601-609
Authors: Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

PMH65 Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder M.

Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.

Publication: Headache 2012 03; 52(3): 409-421
Authors: Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M.

Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.

Publication: Epilepsy & Behavior 2011 10; 22(2): 370-375
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Early retirement and income loss in patients with early and advanced Parkinson’s disease.

Publication: Appl Health Econ Health Policy 2011 11; 9(6): 367-376
Authors: Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, Siderowf A.

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.

Publication: Am Health Drug Benefits 2011 03; 4(2): 78-87
Authors: Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH.

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.

Publication: Current Medical Research and Opinion 2011 06; 27(6): 1089-1096
Authors: Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH.

Physicians’ decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan.

Publication: Drugs and Aging 2011 01; 28(1): 51-62
Authors: Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emami S, Sheehy M.

Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine.

Publication: Cephalalgia 2011 02; 31(3): 357-367
Authors: Yang M, Rendas-Baum R, Varon SF, Kosinski M.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Publication: Annals of Pharmacotherapy 2011 04; 45(4): 441-451
Authors: Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.
Characteristics and clinical and economic outcomes in Medicaid patients receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.

Abstract: 64th Annual Meeting of the American Epilepsy Society, AES and 3rd Biennial North American Regional Epilepsy Congress, San Antonio, TX.

Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Faught E.

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention deficit/hyperactivity disorder: A retrospective study.


Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

Effect of treatment timing on risk of institutionalization among patients with Alzheimer's disease.


Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Kantor E, Eapen S, Joish VN.

PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.

Authors: Sikirica V, Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu E.

Comparative efficacy of guanfacine extended release and atomoxetine for the treatment of oppositional symptoms in children with attention deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).


Authors: Signorovitch JE, Sikirica V, Lu M, Xie J, Wu EQ, Erder MH.

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of ADHD: A retrospective study.

Abstract: AACAP/CACAP Joint Annual Meeting, Toronto, ON, Canada.

Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

Treatment patterns, resource utilization, and costs associated with atypical antipsychotics vs. non-antipsychotics added to or switched from stimulants among children with attention deficit/hyperactivity disorder (ADHD).

Abstract: AMCP Educational Meeting, Atlanta, GA.

Authors: Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, Wu EQ.

Characteristics, clinical and economic outcomes in Medicaid patients 17 years and younger receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.

Abstract: 29th International Epilepsy Congress, IEC 2011, Rome Italy.

Authors: Helmers SL, Duh MS, Guirin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.

Abstract: 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Chicago, IL.

Authors: Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.
Assessment of parkinson’s disease progression rates by stage of disease.
Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD.
Authors: Johnson SJ, Kaltenboeck A, Diener M, Tarrants M, Birnbaum H.

Comparison of real-world health care costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder.
Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD.
Authors: Swindle R, Ivanova JI, Birnbaum HG, Cummings AK, Kantor E, Schiller M, Clark T, Reed C.

The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents.
Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD.
Authors: Erder M, Chen K, Wu EQ, Hodgkins P, Sikirica V.

Direct and indirect costs of privately-insured patients treated with oxymorphone extended-release or oxycodone controlled-release tablets.
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD.
Authors: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, KH S.

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.
Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD.
Authors: Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Abstract: 30th Annual Scientific Meeting of the American Pain Society Conference Austin, TX United States.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

Uncontrolled epilepsy in a Medicaid population.
Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD.
Authors: Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Mishagina N, Parise H, Rovba L, Lefebvre P, Faught E.

Burden of uncontrolled epilepsy in a privately insured population.
Abstract: 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI.
Authors: Manjunath R, Faught E, Paradis PE, Parisé H, Lafeuille MH, Lefebvre P, Duh MS.

Relationship between adherence to disease-modifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis.
Abstract: 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI.
Authors: Philips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by Medicaid or private insurance.
Publication: American Journal of Managed Care 2011 08; 17(8): e314-323
Authors: Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.
Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy.

*Publication:* American Journal of Pharmacy Benefits 2011


Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients.

*Publication:* American Journal of Pharmacy Benefits 2011 12; 3(6): e111-e120

*Authors:* Marynchenko M YA, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM, Bose A.

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.

*Publication:* Journal of Medical Economics 2011 06; 14(4): 508-515

*Authors:* Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

Switch to generic SSRIs may boost costs in MDD.

*Publication:* PharmacoEconomics & Outcomes News 2011 04; 625: 2

*Authors:* Wu E.

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.

*Publication:* Current Medical Research and Opinion 2010 10; 26(10): 2475-2484

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD.


*Publication:* Drugs and Aging 2010 11; 27(11): 903-913

*Authors:* Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, Duh MS.

A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.

*Publication:* Quality of Life Research 2010 11; 19(9): 1349-1358

*Authors:* Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD.

Generic antiepileptic drugs and associated medical resource utilization in the United States.

*Publication:* Neurology 2010 05; 74(20): 1566-1574

*Authors:* Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Helmers SL.

Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.

*Publication:* Epilepsia 2010 05; 51(5): 838-844

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.


*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

The risks and costs of multiple-generic substitution of topiramate (author reply).

*Publication:* Neurology 2010 02; 74(8): 701-702; author reply 701-702

*Authors:* Sethi NK, Torgovnick J, Sethi PK, Arsura E, Emmanuel Paradis P, Duh MS, Durkin MB, Wan GJ.
Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.
*Publication:* Journal of Occupational Environmental Medicine 2010 02; 52(2): 115-124
*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux PY, Greenberg PE.

Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics.
*Publication:* Current Medical Research and Opinion 2010 12; 26(12): 2735-2744
*Authors:* Frois C, Guerin A, Saraogi A, Panish J, Dirani R.

Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative.
*Publication:* Depression and Anxiety 2010 04; 27(4): 351-364

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.
*Publication:* American Journal of Medicine 2010 04; 123(4): 350-357
*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

Compliance and persistence to single-tablet levodopa/ carbidopa/entacapone compound versus levodopa/carbidopa in idiopathic parkinson’s disease.
*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, ACCP 2010 Austin, TX.
*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

Cost of illness of post-traumatic stress disorder compared with major depressive disorder.
*Abstract:* 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA.
*Authors:* Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G.

Descriptive profile of Medicaid patients with post herpetic neuralgia treated and untreated with lidocaine patch 5%.
*Abstract:* 29th Annual Scientific Meeting of the American Pain Society, APS Baltimore, MD.

Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with post herpetic neuralgia.
*Abstract:* 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA.
*Authors:* Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.
*Abstract:* 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA.
*Authors:* Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

Economic value of lidocaine patch 5% versus gabapentin or pregabalin in Medicaid patients with post-herpetic neuralgia.
*Abstract:* 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP Conference San Diego, CA.
*Authors:* Ivanova J, Puenpatom A, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.
Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.


Authors: Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D.

Increased risk of psychiatric disorders in a pediatric population with psoriasis.

Abstract: 68th Annual Meeting of the American Academy of Dermatology, AAD, Conference Miami, FL.

Authors: Kimball A, Yu A, Mulani P, Gupta S.

Impact of levodopa/carbidopa/entacapone compound versus levodopa/carbidopa on hospitalization rates in patients with idiopathic Parkinson’s disease.

Abstract: 2010 Annual Meeting of the American College of Clinical Pharmacy, ACCP 2010 Austin, TX.

Authors: Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.

Publication: Journal of Medical Economics 2010 08; 13(3): 482-491

Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.

Publication: Journal of Medical Economics 2010 08; 13(3): 472-481

Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH.

Economic burden of epilepsy among the privately insured in the US.

Publication: Pharmacoeconomics 2010 07; 28(8): 675-685

Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallet D, Caleo S.

Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.

Publication: Journal of Medical Economics 2010 10; 13(4): 599-609

Authors: Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M.

Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.

Publication: Depression and Anxiety 2010 27(1): 78-89

Authors: Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE.

Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.

Publication: Journal of Medical Economics 2010 05; 13(2): 314-323

Authors: Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A.

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.


Authors: Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.

Publication: Cephalalgia 2009 11; 29(11): 1180-1187

Authors: Cole JC, Lin P, Rupnow MF.

Antidepressant treatment patterns and costs among US employees.

Publication: Journal of Medical Economics 2009 03; 12(1): 36-45

Authors: Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R.
Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.

**Publication:** Current Medical Research and Opinion 2009 03; 25(3): 755-764  
**Authors:** Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G.

Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.

**Publication:** Epilepsia 2009 03; 50(3): 501-509  
**Authors:** Faught RE, Weiner JR, Guerin A, Cunnington MC, Duh MS.

The risks and costs of multiple-generic substitution of topiramate.

**Publication:** Neurology 2009 06; 72(24): 2122-2129  
**Authors:** Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRIs/SNRIs.

**Publication:** Journal of Medical Economics 2009 06; 12(2): 124-135  
**Authors:** Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.

**Publication:** Current Medical Research and Opinion 2009 07; 25(7): 1793-1805  
**Authors:** Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafuette MH, Lefebvre P, Gaudig M, Duh MS.

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.

**Publication:** Current Medical Research and Opinion 2009 04; 25(4): 869-877  
**Authors:** Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D.

Economic consequence of switching to citalopram after its generic entry among major depressive disorder patients treated with escitalopram.

**Abstract:** AMCP’s 2009 Educational Conference, San Antonio, TX.  
**Authors:** Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Erder H.

Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.

**Abstract:** ISPOR 12th Annual European Congress, Paris France.  
**Authors:** Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafuette MH, Lefebvre P, Gaudig M, Duh MS.

The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression.

**Abstract:** AMCP 2009 Educational Conference, San Antonio, TX.  
**Authors:** Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, Wu EQ, Erder H.

The potential economic impact of generic substitution of topiramate on health care costs in the G4 European countries.

**Abstract:** ISPOR 12th Annual European Congress, Paris France.  
**Authors:** Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafuette MH, Lefebvre P, Gaudig M, Duh MS.
Evaluation of cardiovascular diseases (CVDs) risk in French patients receiving milnacipran (MLN) relative to patients receiving other antidepressants therapies.

Abstract: 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Providence, RI.
Authors: Mease PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P, Zimetbaum PJ.

Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G.

Compliance, persistence, and outcomes in patients with Alzheimer’s disease treated with oral cholinesterase inhibitors.

Abstract: Alzheimer’s Association International Conference on Alzheimer’s Disease Conference Vienna, Austria.
Authors: Mody-Patel N, Vekeman F, Laliberte F, Kahler KH, Duh MS, Lefebvre P.

Clinical consequences of generic substitution of topiramate.

Authors: Paradis P, Dominick L, Patrick L, Marie-Helene L, Natalia M, Moore Y, Gaudig M, Duh M.

Economic impact of generic entry of topiramate in Germany.

Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy.
Authors: Paradis P, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh MS.

Impact of generic substitution of topiramate for patients with epilepsy.

Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy. Conference Publication: (var.pagings).
Authors: Paradis P, Latremouille-Viau D, Lefebvre P, Lafeuille M, Mishagina N, Moore Y, Gaudig M, Duh M.

The impact of generic substitution of topiramate on healthcare costs: Conversion of the Canadian experience into the settings of Germany.

Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy.
Authors: Paradis P, Latremouille-Viau D, Lafeuille M, Lefebvre P, Gaudig M, Duh MS.

Antipsychotic drug use in patients with Alzheimer’s disease treated with rivastigmine versus donepezil: Evidence from health claims data.

Abstract: ISPOR 14th Annual International Meeting. Orlando, FL.
Authors: Lefebvre P, Vekeman F, Kahler K, Mody-Patel N, Duh MS, Scharre DW.

Comparison of hospitalizations and health care costs of elderly major depressive disorder (MDD) patients treated with escitalopram, generic SSRIs, or SNRIs.

Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Wu EQ, Cahill KE, Bieri C, Ben-Hamadi R, Yu AP, Erder MH.

Compliance and persistence of oral cholinesterase inhibitors in patients with Alzheimer’s disease.

Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Vekeman F, Laliberte F, Kahler K, Mody-Patel N, Lefebvre P, Duh MS.

Direct costs in older patients with depression treated and untreated with antidepressant therapy.

Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Ivanova J, Birnbaum HG, Samuels S, Emani S, Sheehy M, Cattelin F.
Direct costs of patients with treatment resistant and non-treatment resistant major depressive disorder.
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Ivanova J, Birnbaum HG, Kidolezi Y, Subramanian G, Stensland MD, Khan SA.

Economic assessment of second-line treatment: Switching from a generic ssri to escitalopram, an snri, or another generic ssri by patients with major depressive disorder (MDD).
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.

Economic impact of generic entry of topiramate in the G4 European countries.
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI.
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.

Economic implication of dose escalation in depressed patients treated with escitalopram or venlafaxine XR.
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Yu AP, Bensimon AG, Wu EQ, Ben-Hamadi R, Bourezak A, Erder MH.

The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

Physicians’ attitude to prescribing antidepressant therapy in older patients with depression.
Abstract: ISPOR 14th Annual International Meeting Conference, Orlando, FL.
Authors: Ivanova JI, Birnbaum HG, Connolly C, Emani S, Sheehy M, Bienfait-Beuzon C.

The risk of coronary heart disease and stroke among psoriasis patients.
Authors: Kimball A, Guerin A, Mulani P, Gupta S.

Assessing the relationship between compliance with antidepressant therapy and costs among employees in the United States.
Authors: Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Cremieux P, Greenberg P.

Healthcare resource utilization and costs of mild, moderate, and severe depression in the workforce in the united states.
Authors: Birnbaum H, Kessler R, Joish V, Kelley D, Ben-Hamadi R, M. H, Greenberg P.

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
Publication: Pharmacoeconomics 2009 08; 27(8): 681-691
Authors: Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.
Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.
Publication: Pharmacoeconomics 2009 07; 27(6): 507-517
Authors: Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

Impact of generic substitution of topiramate for patients with epilepsy.
Publication: European Journal of Neurology 2009 16 (S3): 140
Authors: Paradis PE, Latremouille-Viau D, Lefebvre P, Lafayeille MH, Mishagina N, Moore Y, Gaudig M, Duh MS.

Publication: Annals of Pharmacotherapy 2008 09; 42(9): 1229-1238

Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.
Publication: Current Medical Research and Opinion 2008 09; 24(9): 2587-2595
Authors: Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
Publication: Current Medical Research and Opinion 2008 10; 24(10): 2805-2813
Authors: Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.
Publication: Neurology 2008 11; 71(20): 1572-1578
Authors: Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC.

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
Publication: Current Medical Research and Opinion 2008 04; 24(4): 1069-1081
Authors: LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs.
Abstract: 21st ECNP Congress, Barcelona Spain.
Authors: Erder MH, Wu E, Ben-Hamadi R, Beaulieu N, Lu M.

Treatment compliance and health care costs of Medicaid depressed adult patients treated with escitalopram versus citalopram.
Abstract: 21st ECNP Congress, Barcelona Spain.
Authors: Erder MH, Wu E, Lu M, Ben-Hamadi R, Beaulieu N.

Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI.
Abstract: ISPOR 13th Annual International Meeting, Toronto, Canada.
Authors: Wu EQ, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.
Publication: Current Medical Research and Opinion 2007 09; 23(9): 2035-2042
Authors: Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Publication: Journal of Managed Care Pharmacy 2007 09; 13(7): 561-569
Authors: Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.
Publication: Archives of General Psychiatry 2007 05; 64(5): 543-552
Authors: Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC.

Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Publication: Epilepsy 2007 03; 48(3): 464-469
Authors: Andermann F, Duh MS, Gosselin A, Paradis PE.

Factors related to antipsychotic oversupply among Central Texas Veterans.
Publication: Clinical Therapeutics 2007 06; 29(6): 1214-1225
Authors: Yang M, Barner JC, Worchel J.

Considering the costs of bipolar depression.
Publication: Behav Healthc 2007 01; 27(1): 45-47
Authors: Kessler RC, Akiskal HS, Ames M, Birmbaum H, Greenberg PE, Hirschfeld RM, Wang PS.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Publication: Disease Management 2007 08; 10(4): 216-225
Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

Antidepressant Treatment Patterns and Related Costs among U.S. Employees.
Abstract: Institute on Psychiatric Services (APA-I), New Orleans, LA.
Authors: Birnbaum H, Greenberg P, Tang J, Hsieh M, Wu EQ, Reygrobellet C, Ben-Hamadi R.

Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.
Abstract: Institute on Psychiatric Services (APA-I), New Orleans, LA.
Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.
Abstract: International Health Economics Association, Copenhagen, Denmark.
Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIS.
Abstract: New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL.
Authors: Wu EQ, Elaine Y, Greenberg P, Erder M.H., Yu A.

Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI).
Abstract: ISPOR 12th International Meeting, Arlington, VA.
Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Yu A, Buesing M.

MH2 Comparison of health care costs and hospitalization days of elderly major depressive disorder patients treated with escitalopram and other antidepressants.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Yang E, Greenberg P, Erder M, Yu A, Buesing M.
Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram.
Abstract: European College of Neuropsychopharmacology (ECNP) Regional Meeting, Sofia, Bulgaria.
Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Health Economics Impact in the Treatment of Depression.
Abstract: National Association of Managed Care Physicians (NAMCP).
Authors: Navarro R, Wu EQ.

Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.
Publication: American Journal of Psychiatry 2006 09; 163(9): 1561-1568

Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.
Publication: Stroke 2006 10; 37(10): 2567-2572
Authors: Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.
Publication: Psychological Medicine 2006 11; 36(11): 1535-1540
Authors: Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R.

Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies.
Authors: Wu EQ, Birnbaum H, Zhang HF, Radeva J, Yang E, Castor A.

Health-Related Quality Of Life of Stroke Survivors in the U.S.
Authors: Xie J, Wu EQ, Zheng ZJ, Croft JB, Mensah GA, Labarthe D.

MH4 Medical costs and hospitalization of adults diagnosed with attention-deficit/hyperactivity disorder who received alternative therapies.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Birnbaum H, Zhang H, Radeva J, Yang E, Castor A.

Patterns of Antidepressant Treatment Response in an Employed Population.
Authors: Wu EQ, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E.

PMH7 Annual costs associated with patterns of antidepressant treatment response among employees.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.

Economic burden of illness for employees with painful conditions.
Publication: Journal of Occupational Environmental Medicine 2005 09; 47(9): 884-892
Authors: White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA.

The economic burden of schizophrenia in the United States in 2002.
Publication: Journal of Clinical Psychiatry 2005 09; 66(9): 1122-1129
Authors: Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Mouls M, Aggarwal J.
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).
Publication: Biological Psychiatry 2005 10; 58(8): 668-676

The economic burden of depression in the US: societal and patient perspectives.
Publication: Expert Opinion on Pharmacotherapy 2005 03; 6(3): 369-376
Authors: Greenberg PE, Birnbaum HG.

The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.
Authors: Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustun TB.

Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
Publication: Current Medical Research and Opinion 2005 02; 21(2): 195-206
Authors: Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

Costs of schizophrenia have shifted.
Publication: Pharmacoeconomics & Outcomes News 2005 06; 480: 18
Authors: Wu E.

Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L.

Authors: Wu EQ, Birnbaum H, Kessler R, Shi L, Ball D.

PMH37 The economic burden of schizophrenia in the united states in 2002.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Birnbaum H, Shi L, Ball D, Kessler R, Mouls M, Aggarwal J.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Birnbaum H, Aggarwal J, Mouls M.

Unemployment drives high cost of schizophrenia in the US.
Publication: Pharmacoeconomics & Outcomes News 2005 12; 493: 17
Authors: Wu E.

Authors: Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Mouls M, Aggarwal J.

Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients.
Publication: Journal of Adolescent Health 2004 10; 35(4): 346 e341-349
Authors: Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.
Comorbidities and Cost Associated with Bipolar Disorder.
Abstract: American Public Health Association’s (APHA).
Authors: Parece A, Wu EQ, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC.

Cost and Comorbidities Associated with Bipolar Disorder.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Parece A, Wu EQ, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC.

Drug Treatment Patterns of Bipolar Disorder and Associated Costs.
Abstract: National Institute of Mental Health’s (NIIMH) New Clinical Drug Evaluation Unit (NCDEU) meeting.

Economic implications of treatment-resistant depression among employees.
Publication: Pharmacoeconomics 2004 04; 22(6): 363-373
Authors: Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.

What’s so different about anxiety disorders (such as phobias).
Publication: WPA series evidence and experience in psychiatry 2004 7
Authors: Greenberg P, Birnbaum H, Sisitsky T.

Authors: Corey-Lisle PK, Birnbaum H, Greenberg P, Marynchenko M, Dube S.

Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis.
Publication: Journal of Clinical Psychiatry 2003 10; 64(10): 1201-1209
Authors: Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA.

The economics of women and depression: an employer’s perspective.
Publication: Journal of Affective Disorders 2003 03; 74(1): 15-22
Authors: Birnbaum HG, Leong SA, Greenberg PE.

Attention-deficit/hyperactivity disorder: increased costs for patients and their families.
Publication: Journal of the American Academy of Child and Adolescent Psychiatry 2003 12; 42(12): 1415-1423
Authors: Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A.

The economic burden of depression in the United States: how did it change between 1990 and 2000?
Publication: Journal of Clinical Psychiatry 2003 12; 64(12): 1465-1475
Authors: Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK.

The economic burden of depression with painful symptoms.
Publication: Journal of Clinical Psychiatry 2003 05; 64 Suppl 7: 17-23
Authors: Greenberg PE, Leong SA, Birnbaum HG, Robinson RL.

PNP16: The comparison of different methods for determining the impact of migraine prophylaxis on costs.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Barlev A, Globe D, Wu E, Yu W, Johnson K.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
Publication: J Ment Health Policy Econ 2002 03; 5(1): 3-19
Authors: Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.
Identification of a claims data "signature" and economic consequences for treatment-resistant depression.
Publication: Journal of Clinical Psychiatry 2002 08; 63(8): 717-726
Authors: Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

The economic burden of anxiety and stress disorders.
Publication: Neuropsychopharmacology: The fifth generation of progress 2002 67: 982-992
Authors: Kessler RC, Greenberg PE.

Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.
Publication: Neurology 2001 09; 57(6): 957-964

Authors: Greenberg PE, Birnbaum SA.

Depression and work productivity: the comparative costs of treatment versus nontreatment.
Publication: Journal of Occupational Environmental Medicine 2001 01; 43(1): 2-9
Authors: Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC.

Assessing the economic impact of psychiatric disorders: where to begin?
Authors: Greenberg PE, Leong SA, Birnbaum HG.

Survival and Nursing Home Free Survival (NHFS) of Alzheimer’s Disease (AD) Patients.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Hay J.

The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Authors: Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.

The Economics of Anxiety Disorders.
Publication: Psychiatric Times’ Mental Health Economics: Practical Information on Changes in the U.S. Health Care System 2000
Authors: Greenberg P, Sisitsky T.

The Impact of an Over-the-Counter Migraine Medication on Quality of Life.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Burk C, Nichol MB, Wu EQ, Gilderman A, Salas J.

Management of major depression in the workplace.
Publication: Disease Management and Health Outcomes 2000 7(3): 163-171
Authors: Birnbaum HG, Cremieux PY, Greenberg PE, Kessler RC.

The workplace burden of depression: underlying causes, recent empirical findings, and future directions.
Publication: TEN 2000 2(6): 37-40
Authors: Greenberg P, Birnbaum H.

Depression in the workplace: effects on short-term disability.
Publication: Health Affairs 1999 09; 18(5): 163-171
Authors: Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P.
The economic burden of anxiety disorders in the 1990s.
**Publication:** Journal of Clinical Psychiatry 1999 07; 60(7): 427-435  
**Authors:** Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ.

Workplace burden of depression: a case study in social functioning using employer claims data.
**Publication:** Drug Benefits Trends 1999 11: 68H-128H  
**Authors:** Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T.

Workplace performance effects from chronic depression and its treatment
**Publication:** Journal of Health Economics 1998 10; 17(5): 511-535  
**Authors:** Berndt ER, Finkelstein SN, Greenberg PE, Howland RH, Keith A, Rush AJ, Russell J, Keller MB.

Depression in the workplace: an economic perspective.
**Publication:** Selective Serotonin Re-Uptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. New York, NY: John Wiley & Sons 1996: 327-363  
**Authors:** Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER.

Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group.
**Publication:** Psychopharmacology Bulletin 1996 01; 32(1): 33-40  
**Authors:** Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB.

**Publication:** Neurosurgery 1994 08; 35(2): 240-248; discussion 248-249  
**Authors:** Duh MS, Shepard MJ, Wilberger JE, Bracken MB.

The Economics of Clinical Depression.
**Publication:** MIT Management Magazine 1994 Spring  
**Authors:** Greenberg P.

Depression: a neglected major illness.
**Publication:** Journal of Clinical Psychiatry 1993 11; 54(11): 419-424  
**Authors:** Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

The economic burden of depression in 1990.
**Publication:** Journal of Clinical Psychiatry 1993 11; 54(11): 405-418  
**Authors:** Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

Oncology

A Time and Motion Study of Patients Treated with Pembrolizumab and Nivolumab in Australia.
**Abstract:** Society for Melanoma Research 2017 (SMR) Brisbane, Australia.  
**Authors:** Pivneva I, Kothari S, Van Koeverden P, Pellissier J, Stone S, Herawati L, A. G.

Overall survival in patients with glioblastoma before and after bevacizumab approval.
**Publication:** Current Medical Research and Opinion 2017 10: 1-18  
**Authors:** Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH.
First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Publication: Current Medical Research and Opinion 2017 10: 1-17
Authors: Tang DH, Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V.

Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries with Chronic Myeloid Leukemia.
Publication: Journal of Clinical Oncology 2017 05; 35(15): 1744-1745
Authors: Ritchie EK, Guerin A, Wolff J, Joseph G.

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.

Assessment of costs associated with adverse events in patients with cancer.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.

Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the United States based on the FACT-G instrument.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.

A meta-analysis and meta-regression of the efficacy of front-line treatment combinations with ponatinib versus 1st- and 2nd-generation tyrosine kinase inhibitors for ph+ acute lymphoblastic leukemia.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.

Progression-free survival with endocrine-based therapies following progression on a non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A network meta-analysis.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.
Authors: Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Niravath PA.

Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (ARCC): A retrospective analysis of Medicare data.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.
Authors: Vogelzang NJ, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

Real-world treatment patterns and costs in Medicare beneficiaries newly diagnosed with acute myeloid leukemia.
Abstract: ISPOR 22nd Annual European Congress, Boston, MA.

Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
Publication: Medical Oncology 2017 05; 34(5): 88
Authors: Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E.
**Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.**
*Publication:* Advances in Therapy 2017 04; 34(5): 1145-1156  
*Authors:* Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

**Healthcare cost of Medicare patients with previously treated chronic lymphocytic leukemia.**  
*Authors:* Reyes C, Gauthier G, Schmerold L, Guerin A.

**Multi-country retrospective chart audit study to examine deep molecular response (MR4.5) associated with second-line tyrosine kinase inhibitors in chronic phase - Chronic myelogenous leukemia (CML-CP).**  
*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain.  
*Authors:* Cortes J, Huynh L, Brandt P, DerSarkissian M, Zaccardelli G, Dalal D, Hussein J, Duh MS.

**Progression-free survival and overall survival in patients with chronic lymphocytic leukemia - Clinical benefits of achieving a deep response to first-line therapy.**  
*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain.  
*Authors:* Samp J, Guerin A, Foster R, Meissner B, Rokito A, Enschede SH, Gauthier G.

**Reduced healthcare resource utilization in patients with chronic lymphocytic leukemia achieving complete remission to first-line therapy.**  
*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain.  
*Authors:* Heitner Enschede S, Samp J, Guerin A, Foster R, Meissner B, Rokito A, Gauthier G.

**Relative progression-free survival over time of novel triplet regimens for the treatment of relapsed/refractory multiple myeloma.**  
*Abstract:* 22th Congress of the European Hematology Association, Spain, Madrid, Spain.  
*Authors:* Betts K, Chen C, Zichlin M, Brun A, Signorovitch J, Makenbaeva D.

**Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.**  
*Publication:* Journal of Medical Economics 2017 05: 1-7  
*Authors:* Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.

**Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.**  
*Publication:* Clinical Genitourinary Cancer 2017 07;  
*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

**Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.**  
*Publication:* Advances in Therapy 2017 06; 34(7): 1673-1685  
*Authors:* Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

**Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.**  
*Authors:* Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.
Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.
Publication: Cancer Research and Treatment 2017 07; 49(3): 578-587

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Publication: Journal of Medical Economics 2017 01; 20(1): 54-62

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Publication: Journal of Medical Economics 2017 09; 20(1): 63-71
Authors: Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.

Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
Publication: Prostate Cancer and Prostatic Diseases 2017
Authors: McKay R, Haider B, Duh MS, Valderrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen L, Kantoff P.

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Publication: Journal of Medical Economics 2017 09; 20(2): 121-128
Authors: Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.

Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Publication: Medical Oncology 2017 08; 34(9): 160
Authors: Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Publication: Cancer 2017 08; 123(15): 2875-2880

Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer.
Publication: Expert Opinion on Pharmacotherapy 2017 08; 18(12): 1167-1178
Authors: Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH.

Publication: Clinical Genitourinary Cancer 2017 15(4): e573-e582
Authors: Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ.

Publication: Leukemia and Lymphoma 2017 01; 58(8): 1968-1972
Authors: Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.
Access to Cancer Specialist Care and Treatment in Patients with Advanced Stage Lung Cancer.
Publication: Clinical Lung Cancer 2017
Authors: Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H.

Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.
Publication: Asia-Pacific Journal of Clinical Oncology 2017 04;

Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Publication: Journal of Medical Economics 2017 01; 20(4):
Authors: Rose DB, Nellesen D, Neary MP, Cai B.

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Authors: Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ.

Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.
Publication: Expert Review of Pharmacoeconomics & Outcomes Research 2017 03; 17(2): 153-164
Authors: Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, Chawla A.

Economic analysis of molecular mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Abstract: 5th Annual NASP Annual Meeting and Educational Conference, Washington, DC.
Authors: Dalal A, Dea K, Guerin A, Culver K.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Publication: Journal of Medical Economics 2017 04; 20(4): 328-336
Authors: Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.

Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC).
Abstract: American Academy of Dermatology 75th Annual Meeting, Orlando, FL.
Authors: Li N, Du EX, Chu L, Peeples M, Xie J, Barghout VE, Tang DH.

Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Publication: Journal of Medical Economics 2017 20(9): 945-951
Authors: Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.

Treatment Disruption of First-line Endocrine and Chemotherapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer (mBC).
Abstract: NCCN Annual Conference General Poster Session, Orlando, Florida.
Authors: Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.
Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.
Publication: Urology Practice. 2017 04; 4(3): 218-224
Authors: Pilon D, Ellis LA, Behl AS, Gozalo L, Emond B, Lefebvre P, Calabrese R, Prime H, Gaylis F.

Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy.
Publication: American Health and Drug Benefits 2017 05; 10(3): 143-152
Authors: Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Emond B, Romdhani H, Senbetta M.

Association between Duration of Somatostatin Analogs (SSAs) Use and Quality of Life in Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument.
Abstract: ASCO 2017, Chicago, IL.
Authors: Halperin DM, Huynh L, Beaumong J, Cai B, Totev t, Bhak R, Duh MS, Vekeman F, Neary M, Cella D.

Burden of illness in patients with acute myeloid leukemia aged 65 years ineligible for intensive chemotherapy.
Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, United States.
Authors: Lafeuille MH, Sundaram M, Lefebvre P, Emond B, Romdhani H, Senbetta M.

Abstract: American Society of Hematology (ASH)’s 59th Annual Meeting and Exposition, Atlanta, GA.
Authors: Wierda WG, Gauthier G, Meissner B, Guerin A, Samp JC.

Comparative efficacy with endocrine-based combination versus monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: A network metaanalysis.
Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, IL.

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States.

Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. Health plan population.
Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, IL.
Authors: Signorovitch J, Zhou Z, Ryan J, Chawla A.

Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.
Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, IL.

Cost-effectiveness of ceritinib in previously untreated alk-positive non-small cell lung cancer in the united states
Abstract: AMCP Nexus 2017 Dallas, TX.
Authors: Zhou ZY, Mutebi A, Han S, Bensimon A, Ricculli ML, Xie J, Dalal AA, Culver KW.

Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide.
Publication: Journal of Managed Care and Specialty Pharmacy 2017 02; 23(2): 225-235
Authors: Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA.
Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Data From a Multicenter Chart Review Study.

Abstract: AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA.
Authors: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, IL.
Authors: Signorovitch J, Janku F, Wheler JJ, Miller VA, Ryan J, Zhou Z, Chawla A.

Healthcare resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency.

Publication: Journal of Managed Care and Specialty Pharmacy 2017 23(2): 214-224
Authors: Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

Impact of FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO.
Authors: Xie J, Parikh K, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

Oncologist preferences in advanced soft tissue sarcoma: A discrete choice experiment.

Abstract: ASCO Quality Care Symposium, Orlando, FL.

Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval.

Authors: Johnson DR, Omuro AM, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Uhm JH.

Overall survival in patients with metastatic urothelial cancer by first-line therapy.

Abstract: ISPOR 20th Annual European Congress, Glasgow, Scotland.

Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.

Abstract: ASCO Quality Care Symposium, Orlando, FL.
Authors: Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory posthoc analysis of COU-AA-302 trial data.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, United States.
Authors: Pilon D, Behl AS, Kamstra R, Xiao Y, Lafeuille MH, Lefebvre P, Freedland SJ.

Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data

Dominic Pilon.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO.
Authors: Behl AS, Kamstra R, Xiao Y, Lafeuille MH, Lefebvre P, Freedland SJ.
Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL.
Authors: Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.

Abstract: Genitourinary Cancers Symposium. Orlando, FL.

Real-world economic outcomes during time on treatment among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.

Abstract: AMCP Managed Care & Specialty Pharmacy Annual Meeting. Denver, CO.
Authors: Nicholas J. Vogelzang, Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Mark Meiselbach, Jose Ricardo Perez, Neeraj Agarwal.

Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.

Authors: Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.

Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.

Abstract: Genitourinary Cancers Symposium. Orlando, FL.
Authors: Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among postmenopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC).

Abstract: ASCO Quality Care Symposium. Orlando, FL.
Authors: Li N, Du EX, Chu L, Peeples M, Xie J, Barghout VE, Tang DH.

Real-world treatment patterns and costs in patients with newly diagnosed acute myeloid leukemia.

Abstract: AMCP Managed Care Specialty Pharmacy Annual Meeting. Denver, Colorado.

Refill gaps and dose reductions in patients treated with abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ).

Authors: Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

Severe Adverse Events Impact Overall Survival and Costs In Elderly Patients with Advanced NSCLC On Second-Line Therapy.

Authors: Borghaei H, YimYM, Guerin A, Gandhi M, Pivneva I, S S, Ionescu-Ittu R.

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation.

Abstract: 59th ASH Annual Meeting and Exposition, Atlanta, GA.
Authors: Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL.
Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, IL.

Authors: Ritchie EK, Wolff JE, Latremouille-Viau D, Guerin A, Pivneva I, Briggs O, Joseph GJ, Atallah EL.

What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?


Authors: Bajaj P, Latremouille-Viau D, Guerin A, Reyes C, Kurian A, Stein A, Cortazar P.

Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC).

Abstract: 41st European Society for Medical Oncology Congress, ESMO., Denmark.


Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer.

Publication: Current Medical Research and Opinion 2016 11; 32(11): 1911-1918

Authors: Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J.

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices.

Publication: Clinical Lymphoma, Myeloma & Leukemia 2016 10; 16(11): 625-636 e623


PS01.70: Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States: Topic: Medical Oncology.

Publication: Journal of Thoracic Oncology 2016 12; 11(11s): S314-s315

Authors: Bendaly E, Dalal A, Culver K, Galebach PJ, Bocharova I, Foster R, Struebbe G, Guerin A.

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.

Publication: Journal of Medical Economics 2016 05; 19(5): 526-536


Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.

Publication: Breast Cancer Research and Treatment 2016 05; 157(1): 145-156


The economic burden of brain metastasis among lung cancer patients in the United States.

Publication: Journal of Medical Economics 2016 05; 19(5): 526-536


Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.

Publication: Journal of Medical Economics 2016 05; 19(5): 462-468

Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.

*Publication:* Current Medical Research and Opinion 2016 05; 32(5): 817-827
*Authors:* Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.

Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors.

*Authors:* Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.

*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

Economic burden of common adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).

*Publication:* Journal of Clinical Oncology 2016 34(7_suppl): 21

Efficacy of front-line treatment combinations with ponatinib versus 1st-and 2nd-generation tyrosine kinase inhibitors for Ph+ acute lymphoblastic leukemia: A meta-analysis and meta-regression.

*Publication:* Haematologica 2016 101: 33
*Authors:* Jabbour E, DerSarkissian M, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, Duh MS.

Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.

*Publication:* Advances in Therapy 2016 05; 33(6): 983-997
*Authors:* Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A.

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.

*Publication:* Expert Opinion on Pharmacotherapy 2016 04; 17(9): 1189-1196

Economic burden of relapsed/refractory chronic lymphocytic leukemia.

*Abstract:* 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, NSW Australia.


*Publication:* Cancer Med 2016 02; 5(2): 209-220
*Authors:* Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ.

Cost per month of overall survival and progression-free survival: Everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma.

*Authors:* Swallow E, Ghate S, Messali A, McDonald E, Duchesneau E, Perez JR.


*Abstract:* 15th International Kidney Cancer Symposium. Miami, FL.
*Authors:* Ghate S, Li N, Swallow E, Zichlin M, Duchesneau E, Kang B, Perez JR.

**Abstract:** 15th International Kidney Cancer Symposium. Miami, FL.

**Authors:** Vogelzang N, Pal S, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Perez JR, Agarwal N.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

**Publication:** Lung Cancer 2016 08; 98: 9-14

**Authors:** Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J.

Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.

**Publication:** Journal of Medical Economics 2016 08; 19(8): 777-784

**Authors:** Pilon D, Queener M, Lefebvre P, Ellis LA.

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.

**Publication:** Current Medical Research and Opinion 2016 01; 32(4): 741-747

**Authors:** Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.

Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.

**Publication:** Journal of Medical Economics 2016 04; 19(4): 414-423

**Authors:** Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.

Effectiveness of Everolimus versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients with Multiple Metastatic Sites.

**Publication:** Clinical Therapeutics 2016 03; 38(4): 905-917

**Authors:** Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.

**Publication:** Clinical Genitourinary Cancer 2016 04; 14(2): 160-167 e163

**Authors:** Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

**Publication:** Leukemia 2016 04; 30(4): 995-998

**Authors:** Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.

Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer.

**Abstract:** International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer, Vienna, Austria.

**Authors:** Ganti AK, Hirsch F, Wynes MW, Ravelo A, Ramalingam S, Ionescu-Ittu R, Pivneva I, Borghaei H.

Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States.

**Abstract:** Chicago Multidisciplinary Symposium in Thoracic Oncology (CMSTO), Chicago, IL.

**Authors:** Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebke G, Guerin A.
Abstract: IASLC 17th World Conference on Lung Cancer (IASLC WCLC 2016) Vienna, Austria.
Authors: Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

Severe adverse events impact overall survival (OS) and costs in elderly patients with advanced NSCLC on second-line therapy.
Abstract: International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer, Vienna, Austria.
Authors: Borghaei H, Yim YM, Guerin A, Gandhi M, Pivneva I, Shi S, Ionescu-Ittu R.

Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US.
Authors: Li N, Ohashi E, Koo V, Xie J, Hao Y, Tang DH.

Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
Abstract: IASLC 17th World Conference on Lung Cancer (IASLC WCLC 2016) Vienna, Austria.
Authors: Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

Abstract: IKCS 2016 Annual Meeting, Miami, FL.
Authors: Nicholas J. Vogelzang, Sumanta K. Pal, Sameer Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Jose Ricardo Perez, Neeraj Agarwal.

Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.
Abstract: Annals of Oncology Conference: 41st European Society for Medical Oncology Congress, ESMO, Denmark.
Authors: Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB.

Epidemiological assessment of real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.
Authors: Huynh L, Herring M, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

Patient characteristics and Overall Survival (OS) in the post-docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) community setting.
Authors: Cheng WY, Miao R, Duh MS, Vekeman F, Sung J, Gauthier-Loiselle M, Fortier J, Dhawan R, Oh WK.

Access to biomarker testing in patients with advanced nonsmall cell lung cancer.
Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 (Date of Publication: May 2016), United States.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 United States. (Date of Publication: May 2016), United States.
Authors: Ganti AK, Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ionescu-Ittu R, Pivneva I, Ramalingam SS.
Disparities in treatment patterns and outcomes between caucasian and African American patients with multiple myeloma (MM).

Abstract: ASCO Annual Meeting, Chicago, IL.


Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 (Date of Publication: May 2016), United States.


Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval.


Authors: Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Macalalad AR, Shi S, Uhm JH.

Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 United States. (Date of Publication: May 2016), United States.

Authors: Bonnet P, Cloutier M, McKee MD, Loiselle MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL.

Reduction in hospital visits in patients with chronic myeloid leukemia (CML) with better adherence to tyrosine kinase inhibitors (TKI) and increased molecular monitoring frequency.

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 United States. (Date of Publication: May 2016), United States.

Authors: Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis.


Authors: Vogelzang NJ, Signorovitch JE, Swallow E, Peeples M, Koo V, Perez JR, Ghate S, Pal SK.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.

Abstract: International Association for the Study of Lung Cancer, Chicago, IL.


Economic model to examine the cost benefit associated with resolution or improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide lar in patients with neuroendocrine tumors based on data from a retrospective chart review study at three large tertiary oncology centers in the United States.

Abstract: ISPOR 21st Annual International Meeting Research, Washington, DC.

Authors: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy.

Abstract: ISPOR 21st Annual International Meeting Research Washington, DC

Authors: Hao Y, Li N, Fang A, Koo V, Peeples M, Kageleiry A.
Real-world treatment patterns of everolimus + exemestane in patients with hormone-receptor-positive, human epidermal growth factor receptor-negative advanced breast cancer by line of therapy: A global chart review.

Abstract: 
ISPOR 21st Annual International Meeting Research, Washington, DC.

Treatment sequences, patient characteristics, and overall survival of patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.

Abstract: 
ISPOR 21st Annual International Meeting Research, Washington, DC.
Authors: Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Fortier J, Dhawan R.

Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.

Authors: Daniel Shao-Weng Tan, Geoffrey Liu, Dong-Wan Kim, Michael Thomas, Enriqueta Felip, James Signorovitch, Jie Zhang, Tomek Szzcudlo, Alice Shaw, et al.

The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.

Authors: Jie Zhang, Yan Song, Zheng-Yi Zhou, Chenxue Zhang, James Signorovitch.

Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer.

Abstract: AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA.

Real-World Treatment Patterns and Brain Metastases Development in ALK-Positive Non-Small Cell Lung Cancer.

Abstract: 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA.
Authors: Betts K, Song J, Guo J, Wong W, Ravelo A, M. S.

Treatment patterns and healthcare costs in newly diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States: A retrospective claims database analysis.

Abstract: Academy of Managed Care Pharmacy (AMCP) 2016, San Francisco, CA.
Authors: Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon-Sanschagrin P, Chen L.

Treatment patterns and key factors associated with high treatment costs among commercially insured patients with advanced basal cell carcinoma.

Abstract: 74th Annual Meeting of the American Academy of Dermatology, Washington, DC.
Authors: Migden M, Wei J, Tang W, Herrera V, Xie J, Palmer J.

Survival and Tumor Response Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Systematic Literature Review.

Abstract: Multidisciplinary Head and Neck Cancer Symposium, Scottsdale AZ.
Authors: Signorovitch J, Li N, Zhang C, Shaw J, Dastiani H, Orsini L.
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US.

**Publication:** Current Medical Research and Opinion 2016 02; 32(2): 385-394

**Authors:** Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.

Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.

**Abstract:** Genitourinary Cancers Symposium San Francisco, CA United States.

**Authors:** McKay RR, Haider B, Duh MS, Valdarrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen LK, Kantoff PW.

Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.

**Abstract:** Genitourinary Cancers Symposium, San Francisco, CA.

**Authors:** Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T.

Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: A US claims study.

**Abstract:** NCCN 21st Annual Conference, Hollywood, FL.

**Authors:** Li N, Hao Y, Tang D, Koo V, Fang A, Peeples M, Kageleiry A.

Factors and treatment patterns associated with everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer.

**Abstract:** NCCN 21st Annual Conference, Hollywood, FL.

**Authors:** Hao Y, Tang D, Li N, Peeples M, Fang A, Kageleiry A, V K.

Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

**Publication:** International Journal of Hematologic Oncology 2016 07; 5(2): 63-75

**Authors:** Maziarz RT, Guérin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.

**Publication:** Springerplus 2016 03; 5: 395


**Publication:** Journal of Thoracic Oncology 2015 09; 10(9 SUPPL. 2): S380

**Authors:** Zhou J, Han S, Yang F, Wu E.Q, Xie J, Wang X, Li H, Wang J.

Patient outcomes following curative-intent lung resection among non-small cell lung cancer (NSCLC) patients in China.

**Publication:** Journal of Thoracic Oncology 2015 09; 10(9 SUPPL. 2): S677

**Authors:** Zhou J, Wu E.Q, Yang F, Xie J, Han S, Wang X, Song H, Wang J.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection.

**Publication:** JAMA Oncol 2015 09; 1(6): 797-805

**Authors:** Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.
Authors: Xie J, Hao Y, Zhou ZY, Qi CZ, De G, Gluck S.

Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Publication: Expert Opinion on Pharmacotherapy 2015 10; 16(14): 2101-2111
Authors: Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment.
Publication: J Manag Care Spec Pharm 2015 11; 21(11): 1088
Authors: Chen L, Wu EQ.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Publication: Current Medical Research and Opinion 2015 05; 31(5): 993-1001

Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.
Abstract: 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, United States.
Authors: Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Publication: Current Medical Research and Opinion 2015 03; 31(3): 537-545
Authors: Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
Publication: Cancer Epidemiology 2015 06; 39(3): 307-312

Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Publication: Current Medical Research and Opinion 2015 06; 31(6): 1095-1103
Authors: Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA.

Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.
Publication: Am Health Drug Benefits 2015 06; 8(4): 185-195
Authors: Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

The epidemiology of herpes zoster and its complications in Medicare cancer patients.
Publication: BMC Infectious Diseases 2015 02; 15: 106
Authors: Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Publication: Current Medical Research and Opinion 2015 02; 31(02): 263-273
Authors: Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C.
Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.

Publication: Exp Hematol Oncol 2015 12; 4(31): 31
Authors: Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ.

Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.

Publication: Current Medical Research and Opinion 2015 08; 31(8): 1561-1572
Authors: Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS.

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.

Publication: Current Medical Research and Opinion 2015 06; 31(8): 1573-1582
Authors: Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.

Publication: J Comp Eff Res 2015 05; 4(4): 315-326
Authors: Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J.

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Publication: Cancer Med 2015 05; 4(8): 1205-1213
Authors: Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM.

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.

Publication: Current Medical Research and Opinion 2015 08; 31(8): 1587-1597


Publication: Journal of Medical Economics 2015 04; 18(4): 312-322
Authors: Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.


Publication: Expert Opinion on Pharmacotherapy 2015 04; 16(6): 805-819

A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.

Publication: BMC Cancer 2015 03; 15: 175
Authors: Wagner MJ, Amodu LI, Duh MS, Korves C, Solleza F, Manson SC, Diaz J, Neary MP, Demetri GD.

Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study.

Abstract: 57th Amererican Society of Hematology Annual Meeting and Exposition, Orlando, FL.
Authors: Leleu X, Mateos M-V, Delforge M, Lewis P, Schindler T, Gibson CJ, Yang M, Weisel K.
A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond.

Abstract: San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX.
Authors: Gauthier G, Guerin A, Zhdanava M, Wu E.

Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites.

Authors: Xie J, Hao Y, Li N, Lin P, Ohashi E, Koo V, Wu E.

Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from US payers’ perspective.

Abstract: 57th Annual Meeting of the American Society of Hematology, ASH 2015, Orlando, FL.
Authors: Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.

Abstract: 57th ASH Annual Meeting and Exposition.
Authors: Guerin A, Ray S, Gauthier G, Hsu L-I, Zhdanava M, Wu E.

Nilotinib vs Dasatinib as Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) based on Real-World Data.

Abstract: ASH annual meeting, Orlando, FL.
Authors: Li N, Yang C, Fan L, Totev T, Guerin A, Chen L.

Real-world effectiveness of everolimus subsequent to different first targeted therapies (TTs) for the treatment of advanced renal cell carcinoma (arCC): Synthesis of three retrospective chart reviews.

Abstract: 14th International Kidney Cancer Symposium, Miami, FL.
Authors: Pal SK, Signorovitch JE, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2-metastatic breast cancer patients with liver metastasis or multiple metastatic sites.

Authors: Li N, Hao Y, Lin P, Koo V, Ohashi E, Wu E, Xie J.

Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US.

Abstract: Breast Cancer Symposium, San Antonio, TX.
Authors: Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guerin A.

Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients.

Abstract: 57th ASH Annual Meeting and Exposition.
Authors: Guerin A, Ray S, Gauthier G, Hsu L-I, Zhdanava M, Wu EQ.

What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?

Abstract: San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX.
Authors: Cloutier M, Guerin A, Heroux J, Emond B, Wu E.

Comparative efficacy of treatments for previously treated advanced or metastatic non-small cell lung cancer (NSCLC): a network meta-analysis.

Abstract: ISPOR 18th Annual European Congress, Milan, Italy.
Authors: Zhang J, Zhou Z, Cai X, J. S.
Cost-effectiveness of ceritinib in previously treated patients with crizotinib in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.

Abstract: ISPOR 18th Annual European Congress, Milan, Italy.


Abstract: ISPOR 18th Annual European Congress, Milan, Italy.


Overall Survival (Os) and Quality-of-Life (Qol) Outcomes in Recurrent Or Metastatic Squamous Cell Carcinoma of the Head And Neck (Scchn): A Systematic Literature Review.

Abstract: ISPOR 18th Annual European Congress, Milan, Italy.

Authors: Signorovitch J, Li N, Zhong Y, Shaw J, Dastani H, L. O.

Overall Survival (Os), Quality of Life (Qol), and Neurocognitive Function (Nf) in Recurrent Glioblastoma Multiforme (Gbm): A Systematic Literative Review.

Abstract: ISPOR 18th Annual European Congress, Milan, Italy.

Authors: Signorovitch J, Li N, Ohashi E, Dastani H, Shaw J, L. O.

Patient relevant outcomes in recurrent glioblastoma: a systematic literature review.

Abstract: Society for Neuro-Oncology Annual Scientific Meeting and Education Day, San Antonio, TX.

Authors: Signorovitch J, Li N, Kim S, Dastani H, Shaw J, Orsini L.

Real-world effectiveness, dosing, and drug costs of everolimus (EVE) and axitinib (AXI) as second targeted therapies (T Ts) for advanced renal cell carcinoma (aRCC) in the US: A retrospective chart review.

Abstract: 14th International Kidney Cancer Symposium, Miami, FL.

Authors: Jonasch E, Pal SK, Signorovitch JE, Li N, Liu Z, Perez JR, Vogelzang NJ.


Abstract: AMCP Nexusus, Orlando, FL.


Access to cancer directed therapies and cancer specialists in patients with metastatic lung cancer.

Abstract: 16th World Conference on Lung Cancer (WCLC), Denver, CO.


Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study.

Abstract: European Cancer Congress (ECC) 2015, Vienna Austria.

Authors: Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J.

Diverse characteristics of ALK+ NSCLC patients in the United States.

Abstract: 2015 World Conference on Lung Cancer (WCLC), Denver, CO.

Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?

Abstract: European Cancer Congress 2015, ECC 2015, Vienna Austria.

Physician decision-making on modifying or discontinuing crizotinib in ALK+ NSCLC: A survey of U.S. physicians.

Abstract: 2015 World Conference on Lung Cancer (WCLC), Denver, CO.

Real-world characteristics and outcomes for ALK+ NSCLC in Korea.

Abstract: 2015 World Conference on Lung Cancer (WCLC), Denver, CO.


Abstract: 16th World Conference on Lung Cancer (WCLC), Denver, CO.

Symptoms of bone and liver metastases in patients with ALK+ Non-Small Cell Lung Cancer (NSCLC).

Abstract: 2015 World Conference on Lung Cancer (WCLC), Denver, CO.
Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ, Macalalad A.

Testing and treatment practice of oncologists managing ALK+ NSCLC: International physician survey across four regions.

Abstract: European Cancer Congress (ECC) 2015, Vienna Austria.

Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC.

Abstract: 16th World Conference on Lung Cancer, Denver, CO.
Authors: Geoffrey Liu, J Zhang, Zheng-Yi Zhou, Junlong Li, Xiaopeng Cai, James Signorovitch.

Treatment patterns and best response in a contemporary cohort of patients with relapsed / refractory chronic lymphocytic leukemia with 17p deletion.

Abstract: Leukemia and Lymphoma Conference, Sydney, NSW Australia
Authors: Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Ittu, Guerin A, Yim YM, Reyes C.

Treatment patterns and survival among ALK+ non-small cell lung cancer (NSCLC) patients: A chart review study.

Abstract: European Cancer Congress (ECC) 2015, Vienna Austria.
What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses.

Abstract: European Cancer Congress (ECC) 2015, Vienna Austria.

Bone Pain, Skeletal-Related Events and Opioid Analgesic Use in Prostate Cancer Patients with Bone Metastases.

Abstract: ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA.
Authors: Eapen S, Valderrama A, Hennessey K, Jones CP, Wen L, Germino J, Duh MS, Vekeman F.

Treatment patterns and characteristics of postmenopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.

Abstract: ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA.
Authors: Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.

Median overall survival meta-analysis comparing brentuximab vedotin with other therapies in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant.

Abstract: 13th International Conference on Malignant Lymphoma, Lugano Switzerland.

Real-world outcomes of patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion.

Abstract: ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA.
Authors: Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.

Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.

Abstract: 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Ayyagari R, Cheng WY, Cai X, Jones C, Ma E, Bonthapally V, Zhu Y, Lefebvre P, Wei LJ, Duh MS.

Association between duration of treatment (DOT) and healthcare costs in multiple myeloma (MM) patients receiving initial therapy with bortezomib.

Abstract: 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Xiao Y, Wong BJ, Lefebvre P, Fortier J, Ma E, Bonthapally V, Duh MS.

Budgetary impact analysis of abiraterone acetate plus prednisone (AA+P) versus enzalutamide (ENZ) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract: AVBCC 5th Annual Conference, Washington, D.C.
Authors: Ellis L, Pilon D, Lefebvre P.

Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: A comparison of retrospective chart reviews conducted in 2012 and 2014.

Abstract: 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Perez JR, Pal SK, Signorovitch JE, Reichmann WM, Li N, Liu Z, Jonasch E, Vogelzang NJ.

Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.

Abstract: 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R.
Comparative effectiveness of everolimus and axitinib as second targeted therapy of metastatic renal cell carcinoma in the United States: a retrospective chart review.

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Signorovitch JE, Pal SK, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ, Jonasch E.

Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ.

Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer.

**Abstract:** ISPOR 20th Annual International Meeting Research Philadelphia, PA.
**Authors:** Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naive anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Tan DSW, Araujo A, Zhang J, Signorovitch JE, Zhou ZY, Cai X, Liu G.

Economic burden of relapsed/refractory chronic lymphocytic leukemia.

**Abstract:** Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Guerin A, Ray S, Gauthier G, Hsu L, Zhdanava M, Heroux J, Wu EQ.

The evolving treatment patterns in multiple myeloma (MM): Retrospective database analyses of U.S. community oncology electronic medical records and administrative claims.

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** MS D, Lefebvre P, Fortier J, Ma E, Bonthapally V, Wong BJ.

Overall survival in post-menopausal women with HR+/HER2-metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy.

**Abstract:** ISPOR 20th Annual International Meeting Research, Philadelphia, PA.
**Authors:** Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille M, Duh MS.

Realworld treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with zivafibercept (Z) in community oncology practices in the United States (US).

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Ivanova JI, Saverno K, Sung J, Sheng Duh M, Zhao C, Cai X, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

Systematic literature review (SLR) of clinical and realworld observational studies of octreotide LAR for treatment of neuroendocrine tumors (NETs).

**Abstract:** 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
**Authors:** Sorg R, Neary M, Tang C, Song C, Xie J.
Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.

Abstract: 2015 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.

Treatment patterns of endocrine therapy and chemotherapy among post-menopausal women with HR+/HER2-Metastatic Breast Cancer.

Authors: Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR, Ohashi E, Zhou Z, Wu EQ.

Overall survival with first line endocrine therapy or chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review study in the US.

Abstract: AMCP’s 27th Annual Meeting, San Diego, CA.
Authors: Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, Wu EQ.

Real-World Dosing and Drug Costs with Everolimus (EVE) and Axitinib (AXI) as 2nd Targeted Therapies (TTs) for Metastatic Renal Cell Carcinoma (mRCC): A Retrospective Chart Review.

Abstract: AMCP 27th Annual Conference, San Diego, CA.
Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: considerations for U.S. payors.

Abstract: AMCP 27th Annual Meeting & Expo, San Diego, CA.
Authors: Ellis L, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) with the T315i mutation.

Abstract: 57th Annual Meeting of the American Society of Hematology, San Diego, CA.

Current treatment characteristics in postmenopausal women with HR+/HER2- metastatic breast cancer.

Authors: Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille MN, Duh MS.

Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.

Abstract: 2015 Genitourinary Cancers Symposium, Orlando, FL.

Treatment patterns of recently approved therapies for metastatic castration resistant prostate cancer (mCRPC): Real world evidence from three datasets.

Abstract: ASCO Genitourinary Cancers Symposium, Orlando, FL.
Authors: Ellis L, Lafeuille MH, Gozalo L, P L, Malangone-Monaco E, Wilson K, McKenzie S.

Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.

Publication: Current Medical Research and Opinion 2015 05; 31(7): 1377-1389
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.
Publication: Breast Cancer (Auckl) 2015 09; 9: 67-72
Authors: Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ.

Cost-effectiveness of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).
Abstract: Association of Value-Based Cancer Care, Fifth Annual Conference, Washington, DC.
Authors: Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Assessment Based on Data from a Multicenter Retrospective Chart Review Study.
Abstract: 12th Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO), Arlington, VA.
Authors: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke MH, Benson AB.

Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).
Abstract: 2015 NANETS Symposium, Austin, Texas.
Authors: Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
Authors: Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.
Publication: Drugs Context 2015 03; 4
Authors: Girvan AC, Carter GC, Li L, Kaltenboeck A, Ivanova J, Koh M, Stevens J, Hayes-Larson E, Lahn MM.

Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.
Publication: Current Medical Research and Opinion 2015 01; (0): 1-38
Authors: Fuldeore M, Yang H, Soliman AM, Winkel C.

Publication: Oncologist 2014 09; 19(9): 930-936
Authors: Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Publication: Oncologist 2014 09; 19(9): 901-908
Authors: Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Publication: Clinical Lymphoma, Myeloma & Leukemia 2014 10; 14(5): 380-388
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.
*Publication:* Current Medical Research and Opinion 2014 10; 30(10): 2041-2050

One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
*Publication:* Current Medical Research and Opinion 2014 11: 1-8
*Authors:* Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ.

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
*Publication:* Current Medical Research and Opinion 2014 11; 30(11): 2343-2353

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
*Publication:* Current Medical Research and Opinion 2014 11; 30(11): 2317-2328

Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.
*Publication:* J Manag Care Spec Pharm 2014 05; 20(5): 477-484
*Authors:* Lafeuille MH, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, Kozma C.

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
*Publication:* Cancer Treatment Reviews 2014 03; 40(2): 285-292
*Authors:* Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L.

Real-world treatment patterns among patients with advanced gastric cancer in Taiwan.
*Abstract:* 16th World Congress on Gastrointestinal Cancer, Barcelona, Spain

Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2014 06; 14(3): 245-251
*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ.

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
*Publication:* Current Medical Research and Opinion 2014 07; 30(7): 1345-1352
*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
*Publication:* Journal of Medical Economics 2014 02; 17(2): 89-98
*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.

**Publication:** Journal of Medical Economics 2014 12: 1-8

**Authors:** Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ.

Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.

**Publication:** PloS One 2014 12; 9(12): e114264

**Authors:** Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

**Publication:** Lung Cancer 2014 12; 86(3): 350-357

**Authors:** Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S.

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.

**Publication:** Journal of Medical Economics 2014 12; 17(12): 837-845

**Authors:** Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.

Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.

**Publication:** Melanoma Research 2014 12; 24(6): 602-610

**Authors:** Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

**Publication:** Cancer Med 2014 12; 3(6): 1517-1526


Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.

**Publication:** Journal of Gastrointestinal Cancer 2014 12; 45(4): 431-440

**Authors:** Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.

**Publication:** Current Medical Research and Opinion 2014 08; 30(8): 1537-1545

** Authors:** Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J.

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

**Publication:** Current Medical Research and Opinion 2014 04; 30(4): 537-545

**Authors:** Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.

Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer.

**Abstract:** 2014 San Antonio Breast Cancer Symposium, San Antonio, TX.

Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).

Abstract: SABSC, San Antonio, TX.
Authors: Signorovitch J, Wang J, Tan R, Thomason D, Kageleiry A, Swallow E.

Real-world treatment durations without chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).

Abstract: SABSC, San Antonio, TX.

A retrospective analysis of treatment patterns in elderly patients with chronic myeloid leukemia receiving dasatinib or nilotinib as second-line therapy after imatinib.

Abstract: 56th Annual Meeting of the American Society of Hematology, San Francisco, CA.

Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP).

Abstract: 56th Annual Meeting of the American Society of Hematology, San Francisco, CA.
Authors: Guerin A, Revol C, Ramanakumar AV, Foster R, Wu EQ, Mhatre SK, Chen L.

Overall survival in patients with HER2+ early stage breast cancer patients treated with trastuzumab in the US department of defense practice setting.


Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.

Abstract: 19th Annual Scientific Meeting of the Society for Neuro-Oncology Conference, Miami, FL.

Above standard dose of octreotide-lar in patients with neuroendocrine tumors (NET) for control of carcinoid syndrome symptoms: A multi-center retrospective chart review study.

Abstract: 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei Taiwan (Republic of China).
Authors: Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States.

Abstract: ACMP 2014 Nexus Meeting, Boston, MA.
Authors: Xie J, Hao Y, Zhou J, Qi C, De G, S G.

Authors: Senbetta M, Robitaille M-N, McKenzie RS, Lefebvre P.

Description of ALK+ NSCLC patient characteristics and ALK testing patterns.
Abstract: 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL.
Economic burden and treatments of progression to metastatic disease in ALK+ NSCLC patients.

Economic burden of brain metastases among lung cancer patients.
Abstract: AMCP’s 2014 Nexus meeting, Boston, MA.
Authors: Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Guérin A.

Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review.
Abstract: 13th International Kidney Cancer Symposium, Chicago, IL.
Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Liu Z, Perez JR, Vogelzang NJ.

Association between Risk of Recurrence Assessment and Adjuvant Treatment (Tx) Duration in Patients (Pts) with Resected Gastrointestinal Stromal Tumors.
Authors: Guérin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu EQ, Conley AP.

Abstract: SOHO Annual Meeting, Houston, TX.
Authors: Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Predictors of treatment (tx) response and progression in BRAF V600E metastatic melanoma (mM) patients (pts) with brain metastases (BM) receiving vemurafenib (vem) in a real-world setting.
Authors: Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Yeun MY, Sarang A, Reyes C, Guerin A.

Treatment failure patterns in patients with mantle cell lymphoma: results of a large U.S. observational study.
Abstract: ESMO Congress, Madrid, Spain.
Authors: Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Incidence of hepatic resection among colorectal cancer patients with liver metastases.
Abstract: 16th World Congress on Gastrointestinal Cancer, ESMO 2014, Spain.
Authors: Betts K, Lu M, Zhuo D, Sharma H, Morlock R, Sommer N, Ogale S.

Treatments and clinical burden among hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature review.
Abstract: 19th Congress of the European Hematology Association, Milan Italy.
Authors: Bonthapally V, Ayyagari R, Yang H, Wu EQ, Shonukan O.

Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices.
Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamidedexamethasone (VCd) compared to bortezomiblenalidomide-dexamethasone (VRd) for initial treatment of newly diagnosed multiple myeloma (MM).
Abstract: AVBCC 3rd Annual Conference, Hollywood, FL.
Authors: Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanans, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV.
Description of ALK+ NSCLC patient characteristics and ALK testing patterns.

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Impact of underestimation of risk on treatment duration and recurrence in GIST patients.

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Guerin A, Conley AP, Sasane M, Macalalad AR, Huang Q, Schwiep FA, Keir CH, Wu EQ.

One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.

Abstract: ASCO 50th Annual Meeting, Chicago, IL.
Authors: Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ.

Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice.

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States.

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.


Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Bonthapally V, Lafeuille MH, Fortier J, Duh MS, Ng Y, Van De Velde H, Niculescu L, Ma E, Goy A.

Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.


Treatment and survival patterns among ALK+ NSCLC patients following crizotinib discontinuation.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.

Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Abstract: 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guerin A.
**Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices.**

*Abstract:* 2014 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.


**Brain Metastases in Patients with ALK+ Non-Small Cell Lung Cancer: Treatment Patterns and Economic Burden.**

*Abstract:* AMCP's 26th Annual Meeting & Expo, Tampa, FL.

*Authors:* Macalalad AR, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Guérin A.

**Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies.**


**Duration of treatment by line of therapy among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* AMCP’s 27th Annual Meeting & Expo, San Diego, CA.

*Authors:* Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin PL, Ohashi E, Zhou Z, Wu EQ.

**Economic burden of bone and liver metastases in patients with ALK+ non-small cell lung cancer.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ.

**Monitoring of multifunctional nanocomplex containing gold coated iron oxide particles in human prostate tumoral cells through MRI.**

*Abstract:* 2014 World Molecular Imaging Congress, Seoul, South Korea.

*Authors:* Oghabian MA, Montazerabadi A, Delavari HH, Irajirad R, Muhammadnejad S.

**Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among post-menopausal women with recurrent HR+/HER2- metastatic breast cancer.**

*Abstract:* AMCP’s 27th Annual Meeting & Expo, San Diego, CA.

*Authors:* Song Y, Hao Y, Macalalad A, Lin PL, Signorovitch JE, Wu EQ.

**Robust feature selection and gene committee predictor for breast cancer patient survival prediction.**

*Abstract:* 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA.

*Authors:* Yang HH, Lee MP.

**Symptoms of bone and liver metastases in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).**

*Abstract:* AMCP’s 27th Annual Meeting & Expo, San Diego, CA.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver KW, Macalalad AR, Wu EQ.

**Treatment and Costs Post Crizotinib Monotherapy in Patients with ALK+ Non-Small Cell Lung Cancer: A Retrospective Claims Database Analysis.**

*Abstract:* AMCP’s 26th Annual Meeting & Expo, Tampa, FL.


**Treatment patterns and predictors of everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer in the US.**

*Abstract:* AMCP’s 27th Annual Meeting & Expo, San Diego, CA.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.
Underestimation of the Risk of Recurrence in Patients with Primary Resected Gastrointestinal Stromal Tumors.

**Abstract:** NCCN 19th Annual Conference, Hollywood, FL.

**Authors:** Conley AP, Sasane M, Guérin A, Macalalad AR, Huang Q, Schwiep F, Wu E.

Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors.

**Abstract:** 2014 Gastrointestinal Cancers Symposium, San Francisco, CA.

**Authors:** Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ.

Prostate cancer patients demonstrate adherence to medication use while on abiraterone acetate (AA) therapy.

**Abstract:** ASCO- Genitourinary Cancers Symposium, San Francisco, CA.

**Authors:** Kozma C, Slaton TS, Ellis LA, McKenzie RS, Lafeuille M, Grittner AM, Lefebvre P.

Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.

**Abstract:** ASCO- Genitourinary Cancers Symposium, San Francisco, CA.

**Authors:** Lafeuille M, Ellis LA, McKenzie RS, Grittner AM, Lefebvre P.

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

**Abstract:** 2014 Gastrointestinal Cancers Symposium, San Francisco, CA.

**Authors:** Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, Roman AS, Koh M, Lee HJ, Rajan N, Ballal S, Birnbaum H, Bang YJ.

Comparison of Survival, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.

**Abstract:** American Society of Hematology (ASH Annual Meeting), San Francisco, CA.


Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.

**Publication:** Springerplus 2014 05; 3: 236

**Authors:** Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG.

Comparison of Treatment Patterns of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.

**Abstract:** American Society of Hematology (ASH Annual Meeting), San Francisco, CA.


Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.

**Publication:** Current Medical Research and Opinion 2013 09; 29(9): 1075-1082

**Authors:** Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.


**Publication:** Journal of Oncology Practice 2013 09; 9(5): e212-219

**Authors:** Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L.

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.

**Publication:** Current Medical Research and Opinion 2013 06; 29(6): 623-631

**Authors:** Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.

**Publication:** Journal of Gastrointestinal Cancer 2013 06; 44(2): 190-198

**Authors:** Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.

**Publication:** Am Health Drug Benefits 2013 07; 6(6): 307-316

**Authors:** Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS.


**Publication:** Expert Opin Drug Saf 2013 07; 12(4): 455-463

**Authors:** Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernandez Pastor LJ, Bellmunt J.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.

**Publication:** Cancer 2013 119(16): 2990-2998

**Authors:** Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Impact of low-grade adverse events (AES) on health-related quality of life (HRQOL) in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (PH+CML-CP) from the enestnd trial: 48-month follow-up.

**Abstract:** 55th Annual Meeting of the American Society of Hematology, New Orleans, LA.

**Authors:** Chen L, Guerin A, Marynchenko M, Ionescu-Ittu R, Hiscock R, Nitulescu R, Pooja C, Hsu LI, Keir C, Wu EQ.

Multi-center experience with CELLSEARCH circulating tumor cell kit on patients with metastatic breast cancer.

**Abstract:** 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX.

**Authors:** Montero AJ, Eapen S, Tran KN, Gorin B, Adler P.

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer.

**Abstract:** ISPOR 16th Annual European Congress, Dublin, Ireland.

**Authors:** Campone M, Yang H, Faust E, Kageleiry A, Signorovitch J, Zhang J, Gao H.

Efficacy of brentuximab vedotin and other treatments in patients with relapsed or refractory (RR) systemic anaplastic large-cell lymphoma (SALCL): A systematic review.

**Abstract:** ISPOR 16th Annual European Congress, Dublin, Ireland.

**Authors:** Bonthapally V, Yang H, Macalalad AR, Wu EQ, Lutes R, Shonukan O, Chi A, Huebner D.

Glioblastoma treatment patterns and outcomes and resource use in the united states.

**Abstract:** 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology Conference, San Francisco, CA.

**Authors:** Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M.


**Abstract:** 9th International Symposium on Hodgkin Lymphoma Conference, Cologne, Germany.

**Authors:** Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.
Association between guideline-adherent imaging and overall survival following 2nd-line targeted therapy for metastatic renal cell carcinoma.

Abstract: 12th International Kidney Cancer Symposium, Chicago, IL.

Authors: Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver K, Scott JA, Vogelzang NJ.

Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.

Abstract: 12th International Kidney Cancer Symposium, Chicago, IL.


Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Abstract: 2013 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM.

Authors: Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL.

Overall survival and hospitalization rates in Medicare patients diagnosed with advanced NSCLC treated with bevacizumab-paclitaxel-carboplatin vs paclitaxel-carboplatin: A retrospective cohort study.

Abstract: 15th World Conference on Lung Cancer, Sydney, NSW Australia.

Authors: Langer CJ, Ravelo A, Hazard S, Guerin A L-VD, Ionescu-Ittu R, Wu EQ, Ramalingam SS.

Survival advancements in advanced non-small cell lung cancer in the past 20 years: A story of hope.

Abstract: 15th World Conference on Lung Cancer Conference, Sydney, NSW Australia.

Authors: Ravelo A, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Wu EQ.


Abstract: 12th International Kidney Cancer Symposium, Chicago, IL.


Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+), HER2−, Que Fallaron a Los Inhibidores De Aromatasa No Esteroides (IANES) En México.


Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

Abstract: 29th International Conference on Pharmacoeconomics and Therapeutic Risk Management Conference Montreal, QC Canada.

Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ.

Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver KW, Scott JA, Vogelzang NJ.
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Brammer M, Lalla D, Gauthier G, Guerin A, Giguere-Duval P, Wu EQ, Santos E.

Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Lalla D, Brammer M, Guerin A, Gauthier G, Giguere-Duval P, Wu EQ, Santos E.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Chen L, Guerin A, Wu EQ, Dea K, Goldberg SL.

The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Eapen S, Andrews R, Gorin B, Higano CS.

Health care resource utilization and cost of Medicare patients with non-small cell lung cancer (NSCLC).

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA.
Authors: Yenikomshian M, Hackshaw M, Cai X, Trahey A, Arondekar B, Knoll S, Duh MS.

Incremental cost of brain metastases among patients with metastatic melanoma.

Abstract: ISPOR 18th Annual International Meeting Conference, New Orleans, LA.
Authors: Vekeman F, Cloutier M, Yermakov S, Amonkar M, Arondekar B, Duh MS.

Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA.
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Observed abiraterone acetate utilization by prostate cancer (PC) patients in a large administrative claims database in the united states.

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA.
Authors: Lafeuille MH, Dean J, Lefebvre P, Ellis L, Senbetta M.

Prescribing decision drivers in patients with recurrent gastrointestinal stromal tumor (GIST) previously treated with adjuvant imatinib: A retrospective chart extract-based approach.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

A single-center experience with CELLSEARCH system circulating tumor cell test on patients with metastatic breast cancer.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Montero AJ, Eapen S, Andrews RM, Gorin B.
Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.

Abstract: Digestive Disease Week, Orlando, FL.
Authors: Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.


Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract-based approach.

Abstract: 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.
Authors: Gauthier G, Sasane M, Guérin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer.

Authors: Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E.

Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

Abstract: 14th International Myeloma Workshop Conference, Kyoto, Japan.
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States.

Abstract: 2013 Genitourinary Cancers Symposium, Orlando, FL.
Authors: Jonasch E, Signorovitch JE, Lin P, Liu Z, Culver KW, Pal SK, Scott JA, Vogelzang NJ.


Abstract: 2013 Genitourinary Cancers Symposium, Orlando, FL.
Authors: Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver KW, Scott JA, Pal SK, Jonasch E.

Above Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).

Authors: Goldman J, Hulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker A, Benso AB.

Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.

Publication: Journal of Medical Economics 2013 11; 16(2): 278-288
Authors: Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States (Re.).

Publication: Journal of Medical Economics 2013 12; 16(2): 260-262
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

Publication: Oncologist 2013 01; 18(1): 27-36
Authors: Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS.

Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.

Publication: Sarcoma 2013 12; 2013: 947413
Authors: Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B.

Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).

Abstract: NANETS 2013 Annual Conference, Charleston, SC.
Authors: Kulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker AW, Benson AB.

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.

Publication: Journal of Medical Economics 2013 11; 16(2): 221-230
Authors: Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guerin A.

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Publication: Journal of Medical Economics 2013 06; 16(1): 125-133
Authors: Guerin A, Wu EQ, Bolliu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A.

Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data.

Publication: Patient 2013 07; 6(3): 189-200
Authors: Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW.

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.

Publication: Exp Hematol Oncol 2013 12; 2(1): 32
Authors: Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.

Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Publication: Journal of Medical Economics 2013 16(2): 260-262
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.

Publication: Urologic Oncology 2012 11; 30(6): 848-855
Authors: Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.

Publication: Current Medical Research and Opinion 2012 11; 28(11): 1831-1839
Authors: Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E.
**Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.**

*Publication:* Leukemia and Lymphoma 2012 06; 53(6): 1146-1154

*Authors:* Lafeuillez MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS.

**Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.**

*Publication:* Medical Oncology 2012 06; 29(2): 786-794

*Authors:* Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS.

**Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.**

*Publication:* UroToday.com 2012 07

*Authors:* Xie J.

**The economic burden of metastatic breast cancer: a U.S. managed care perspective.**

*Publication:* Breast Cancer Research and Treatment 2012 07; 134(2): 815-822

*Authors:* Montero AJ, Eapen S, Gorin B, Adler P.


*Publication:* Current Medical Research and Opinion 2012 07; 28(7): 1164; author reply 1164-1165

*Authors:* Wu E, Chen L.

**A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.**

*Publication:* Current Medical Research and Opinion 2012 07; 28(7): 1155-1162

*Authors:* Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

**Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.**

*Publication:* Current Medical Research and Opinion 2012 02; 28(2): 213-219

*Authors:* Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C.

**Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.**

*Publication:* European Journal of Cancer 2012 02; 48(3): 311-323

*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN.


*Publication:* Journal of Medical Economics 2012 12;

*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.**


*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model.**

*Publication:* Applied Radiation and Isotopes 2012 04; 70(4): 583-588

Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12 month complete cytogenetic response failure: A chart review analysis.
Abstract: 54th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Authors: DeAngelo DJ, Chen L, Guerin A, Styles A, Aberki C, Giguere-Duval P, Wu EQ.

Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States.
Abstract: 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX.
Authors: Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.
Abstract: 54th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Authors: Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.
Abstract: 54th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Authors: Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Wu EQ.

Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib as second-line therapy.
Abstract: 54th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Authors: Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; A retrospective analysis.
Abstract: 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX.
Authors: Gauthier G, Guerin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D.

Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey.
Abstract: 54th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Authors: Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guerin A, Liu N, Kaminsky M, Wu EQ.

Meta-analysis of the efficacy and safety of bortezomib retreatment in patients with multiple myeloma (MM).
Abstract: 54th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with firstand second-line chemotherapies.
Authors: Hurvitz SA, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.
Abstract: ASCO’s Quality Care Symposium 2012, San Diego, CA.
Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.
A systematic review of the heterogeneity of treatment effect in ovarian cancer (OC)-Are there implications for outcomes research?


Authors: Chawla A, Nellesen D, Yee K, Brown J, Boye ME.

Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.

Abstract: 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV.


Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review in community oncology practices.

Abstract: 11th International Kidney Cancer Symposium Annual Meeting Proceedings, Chicago, IL.

Authors: Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Jonasch E.

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP).

Abstract: ESH-iCML International Conference, Baltimore, MD.

Authors: Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

Budget impact analysis of everolimus for ER+, HER2-metastatic breast cancer patients in the united states.

Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC.

Authors: Xie J, Diener M, De G, Wu EQ, Namjoshi M.

Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Guerin A, Conley AP, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Gauthier G, Guerin A, Styles A, Wu EQ, Brammer MG, Lalla D.

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.

Abstract: 2012 International MASCC/ISOO Symposium: Supportive Care in Cancer Conference, New York City, NY.

Authors: Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky M, Wu EQ, Lalla D.

Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Wagner M, Amodu L, Duh MS, Korves C, Solzeza F, Mykletun A, Manson S, Diaz J, Neery MP, Demetri GD.
Economic burden of hepatocellular carcinoma in China.

Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC.


Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI).

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Bonthapally V, Guerin A, Wu EQ, Gauthier G, Cloutier M, Holen KD, Ray S.

Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Chen L, Guerin A, Aberki C, Wu EQ, Ericson S, Jabbour E.

Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.


Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Signorovitch JE, Swallow E, Kantor E, Wang X, Hass T, Klimovsky J, Metrakos P.

PCN42 Health Care Utilization and Costs Among Lung Cancer Patients in China.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.


Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis.

Abstract: 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.

Abstract: American Urological Association Annual Meeting, Atlanta, GA.

Authors: Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M.

Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML).

Abstract: 8th Annual Meeting of the Hematology/Oncology Pharmacy Association, Orlando, FL.

Authors: Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ.

Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with colorectal cancer treated with an epidermal growth factor receptor inhibitor (EGFRI).


Authors: Bonthapally V, Guerin A, Wu EQ, Gauthier G, Holen KD, Ray S.
Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed with Advanced Ovarian Cancer.
*Publication:* Clinical Ovarian and Other Gynecologic Cancer 2012 12; 5(2): 67-77. e61  
*Authors:* Johnson SJ, Sorg RA, Borker RD, Duh MS.

Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.
*Publication:* Chemother Res Pract 2012 04; 2012: 913848  
*Authors:* Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB.

Re: Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases.
*Publication:* European Urology 2012 61(2): 427-428  
*Authors:* XIE J, NAMJOSHI M, WU E.

Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.
*Authors:* Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
*Publication:* Journal of Managed Care Pharmacy 2011 10; 17(8): 621-643  
*Authors:* Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
*Publication:* Urologic Oncology 2011 11; 29(6): 756-763  
*Authors:* Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
*Publication:* Prostate Cancer and Prostatic Diseases 2011 03; 14(1): 79-84  

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
*Publication:* Current Medical Research and Opinion 2011 06; 27(6): 1263-1271  
*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2011 08; 11(4): 326-335  
*Authors:* Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.
*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA.  
*Authors:* Guerin A, Bollu VK, Guo A, Stepner M, Griffin JD, Wu EQ.
Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting.
Abstract: 2011 Annual Meeting of the American College of Clinical Pharmacy Conference, Pittsburgh, PA.
Authors: Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E.

The association between treatment (TX) modifications due to adverse events (AES) and overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with sunitinib and sorafenib: Results from a multi-country study in Europe.
Authors: Oudard S, Porta C, Castellano D, McDermott R, Nathan P, McCaffrey J, Neary MP, Korves C, Dial Suthoff E, Duh M.

Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population.
Abstract: 10th International Conference on Cancer-Induced Bone Disease Conference, Sheffield, United Kingdom.
Authors: Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Veide N.

Complications associated with chemotherapy in patients with metastatic breast cancer.
Authors: Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S.

Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.
Authors: Yu AP, Diener M, Wu EQ, Namjoshi M.

Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.
Abstract: 2011 Breast Cancer Symposium, Chicago, IL.
Authors: Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.
Authors: Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

A pan-European study of treatment (TRX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC).

Treatment (TX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in Spain.
Authors: Castellano D, Duh MS, Dial Suthoff E, Korves C, Vekeman F, Ramamurthy P, Mykletun A, Lyon-Caen S, Neary MP, Bellmunt J.
Sunitinib (SU) treatment (Trx) patterns and toxicity in patients (Pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).

Abstract: 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL.

Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting.

Abstract: ASCO Annual Meeting 2011, Chicago, IL.
Authors: Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M.

Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.

Abstract: ASCO Annual Meeting 2011, Chicago, IL.
Authors: Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA.

Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.

Abstract: ASCO Annual Meeting 2011, Chicago, IL.
Authors: Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial.

Abstract: ASCO Annual Meeting 2011 Conference, Chicago, IL.

Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML).

Abstract: ASCO Annual Meeting 2011 Conference, Chicago, IL.
Authors: Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, Ericson S, Quintas-Cardama A.

Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France.

Abstract: ASCO Annual Meeting 2011, Chicago, IL.

Sunitinib (SU) treatment (trx) patterns and toxicity in patients (Pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).

Abstract: ASCO Annual Meeting 2011, Chicago, IL.

Treatment (trx) of metastatic renal cell carcinoma (mRCC) with angiogenesis inhibitors (AIs): Safety and treatment patterns observed in Taiwanese patients.

Abstract: ASCO Annual Meeting 2011, Chicago, IL.
The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the United States.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

**Authors:** Wang ST, Huang H, Ba-mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Van De Velde H, Duh MS.

Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

**Authors:** Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

New methods to adjust for selective crossover in survival analysis: In assessments of cost-effectiveness of cancer therapies.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

**Authors:** Delea TE, Duh MS, Wei LJ, Robins J.

Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma (MRCC) in Ireland.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

**Authors:** McDermott R, Donnellan P, McCaffery J, Keane F, Sarda SP, Korves C, Luka A, Wei R, Neary MP, Hanley R, Duh MS.

Real world clinical resource utilization of metastatic prostate cancer patients in the United States: Results from two large claims databases.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

**Authors:** Senbetta M LM, Dean J, McKenzie RS, Lefebvre P.


**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.


Treatment patterns and healthcare resource utilization of metastatic prostate cancer patients by physician specialty.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.

**Authors:** Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P.

Health care resource utilization and costs associated with bevacizumab versus cetuximab in second-line treatment of metastatic colorectal cancer patients.

**Abstract:** 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, Minneapolis, MN.

**Authors:** Yang H, Yu A, Yim Y, Yu E, Wu E.
Treatment (trx) patterns and toxicity of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in United Kingdom (UK).

Abstract: 26th Annual Congress of the European Association of Urology, Vienna, Austria.

Treatment (trx) patterns of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in Ireland.

Abstract: 2011 Genitourinary Symposium, Orlando, FL.
Authors: McDermott RS, Donnellan PP, McCaffery J, Sarda SP, Korves C, Luka A, Wei R, Neary M, Hanley R, Duh MS.

Treatment patterns and health care resource utilization of metastatic colorectal cancer (mCRC) patients who received bevacizumab or cetuximab in second-line regimen.

Authors: Yang H, Yu AP, Yim Y, Yu E, Wu E.

5002 ORAL Complications Associated with Chemotherapy in Patients with Metastatic Breast Cancer.
Publication: European Journal of Cancer 2011 09; 47: S330
Authors: Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu A, Wu E, Hurvitz S.

The economics of the hematopoietic growth factors.
Publication: Cancer Treatment and Research 2011 11; 157: 403-418
Authors: Eldar-Lissai A, Lyman GH.

Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Publication: Journal of Medical Economics 2011 07; 14(5): 542-552
Authors: Yang H, Yu AP, Wu EQ, Yim YM, Yu E.

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Publication: BMC Cancer 2011 03; 11: 105
Authors: Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.

Publication: BJU International 2010 05; 105(9): 1247-1254

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Publication: Current Medical Research and Opinion 2010 01; 26(1): 61-69
Authors: Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Publication: Current Medical Research and Opinion 2010 12; 26(12): 2861-2869
Authors: Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.
Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.

Abstract: 52nd Annual Meeting of the American Society of Hematology, Orlando, FL.
Authors: Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ.

The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML).

Abstract: 52nd Annual Meeting of the American Society of Hematology, Orlando, FL.
Authors: Wu EQ, Guerin A, Bollu V, Williams D, Guo A, De Leon Barido DP, Yu AP, Quintas-Cardama A.

Comparison of skeletal complications and treatment patterns associated with early versus delayed zoledronic acid therapy in multiple myeloma.

Abstract: 52nd Annual Meeting of the American Society of Hematology, Orlando, FL.
Authors: Yu AP, Bensimon AG, Marynchenko M, Wu EQ, Namjoshi M, Guo A, Ericson SG, Raje N.

Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX).

Abstract: 35th ESMO Congress, Milan Italy.
Authors: Yim Y, Wu EQ, Yu AP, Yang HY, Yu E.

Active dose re-escalation of nilotinib following dose reduction is associated with improved efficacy in patients with chronic phase chronic myeloid Leukemia (CML-CP) who fail imatinib.


Costs of treatment with angiogenesis inhibitors (AIS) in patients with metastatic renal cell carcinoma (MRCC): Results from a medical chart review study.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Oh WK, McDermott DF, Duh MS, Antras L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK.

Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS.

Health care costs associated with angiogenesis inhibitors (AIS) and mtor inhibitors (MTORS) in patients with metastatic renal cell carcinoma (MRCC) treated at US community oncology clinics.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Chen K, SP S, Antras L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P.

Health care costs associated with multikinase inhibitors (MKIS) for treatment of metastatic renal cell carcinoma (MRCC) in a clinical practice setting in Italy.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).

Abstract: ISPOR 15th Annual International Meeting, Atlanta, GA.
Authors: Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Guerin A, Bollu V, Williams D.

Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short-and long-term negative impacts on health care resource utilization and costs.

Abstract: Cited from Google Scholar.
Authors: Guerin A, Bollu V, Guo A, Wu E, Yu A, Sirulnik L, Griffin J.

PCN47 Comparison of health care resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML).

Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Bollu V, Guo A, Guerin A, Tsaneva M, Williams D, Griffin J.

Puk1 incidence and cost of adverse events (AES) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Publication: Oncologist 2010 10; 15(10): 1073-1082
Authors: Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Publication: Cancer 2009 10; 115(20): 4839-4848
Authors: Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Publication: Journal of Medical Economics 2009 03; 12(1): 1-8
Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Publication: Supportive Care in Cancer 2009 06; 17(6): 719-725
Authors: Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Publication: Cancer 2009 02; 115(4): 706-715
Authors: Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
Publication: Current Medical Research and Opinion 2009 08; 25(8): 2081-2090
Authors: Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK.

Comparison of healthcare utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia.
Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.
Authors: Wu EQ, Bollu VK, Guo A, Guerin A, Tsaneva M, Williams D, Griffin JD.

Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.
Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.
Authors: Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh M.

Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): A sub-analysis of the ENACT (expanding nilotinib access in clinical trials) study.
Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.

Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): Sub-analyses of the ENACT (expanding nilotinib access in clinical trials) study.
Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.

Lower healthcare resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients - Evidence from a clinical practice setting study.
Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.
Authors: Guerin A, Bollu VK, Williams D.

Molecular response, efficacy and safety analysis of 168 adult french patients with chronic myeloid leukemia (CML) in chronic phase (CP) from the ENACT (expanding nilotinib access in clinical trials) study.
Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.
Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs.

Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.

Authors: Wu EQ, Bollu VK, Guo A, Guerin A, Yu AP, Sirulnik A, Griffin JD.

Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the enact (expanding nilotinib access in clinical trials) study.

Abstract: 51st Annual Meeting of the American Society of Hematology, New Orleans, LA.


Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): Evidence from US community oncology clinics.

Abstract: Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany.


Safety and treatment (trx) patterns of multikinase inhibitors (MKI) in patients (pts) with metastatic renal cell carcinoma (mRCC) in Italy.

Abstract: Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany.

Authors: Di Cesare P, Porta C, Lasagna A, Ferraris E, Imarisio I, Paglino C, Antras L, Chen K, Neary MP, Duh MS.

Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Abstract: 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Providence, RI.

Authors: Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Patients (Pts) with metastatic Renal Cell Carcinoma (mRCC) receiving Angiogenesis Inhibitor (AI) therapies: Treatment efficacy and safety in clinical practice.

Abstract: 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Providence, RI.


Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

Abstract: 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Providence, RI.

Authors: Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

Treatment (Tx) and dosing patterns for Angiogenesis Inhibitor (AI) therapies in patients (Pts) with metastatic Renal Cell Carcinoma (mRCC).

Abstract: 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Providence, RI.


Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia.

Abstract: ASCO Annual Meeting, Orlando, FL.


Abstract: 2009 International MASCC/IS00 Symposium, Rome, Italy.
Authors: Pike C, Birnbaum H, Kaufman R, Muehlenbein C, Pohl G, Natale R.

Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.

Abstract: ISPOR 14th Annual International Meeting, Orlando, FL.
Authors: Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Abstract: ISPOR 14th Annual International Meeting, Orlando, FL.
Authors: Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Direct health care and workloss burden of chemotherapy- associated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer.

Abstract: ISPOR 14th Annual International Meeting, Orlando, FL.
Authors: Pike C, Birnbaum HG, Kaufman R, Muehlenbein CE, Pohl G, Natale R.

Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Abstract: ISPOR 14th Annual International Meeting, Orlando, FL.
Authors: Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E.

Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

Abstract: ISPOR 14th Annual International Meeting, Orlando, FL.
Authors: Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

Real world treatment patterns of gastrointestinal stromal tumor patients.

Abstract: ASCO Annual Meeting, Orlando, FL.
Authors: Wu EQ.

Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib.

Abstract: ASCO Annual Meeting, Orlando, FL.
Authors: Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD.

Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Publication: J Clin Oncol (Meeting Abstracts) 2009 05; 27(15S): 7092
Authors: Wu E, Guo A, Williams D, Guérin A, Yu A, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin J, Bollu V.

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

Publication: Current Medical Research and Opinion 2008 04; 24(4): 967-974
Authors: Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT.


Abstract: International Association for the Study of Lung Cancer.
Authors: Chen L, Antras L, Duh MS, Neary M, O’Brien ME.
Patients (PTS) with metastatic renal cell carcinoma (MRCC) receiving angiogenesis inhibitor (AIS) therapies: Treatment efficacy and safety in clinical practice.

**Abstract:**
34th Congress of the European Society for Medical Oncology (ESMO) Conference, Stockholm, Sweden.

**Authors:**

Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC).

**Abstract:**
34th Congress of the European Society for Medical Oncology (ESMO) Conference, Stockholm, Sweden.

**Authors:**
Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Chen K, Duh MS, Neary MP, Oh WK.

Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.

**Publication:**
Value in Health 2007 09; 10(5): 408-414

**Authors:**
Wu EQ, Mulani P, Farrell MH, Sleep D.

Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.

**Publication:**
Current Medical Research and Opinion 2007 11; 23(11): 2741-2752

**Authors:**
Chen L, Antras L, Duh MS, Levy N, Neary M, O’Brien ME, von Pawel J.

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

**Publication:**
Cancer 2007 03; 109(6): 1090-1096

**Authors:**
Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?

**Publication:**
Hepatology 2007 07; 46(1): 283; author reply 283-284

**Authors:**
Wu WK, Duh MS, Lefebvre P.

Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients.

**Abstract:**
ASCO Annual Meeting, Chicago, IL.

**Authors:**
Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.

**Publication:**
Journal of Oncology Pharmacy Practice 2006 09; 12(3): 165-178

**Authors:**
Cremieux P, Vekeman F, Lefebvre P.

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.

**Publication:**
Current Medical Research and Opinion 2006 09; 22(9): 1623-1631

**Authors:**
Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.

**Publication:**
Clinical Therapeutics 2006 10; 28(10): 1701-1708

**Authors:**
Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.
Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.
Publication: Digestive Diseases and Sciences 2006 05; 51(5): 877-884
Authors: Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH.

Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Publication: Journal of Supportive Oncology 2006 05; 4(5): 243-250
Authors: Chu E, Einhorn LH, Lefebvre P.

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Publication: Clinical Breast Cancer 2006 06; 7(2): 127-132
Authors: Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynychenko M, Boyce SP, Mallett D, Perez EA.

Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy.
Publication: J of Urology 2006 01; 175(1): 136-139
Authors: Smith M, Boyce S, Moyneur E, Duh MS, Raut M, Brandman J.

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
Publication: Journal of Urology 2006 01; 175(1): 136-139; Discussion 139
Authors: Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J.

PCN33 Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D health utility in metastatic hormone-refractory prostate cancer patients.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Mulani P, Farrell M, Sleep D.

Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.
Publication: P AND T 2006 31(10): 594
Authors: Gosselin A, McKenzie R, Lifebvre P, Mody S, Piech C, Duh M.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Publication: Drugs and Aging 2006 12; 23(12): 969-976
Authors: Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Lifetime Costs of Patients with Clinically Detected Uterine Fibroids: An Employer’s Perspective.
Publication: Drug Benefit Trends 2006 18(7): 405
Authors: Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Publication: Current Medical Research and Opinion 2005 10; 21(10): 1677-1682
Authors: Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.
Publication: Current Medical Research and Opinion 2005 10; 21(10): 1527-1533
Authors: Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Publication: Journal of the National Comprehensive Cancer Network 2005 11; 3(6): 807-816
Authors: Campos SM, Duh MS, Lefebvre P, Rosberg J.

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.
Publication: Oncologist 2005 06; 10(6): 438-448
Authors: Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.
Authors: Duh MS, L Mark T.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis.
Authors: Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.
Publication: Journal of Clinical Oncology 2002 06; 20(11): 2757-2758
Authors: Gabrilove JL, Sarokhan B, Cremieux P.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
Publication: Cancer 2002 08; 95(4): 888-895
Authors: Crawford J, Cell D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Anemia-related costs for cancer patients.
Publication: Journal of Managed Care Medicine 2002 6(1): 20-28
Authors: Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

Cost Effectiveness of rHuEPO in Oncology.
Publication: Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer 2002
Authors: Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

The costs of cancer: cancer-related conditions can add dramatically to overall costs of care.
Publication: Journal of Managed Care Medicine 2002 6(1): 12-19
Authors: Cremieux P, Slavin M, Fendrick A, Hiriak T, Kosicki G.

The costs of cancer to a major employer in the United States: a case-control analysis.
Publication: American Journal of Managed Care 2000 11; 6(11): 1243-1251
Authors: Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M.
Cost of outpatient blood transfusion in cancer patients.
*Authors:* Cremieux PY, Barrett B, Anderson K, Slavin MB.

Costs Associated with Anemia and Cancer.
*Authors:* Cremieux PY GM, Holland M, Slavin MB.

Understanding the Pharmacoeconomic profile of cancer.
*Publication:* ONE: Oncology Economics 2000 1(10): 36-39
*Authors:* Cremieux PY BH, Greenberg PE.

*Publication:* Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472
*Authors:* Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

Renal

The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.
*Publication:* Current Medical Research and Opinion 2017 05; 33(8): 1473-1480

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1891-1900

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
*Publication:* Diabetes Therapy 2016 09; 7(3): 439-454
*Authors:* Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
*Publication:* J Manag Care Spec Pharm 2016 10; 22(10): 1204-1214
*Authors:* DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

Resource utilization of adult patients with sporadic angiomyolipoma in the Netherlands.
*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Ireland.
*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.
*Publication:* Pharmacoepidemiology and Drug Safety 2016 25(4): 413-421
*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.
*Abstract:* AMCP Nexus 2016 Conference, Baltimore, MD.
*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Holenack K, Singhania A, Wu E.
Natural history for adult patients with sporadic angiomyolipoma in the Netherlands.
Abstract: 53rd ERA-EDTA Congress, Vienna, Austria.
Authors: Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.
Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.
Publication: Journal of Medical Economics 2015 18(12): 1060-1070
Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on antimuscarinic therapy for overactive bladder.
Publication: Journal of Medical Economics 2014 10; 17(10): 741-750
Authors: Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T.

The healthcare cost impacts of switching antimuscarinic agents among patients with overactive bladder in a privately insured population.
Abstract: AUGS/IUGA Scientific Meeting, Washington, DC.
Authors: Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H.

Health care costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.
Authors: Ivanova J, Hayes-Larson E, Sorg RA, Birnbaum HG, Fitzmartin J, Berner T.

Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada.
Authors: Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner G.

Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.
Abstract: 51st ERA-EDTA Congress, Amsterdam, Netherlands.
Authors: Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Serum urate and incidence of kidney disease among veterans with gout
Publication: Journal of Rheumatology 2013 07; 40(7): 1166-1172
Authors: Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.
Abstract: 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Montreal, QC Canada.
Authors: Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.
Development and validation of a new chronic kidney disease risk equation: The role of pulse pressure.
Abstract: ESC Congress 2013, European Society of Cardiology, Amsterdam Netherlands.
Authors: Ayyagari R, Vekeman F, Faust E, Ong S, Trahey A, Lefebvre P, Machnicki G, Duh M.

Authors: Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J.

Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness analysis of mirabegron versus tolterodine extended release in the treatment of patients with overactive bladder in the United States.
Authors: Xie J, Zhou ZY, Bui CN, Yan Y, De G, Runken MC, Wu EQ.

Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.
Publication: Epilepsy & Behavior 2011 10; 22(2): 370-375
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.
Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011, Chicago, IL.
Authors: Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD.
Authors: Lafeuille MH, Bailey RA, Senbeta M, McKenzie RS, Lefebvre P.

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Publication: Journal of Cancer Research and Therapeutics 2010 01; 6(1): 31-35
Authors: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Publication: Consultant Pharmacist 2010 08; 25(8): 493-500
Authors: Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbeta M, Piech CT, Lefebvre P.

Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis.
Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010 Atlanta, GA.
Authors: Lafeuille MH, Bailey RA, Laliberte F, Senbeta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P.
Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis.

**Abstract:** 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010, Atlanta, GA.

**Authors:** Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P.

Seven year trends of pharmacy benefit erythropoiesis stimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis.

**Abstract:** 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010, Atlanta, GA.

**Authors:** Vekeman F, Bailey RA, Laliberte F, Senbetta M, McKenzie RS, Lefebvre P.

Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.

**Publication:** Journal of Medical Economics 2010 11; 13(4): 673-680

**Authors:** Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

**Publication:** Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322

**Authors:** Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

**Publication:** Supportive Care in Cancer 2009 06; 17(6): 719-725

**Authors:** Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.

**Publication:** Clinical Journal of the American Society of Nephrology 2009 04; 4(4): 755-762

**Authors:** Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P.

The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer’s perspective.

**Publication:** Disease Management 2008 02; 11(1): 49-58

**Authors:** Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.

Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer’s perspective.

**Publication:** Journal of Health & Productivity 2007 10: 309

**Authors:** Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.

**Publication:** Current Medical Research and Opinion 2007 07; 23(7): 1571-1573; author reply 1573-1574

**Authors:** Einarson T, Machado M, Walker J, Iskedjian M.

The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.

**Publication:** Disease Management 2007 02; 10(1): 37-45

**Authors:** Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT.

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.

**Publication:** Clinical Therapeutics 2006 09; 28(9): 1443-1450

**Authors:** Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.
Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.

**Publication:** Current Medical Research and Opinion 2006 10; 22(10): 1929-1937  
**Authors:** Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis.

**Publication:** Current Medical Research and Opinion 2006 03; 22(3): 495-500  
**Authors:** Wu EQ, Birnbaum H, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ.

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.

**Publication:** Journal of the American Society of Nephrology 2006 12; 17(12): 3497-3502  
**Authors:** Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.

**Publication:** Current Medical Research and Opinion 2006 12; 22(12): 2329-2336  
**Authors:** Cremieux PY, Van Audenrode M, Lefebvre P.

Comorbidity contributes to high treatment cost of interstitial cystitis.

**Publication:** PharmacoEconomics & Outcomes News 2006 02; (497): 6  
**Authors:** Wu E.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.

**Publication:** Drugs and Aging 2006 12; 23(12): 969-976  
**Authors:** Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population.

**Publication:** PharmacoEconomics 2006 02; 24(1): 55-65  
**Authors:** Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H.

Employees with overactive bladder: work loss burden.

**Publication:** Journal of Occupational Environmental Medicine 2005 05; 47(5): 439-446  
**Authors:** Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D.

Interstitial Cystitis Costs, Treatment and Comorbidities in an Employed Population.

**Abstract:** International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European.  
**Authors:** Wu EQ, Birnbaum H, Parece A, Kang Y, Mareva MN, Taitel H.

Cost of stress urinary incontinence: a claims data analysis.

**Publication:** PharmacoEconomics 2004 01; 22(2): 95-105  
**Authors:** Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.

**Publication:** Women’s Health Issues 2003 11; 13(6): 204-213  
**Authors:** Birnbaum H, Leong S, Kabra A.

Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.

**Publication:** Pharmacotherapy 2003 05; 23(5): 690-693; discussion 693-694  
**Authors:** Barnett AL, Cremieux PY.
Respiratory

**Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists.**
*Publication:* Drugs Real World Outcomes 2017 03; 4(1): 33-41  
*Authors:* Bollu V, Guerin A, Gauthier G, Hiscock R, Wu EQ.

**Burden of systemic glucocorticoid-related complications in severe asthma.**
*Publication:* Current Medical Research and Opinion 2017 01; 33(1): 57-65  
*Authors:* Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

**Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.**
*Authors:* Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr.

**A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on longacting mono- or combination therapy.**
*Publication:* International Journal of COPD 2017 12; 1825-1836  
*Authors:* Mapel D, Laliberte F, Roberts MH, Sama SR, Sundaesan D, Pilon D, Lefebvre P, Duh MS, Patel J.

**Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.**
*Publication:* International Journal of Chronic Obstructive Pulmonary Disease 2017 02; 12: 367-381  
*Authors:* Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.

**Patient Characteristics, Clinical Outcomes and Healthcare Resource Utilization Among IPF Patients Stratified by Lung Function at Diagnosis.**
*Publication:* American Journal of Respiratory and Critical Care Medicine 2017: A1133-A1133  
*Authors:* Nathan S, Macaulay D, Garcia Horton V, Terasawa E, Yu Y.

**A prospective assessment of healthcare utilization and costs associated with symptom burden measured by mmrc and cat.**
*Abstract:* American Thoracic Society International Conference, Washington, DC.  
*Authors:* Stanford RH, Mapel D, Roberts M, Pilon D, Laleiberte F, Lefebvre P, Sama S, Emond B, Duh M.

**Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma.**
*Publication:* J Manag Care Spec Pharm 2016 07; 22(7): 833-847  
*Authors:* Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P.

**Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.**
*Publication:* Ann Am Thorac Soc 2016 04; 13(7): 1067-1075  
*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS, Merrigan JF, Schatz M.
Characteristics and outcomes of patients with hospital-acquired pneumonia (HAP).

**Abstract:** ISPOR 19th Annual European Congress, Vienna, Austria.

**Authors:** Han S, Xie J, Song H, Zhang C, Wu EQ.

Feasibility of matching-adjusted indirect comparison (MAIC) of omalizumab (OMA) vs. mepolizumab (MEPO) in moderate-to-severe asthma.

**Abstract:** ISPOR 19th Annual European Congress, Vienna, Austria.

**Authors:** Ayyagari R, Alves L, Mu F, Hacking V, Martinez R, Signorovitch JE.

Spectrum of idiopathic pulmonary fibrosis severity in clinical practice: implications for clinical trial feasibility and design.

**Abstract:** American Thoracic Society International Conference, ATS 2016, San Francisco, CA.

**Authors:** Macaulay D, Nathan SD, Terasawa E, Yu Y.

Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease.

**Publication:** Ann Am Thorac Soc 2015 03; 12(3): 323-331

**Authors:** Au DH, Macaulay DS, Jarvis JL, Desai US, Bimbaum HG.

Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.

**Publication:** Antimicrobial Agents and Chemotherapy 2015 02; 59(2): 1119-1126

**Authors:** Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.

**Publication:** BMC Pulmonary Medicine 2015 12; 15(167): 167

**Authors:** Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD.

Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.

**Publication:** Journal of Allergy and Clinical Immunology 2015 12; 136(6): 1488-1495

**Authors:** Lefebvre P, Duh MS, Lafaille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.

**Publication:** Respiratory Medicine 2015 12; 109(12): 1582-1588

**Authors:** Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD.

Clinical and Economic Burden of Pulmonary Exacerbations In Patients with Cystic Fibrosis Who are Homozygous for the F508del Mutation.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research.

**Authors:** O’Sullivan AK, Signorovitch JE, Fang A, Wagener J, Hodgkins P.

Inpatient Burden Among Patients with Cystic Fibrosis Who Are Homozygous for the F508del Mutation.

**Abstract:** International Society for pharmacoeconomics and Outcomes Research.

**Authors:** Hodgkins P, Ayyagari R, Guo J, Wagener J, O’Sullivan AK.

Association of change in forced vital capacity with healthcare resource utilization in patients with newly diagnosed idiopathic pulmonary fibrosis.

**Abstract:** ISPOR 20th Annual International Meeting Research, Philadelphia, PA.

**Authors:** Reichmann WM, Yu Y, Macaulay D, Nathan SD.
Change in forced vital capacity and clinical outcomes in newly diagnosed idiopathic pulmonary fibrosis patients.

Authors: Nathan SD, Reichmann WM, Macaulay D, Yu YF.

Cost and resource utilization in hospital-treated cap patients.

Authors: Tuttle EG, Llop CJ.

Economic and clinical burden of acute and chronic systemic corticosteroid-related complications in asthma patients Respiratory Disease.


Impact of suspected idiopathic pulmonary fibrosis acute exacerbations on clinical and healthcare resource utilization outcomes.

Authors: Nathan SD, Reichmann WM, Macaulay D, Yu YF.

Time to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA) combination therapy.

Authors: Patel J, Mapel DW, Roberts MH, Sama S, Gilmore J, Sundaresan D, Laliberte F, Pilon D, Lefebvre P, Duh M.

Pulmonary medication adherence and health-care use in cystic fibrosis.

Publication: Chest 2014 07; 146(1): 142-151
Authors: Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA.

Budget impact model of ORALAIR® for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in adults and children.

Abstract: AMCP 2014 Nexus Conference, Boston, MA.

Assessment of COPD exacerbation risk: Utilizing health claims data to develop and validate a risk equation.

Authors: Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan J, Duh M.

Risk assessment of first severe COPD exacerbation using predictive models based on health claims data.


Burden of illness of patients with allergic asthma versus non-allergic asthma.

Publication: Journal of Asthma 2013 10; 50(8): 900-907
Authors: Lefebvre MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P.

Development and validation of a claims-based prediction model for COPD severity.

Publication: Respiratory Medicine 2013 10; 107(10): 1568-1577
Authors: Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF.
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Publication: Pediatric Pulmonology 2013 10; 48(10): 954-961

Risk of Hospital Readmissions in Patients with Chronic Obstructive Pulmonary Disease Receiving Arformoterol Tartrate versus Nebulized Short-Acting Beta2-Agonists Following Hospital Discharge.
Abstract: COPD8USA Conference, Chicago, IL.
Authors: Bollu VK, Guérin A, Gauthier G, Hiscock R, Wu EQ.

Impact of integrated telehealth and care management program on resource utilization in Medicare beneficiaries with chronic obstructive pulmonary disease.
Authors: Au DH, Jarvis J, Macaulay D, Birnbaum HG.

Re-hospitalization risk in patients with chronic obstructive pulmonary disease (COPD) initiating nebulized long-acting vs. Short-acting beta2-agonists.

Association between consistent omalizumab treatment and asthma control.
Publication: The Journal of Allergy and Clinical Immunology: In Practice 2013 1(1): 51-57
Authors: Lafeuille M-H, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P.

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.
Publication: Journal of Allergy and Clinical Immunology 2012 05; 129(5): 1229-1235
Authors: Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Publication: Annals of Allergy, Asthma, and Immunology 2012 07; 109(1): 59-64
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Publication: Pediatric Pulmonology 2012 01; 47(1): 44-52
Authors: Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L.

Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Publication: Journal of Medical Economics 2012 04; 15(2): 219-224
Authors: Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S.

Annual healthcare costs for patients with cystic fibrosis from a Medicaid perspective.
Abstract: 26th Annual North American Cystic Fibrosis Conference, Orlando, FL.
Authors: Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E.

Lower adherence to chronic pulmonary medications is associated with increased health service utilization in patients with cystic fibrosis.
Abstract: 26th Annual North American Cystic Fibrosis Conference, Orlando, FL.
Authors: Quittner AL, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Riekert KA.

Pulmonary medication adherence among individuals with cystic fibrosis.
Abstract: 26th Annual North American Cystic Fibrosis Conference, Orlando, FL.
Authors: Riekert KA, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Quittner AL.
A validated claims-based prediction model for COPD severity.
Abstract: CHEST 2012, Atlanta, GA.

Impact of omalizumab initiation on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids and long-acting beta2-agonists Respiratory Disease.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Association of allergic rhinitis with asthma exacerbations and health care costs in asthma patients Respiratory Disease.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoepidemiology and Outcomes Research, Washington, DC.
Authors: Ivanova JI, Desai U, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

Development of a pulmonary exacerbation risk score among cf patients not receiving recommended therapies for pulmonary care.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoepidemiology and Outcomes Research, Washington, DC.

Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoepidemiology and Outcomes Research, Washington, DC.

Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoepidemiology and Outcomes Research, Washington, DC.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care.

Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.
Abstract: 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology Conference, Orlando, FL.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Publication: Appl Health Econ Health Policy 2011 09; 9(5): 293-303
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.
Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.

*Publication:* Current Medical Research and Opinion 2011 09; 27(9): 1763-1768
*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.

*Publication:* Appl Health Econ Health Policy 2011 11; 9(6): 377-387
*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.

*Publication:* Journal of Asthma 2011 11; 48(9): 923-930
*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P.

Concomitant asthma medication use in patients using omalizumab: results from three large insurance claims databases Respiratory Disease.

*Publication:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Chicago, IL.
*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.

*Publication:* 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.
*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

Development of a pulmonary exacerbation risk score among CF patients not receiving recommended therapies for pulmonary care.


Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis.


Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.

*Authors:* Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

Cost-effectiveness analysis of roflumilast/tiotropium combination therapy vs. tiotropium monotherapy in patients with severe to very severe COPD.

*Abstract:* 2011 Annual Meeting of the American College of Clinical Pharmacy, Pittsburgh, PA.
*Authors:* Yu AP, Sun S, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu E.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Chicago, IL.
*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.

*Abstract:* 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD.
*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.
PRS7 Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Signorovitch J, Sawicki G, Zhang J, Latremouille-Viau D, Wu E, von Wartburg M, Lzheng S.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.
Authors: Lafuille M, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Swensen A, Stanley EL, Lefebvre P.

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Publication: Journal of Medical Economics 2011 10; 14(6): 805-815
Authors: Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ.

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Publication: Journal of Medical Economics 2011 04; 14(3): 315-323
Authors: Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.
Publication: Journal of Medical Economics 2011 06; 14(4): 486-496
Authors: Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J.

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
Publication: COPD 2010 06; 7(3): 214-228
Authors: Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Publication: Current Medical Research and Opinion 2010 02; 26(2): 355-363
Authors: Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.

Association between private-to-Medicaid change in health insurance & healthcare utilization & outcomes among children with cystic fibrosis.
Authors: Zhivan N, Campbell CR, Signorovitch J, Zhang J, Shi L.

Comparison of drug costs & clinical outcomes with tobramycin solution for inhalation & aztreonam lysine for inhalation in cystic fibrosis.
Abstract: 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD
Authors: Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J.

Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.
Authors: Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.
Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.

**Abstract:** CHEST 2010 Annual Meeting Conference Vancouver, BC Canada.

**Authors:** Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum S.

Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.

**Abstract:** CHEST 2010 Annual Meeting Conference Vancouver, BC Canada.

**Authors:** Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum S.

Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.

**Abstract:** 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD.

**Authors:** Sawicki GS, Signorovitch J, Latremouille-Viau D, Von Wartburg M, Wu E, Zhang J, Shi L.

Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations Respiratory Disease.

**Abstract:** American Thoracic Society International Conference 2010, New Orleans, LA.

**Authors:** Ivanova JI, Bergman RE, Birnbaum HG, Colice GL, Silverman R, McLaurin KK.

Economic burden of exacerbations in chronic obstructive pulmonary disease.

**Abstract:** 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.

**Authors:** Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J.

Relationship between daily dosing frequency, compliance, health care resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD).

**Abstract:** 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.

**Authors:** Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS.

Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple vs Single Long-Acting Inhalers.

**Publication:** CHEST Journal 2010 138(4_MeetingAbstracts): 482A-482A

**Authors:** Yu AP, Guérin A, de Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum S.

Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format.

**Publication:** Current Medical Research and Opinion 2009 03; 25(3): 717-727

**Authors:** Kosinski M, Kite A, Yang M, Rosenzweig JC, Williams A.

Asthma severity categorization using a claims-based algorithm or pulmonary function testing.

**Publication:** Journal of Asthma 2009 02; 46(1): 67-72

**Authors:** Birnbaum HG, Ivanova JI, Yu AP, Hsieh M, Seal B, Emani S, Rosiello R, Colice GL.

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.

**Publication:** Clinical Therapeutics 2009 12; 31(12): 2779-2803

**Authors:** Frois C, Wu EQ, Ray S, Colice GL.

Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.

**Abstract:** ISPOR 12th Annual European Congress, Paris France.

**Authors:** Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.
Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.

**Abstract:** CHEST 2010 Meeting, Vancouver, BC Canada.
**Authors:** Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.

**Abstract:** ISPOR 12th Annual European Congress, Paris France.
**Authors:** Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

The direct economic impact of exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A review of the literature.

**Abstract:** 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Providence, RI.
**Authors:** Toy EL, Gallagher KF, Stanley EL, Duh MS.

The risk of hospitalization or emergency care following outpatient treatment of community-acquired pneumonia (CAP) with levofloxacin versus moxifloxacin.

**Abstract:** 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Providence, RI.
**Authors:** Signorovitch JE, Gu A, Sengupta A, Raut M, Mody SH, Grant R, Schein J, Fisher AC, Ng D, Duh MS.

The direct economic impact of exacerbations of chronic obstructive pulmonary disease (COPD): A review of the literature.

**Abstract:** ISPOR 14th Annual International Meeting, Orlando, FL.
**Authors:** Toy EL, Gallagher KF, Stanley EL, Duh MS.

Costs and resource use of mild persistent asthma patients initiated on controller therapy.

**Publication:** Journal of Asthma 2008 05; 45(4): 293-299
**Authors:** Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C.

Adherence to inhaled corticosteroid use and local adverse events in persistent asthma.

**Publication:** American Journal of Managed Care 2008 12; 14(12): 801-809
**Authors:** Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL.

Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature.

**Publication:** Expert Opinion on Pharmacotherapy 2008 04; 9(5): 751-766
**Authors:** Weiner JR, Toy EL, Sacco P, Duh MS.

Use of inhaled corticosteroids and healthcare costs in mild persistent asthma.

**Publication:** Journal of Asthma 2007 07; 44(6): 479-483
**Authors:** Colice G, Wu EQ, Birnbaum H, Daher M, Maryna BM.

Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.

**Publication:** Critical Care (London, England) 2007 06; 11(3): R63
**Authors:** Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

Development of a COPD severity score.

**Publication:** Current Medical Research and Opinion 2006 09; 22(9): 1679-1687
**Authors:** Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G.
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population.
Publication: Journal of Occupational Environmental Medicine 2006 08; 48(8): 794-802
Authors: Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S.

Inpatient and Emergency Department Utilization of Persistent Asthma Patients.
Authors: Colice G, Crivera C, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST.

Development of a COPD Severity Score in ClaimsDatabase.
Authors: Wu EQ, Birnbaum H, Cifaldi M, Colice G, Kang Y.

Healthcare Costs of Patients with Persistent Asthma.
Abstract: Academy of Managed Care Pharmacy (AMCP).

PRS3 Acute exacerbation of chronic bronchitis (AECB) treatment effectiveness: Comparison of macrolides to fluoroquinolones.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Birnbaum H, Cifaldi M, Kang Y, Colice G.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Publication: Critical Care Medicine 2004 32(3): 666-674
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH.

Treatment costs of community-acquired pneumonia in an employed population.
Publication: Chest 2004 06; 125(6): 2140-2145
Authors: Colice GL, Morley MA, Asche C, Birnbaum HG.

Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Johnson KA, Nichol MB.

Lower respiratory tract infections: impact on the workplace.
Publication: Pharmacoeconomics 2003 06; 21(10): 749-759
Authors: Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

PRP13: Assessing the cost implications of combined pharmacotherapy in the long term management of asthma.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Johnson K, Nichol M.

Direct and indirect costs of asthma to an employer.
Publication: Journal of Allergy and Clinical Immunology 2002 02; 109(2): 264-270
Authors: Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA.

Economic burden of respiratory infections in an employed population.
Publication: CHEST 2002 08; 122(2): 603-611
Authors: Birnbaum HG, Morley M, Greenberg PE, Colice GL.
Economic burden of pneumonia in an employed population.
Publication: Archives of Internal Medicine 2001 12; 161(22): 2725-2731
Authors: Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL.

Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients.
Publication: Annals of Allergy, Asthma, and Immunology 2000 11; 85(5): 356-361
Authors: Duh MS, Walker AM, Lindmark B, Laties AM.

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.
Publication: Clinical Therapeutics 2000 01; 22(1): 140-151
Authors: LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O.

Lack of Intraocular Pressure Effect of Budesonide Inhalation Therapy in a Mixed Asthmatic Population.
Publication: Annals of Asthma, Allergy & Immunology 2000: 356-361
Authors: Duh M, Walker A, Lindmark B, Laties A.

Substance Abuse

Drivers of excess costs of opioid abuse among a commercially insured population.
Publication: American Journal of Managed Care 2017 07; 23(5): 276-282
Authors: Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC.

The Economic Burden of Opioid Abuse: Updated Findings.
Publication: J Manag Care Spec Pharm 2017 23(4): 427-445
Authors: Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ.

(263) A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.
Authors: White AG, Yenikomshian M, Carson M, Masters ET, Roland CL.

The costs and cost drivers of opioid misuse by diagnosis: Abuse, dependence, and overdose/poisoning.
Abstract: 2016 Pain Week Conference, Las Vegas, NV.
Authors: Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

The economic burden of opioid abuse and its drivers: Evidence from a payer perspective.
Abstract: 2016 Pain Week Conference, Las Vegas, NV.
Authors: Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.
Abstract: Annual Scientific Meeting of the American Pain Society, Austin, TX.
Authors: White AG, Yenikomshian M, Carson M, Masters ET, Roland CL.

Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Abstract: ISPOR 21st Annual International Meeting Research, Washington, DC.

Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
Publication: J Opioid Manag 2015 05; 11(3): 199-210
The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.

Publication: Pain Medicine 2015 07; 16(7): 1325-1332
Authors: Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Sources of prescription opioids among diagnosed opioid abusers.

Publication: Current Medical Research and Opinion 2015 04; 31(4): 779-784
Authors: Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Medical resource use and costs among pain patients with potential opioid-tolerability issues.

Publication: J Opioid Manag 2014 09; 10(5): 305-310
Authors: Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R, Michna E.

Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.

Publication: Pain Medicine 2014 09; 15(9): 1450-1454
Authors: Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E.

The economic burden of diagnosed opioid abuse among commercially insured individuals.

Publication: Postgraduate Medicine 2014 07; 126(4): 53-58
Authors: Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R.

Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management.

Authors: Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekan J, Sheng M.

Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.

Publication: Appl Health Econ Health Policy 2014 08; 12(4): 435-446
Authors: Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.

Publication: Current Medical Research and Opinion 2014 08; 30(8): 1589-1598
Authors: Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.

Publication: Journal of Medical Economics 2014 04; 17(4): 279-287
Authors: Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

A model to estimate the health system burden of prescription opioid abuse in Europe.

Abstract: ISPOR 17th Annual European Congress, Amsterdam, Netherlands.
Authors: Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop W.

Examining the use of ICD-9-CM diagnosis codes for opioid abuse and opioid dependence in commercial claims data.

Abstract: AMCP 2014 Nexus Conference, Boston, MA.
Authors: Shei A, Rice B, Kirson NY, Bodnar K, Cummings AKG, Birnbaum HG, Holly P, Ben-Joseph R.

Comparing the prevalence and healthcare costs of opioid abuse using two commercial claims databases.

Abstract: PAINWeek Conference, Las Vegas, NV.
Authors: Rice B, Kirson NY, Shei A, Enloe CJ, Cummings AK, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.
Methods to estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially-insured individuals.

Abstract: PAINWeek Conference, Las Vegas, NV.
Authors: Shei A, Rice B, Kirson NY, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Medical resource use and costs among pain patients with potential opioid tolerability issues.

Abstract: ICOO 2014, Boston, MA.
Authors: Birnbaum H, Kirson N, Shei A.

The burden of opioid abuse among commercially-insured patients.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.
Authors: Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R.

Differences between high-cost and low-cost patients diagnosed with opioid abuse.

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC Canada.
Authors: Rice JB, Kirson NY, Bodnar K, Shei A, Birnbaum HG, Holly P, Ben-Joseph R.

Characteristics of high-cost patients diagnosed with opioid abuse.

Abstract: AMCP 2014, Tampa, FL.
Authors: Birnbaum H, Kirson N, Shei A.

Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database.

Abstract: AMCP 2014, Tampa, FL.
Authors: Birnbaum H, Kirson N, Shei A.

Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation.

Abstract: AMCP 2014, Tampa, FL.
Authors: Birnbaum H, Kirson N, Shei A.

The relationship between positive subjective measures in abuse liability studies and real-world non-medical use: potential impact of abuse deterrent opioids on rates of non-medical use and associated healthcare costs.

Authors: White AG, LeCates J, Cheng W, Roland CL, Schaaf D, Mardekian J.

The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.
Publication: J Opioid Manag 2013 07; 9(4): 239-254
Authors: Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.

Prescription opioid abuse: challenges and opportunities for payers.
Publication: American Journal of Managed Care 2013 04; 19(4): 295-302
Authors: Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.

Estimating the payer-specific excess medical costs of opioid abuse in the United States.
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA.
Authors: Michna E, Kirson NH, Shei A, White A, Birnbaum HG, Ben-Joseph R, Rossiter LF.

A model to identify patients at risk for prescription opioid abuse, dependence, and misuse.
Publication: Pain Medicine 2012 09; 13(9): 1162-1173
Authors: Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL.
Characteristics and use patterns of chronic hydrocodone users.
Abstract: 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI.
Authors: Rice J, Samuelson T, Birnbaum H, Katz N.

A systematic literature review of the efficacy and safety of abuse-deterrent formulation and non-abuse-deterrent formulation prescription opioids in non-cancer pain management.
Abstract: 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI.

Identifying predictors of chronic hydrocodone use.
Abstract: 28th Annual Meeting of the American Academy of Pain Medicine, Palm Springs, CA.
Authors: Rice JB, Samuelson TM, Birnbaum HG, Katz N.

Economic impact of opioid abuse, dependence, and misuse.
Publication: American Journal of Pharmacy Benefits 2011 05; 3(3): e59-e70
Authors: White AG, Birnbaum HG, Schiller M, Waldman T, Cleveland JM, Roland CL.

Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
Authors: Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.
Publication: Pain Medicine 2010 11; 11(11): 1718-1725
Authors: Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafaille MH, Michna E, Greenberg PE.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.
Abstract: 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, United Kingdom.
Authors: Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafaille MH, Michna E, Greenberg PE.

Societal costs of opioid abuse, dependence, and misuse in the United States.
Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, GA.
Authors: Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL.

Analytic models to identify patients at risk for prescription opioid abuse.
Publication: American Journal of Managed Care 2009 12; 15(12): 897-906
Authors: White AG, Birnbaum HG, Schiller M, Tang J, Katz NP.

Health care and work loss burden of prescription opioid abuse, dependence, and misuse.
Abstract: AMCP’s 2009 Educational Conference, San Antonio, TX.
Authors: White AG, Birnbaum H, Schiller M, Waldman T, Cleveland JM, Setnik B, Roland CL.

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
Publication: Appl Health Econ Health Policy 2009 06; 7(1): 61-70
Authors: White AG, Birnbaum HG, Rothman DB, Katz N.
Estimated costs of prescription opioid analgesic abuse in the United States in 2001 - A societal perspective.
Publication: Clinical Journal of Pain 2006 22(8): 667-676
Authors: Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP.

Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.
Publication: Health Services Research 2006 06; 41(3 Pt 1): 837-855
Authors: Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA.

Direct costs of opioid abuse in an insured population in the United States.
Publication: Journal of Managed Care Pharmacy 2005 07; 11(6): 469-479
Authors: White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N.

Other Diseases & Conditions

Dry eye disease ranking among common reasons for seeking eye care in a United States claims database.
Abstract: European Society of Cataract & Refractive Surgeons (ESCRS), Lisbon, Portugal
Authors: Özer-Stillman I, Bradley JL, Pivneva I, Dea K, Guerin A, Evans AM, Dana R.

Ranking of dry eye disease among common reasons for seeking eye care in a United States claims database.
Abstract: Kongress der Deutschen Ophthalmologischen Gesellschaft (DOG), Berlin, Germany
Authors: Özer-Stillman I, Bradley JL, Pivneva I, Guerin A, Evans AM, Dana R.

Engagement in health and wellness: An online incentive-based program.
Authors: Gibson TB, Maclean JR, Carls GS, Moore BJ, Ehrlich ED, Fener V, Goldberg J, Mechanic E, Baigel C.

Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome.
Authors: Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG.

Effect of Adalimumab on Visual Functioning in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Publication: JAMA Ophthalmol 2017 06; 135(6): 511-518
Authors: Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.

Patterns of Disease Monitoring and Treatment Among Patients with Tuberous Sclerosis Complex-related Angiomyolipomas.
Publication: Urology 2017 03; 104: 110-114

Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy.
Publication: J Womens Health (Larchmt) 2017 06; 26(6): 644-654
Authors: Soliman AM, Du EX, Yang H, Wu EQ, Haley JC.

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Publication: Ophthalmology 2017 06;
Authors: Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A.
Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.

Publication: Journal of Medical Economics 2017 08; 20(8): 777-785
Authors: Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

Comorbidities among patients with dry eye disease in a large US healthcare system.

Abstract: American Society of Cataract and Refractive Surgery•American Society of Ophthalmic Administrators (ASCRS•ASOA) Symposium & Congress, Los Angeles, CA.
Authors: Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

A comparison of comorbidities among patients with and without dry eye disease in a large US healthcare system.

Authors: Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

Dry eye disease ranking among common reasons for seeking eye care in a United States claims database.

Abstract: American Academy of Optometry (AAOpt) 2017, Chicago, IL.
Authors: Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

Dry eye disease ranking among the most common reasons for seeking ocular care in a large US claims database.

Authors: Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

Dry eye symptoms and treatment satisfaction with ophthalmic cyclosporine: results of a claims database survey.

Authors: Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

Incidence and prevalence of dry eye disease: Estimates from claims database analysis in a large United States health care system.

Abstract: Congress of the European Society of Ophthalmology Symposium & Congress, Ottawa, ON, Canada.
Authors: Özer-Stillman I, Bradley JL, Guerin A, Pivneva I, Evans AM, Dana R, Schaumberg DA.

Ranking of dry eye disease among common reasons for seeking eye care in a United States claims database.

Abstract: Kongress der Deutschen Ophthalmologischen Gesellschaft (DOG), Berlin, Germany.
Authors: Özer-Stillman I, Bradley JL, Pivneva I, Guerin A, Evans AM, Dana R.

Treatment patterns and clinical characteristics among patients with tuberous sclerosis complex related angiomyolipomas.

Abstract: 2017 International Research Conference on TSC & LAM, Washington, DC.

Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.

Publication: JAMA Ophthalmol 2016 09; 134(11): 1237-1245
Authors: Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, Ganguli A.

Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

Publication: Ophthalmology 2016 03; 123(3): 655-662
Authors: Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M.
Adherence and persistence with cyclosporine ophthalmic emulsion for treatment of dry eye disease in a large US healthcare System.

**Abstract:** 2016 Annual Meeting of the American College of Clinical Pharmacy, Hollywood, FL.

**Authors:** Schaumberg DA, Bradley J, Guerin A, Pivneva I, Evans A, Stillman IO, Dana R.

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

**Publication:** Reprod Health 2016 13(1): 96

**Authors:** Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.

**Publication:** Acta Ophthalmol 2016 03; 94(5): e331-339

**Authors:** Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD.

The direct and indirect costs associated with endometriosis: a systematic literature review.

**Publication:** Human Reproduction 2016 04; 31(4): 712-722

**Authors:** Soliman AM, Yang H, Du EX, Kelley C, Winkel C.

Estimates of incidence and prevalence of dry eye disease across age groups in the US using data from a large healthcare system

**Abstract:** American Academy of Optometry 95th Annual Meeting, Anaheim, CA.

**Authors:** Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Dana R, Schaumberg DA.

Incidence and prevalence of dry eye disease in a large US healthcare system across a wide range of ages.

**Abstract:** American Academy of Ophthalmology, Chicago, IL.

**Authors:** Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Schaumberg DA.

Impact of the introduction of newer Long Acting Reversible Contraceptive (LARC) methods on LARC use in a commercially insured population.

**Abstract:** 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Ireland.

**Authors:** Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

Development of a Risk Score for Fluconazole Failure among Patients with Invasive Candidiasis.

**Abstract:** ASM 2016 | ICAAC 2016, Boston, MA.

**Authors:** Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N HY, Xie J, Lin PL, Ohashi E, Koo V, Wu EQ, Zhao J, Koo V, Wu E.

Comorbidities and symptoms among endometriosis patients: A systematic literature review.

**Abstract:** ISPOR 21st Annual International Meeting Research, Washington, DC.

**Authors:** Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

Impact of the introduction of newer long acting reversible contraceptive (LARC) methods on LARC use in a commercially insured population.

**Abstract:** ISPOR 21st Annual International Meeting Research, Washington, DC.

**Authors:** Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

Income growth trajectory for parents of children with down syndrome in the United States.

**Abstract:** ISPOR 21st Annual International Meeting Research, Washington, DC.

**Authors:** Samuelson D, Kageleiry A, Duh MS, Lefebvre P, Campbell JY, DerSarkissian M, Haider BA, Skotko BG.
Measuring opportunities to improve health outcomes via individualized treatment assignment.
Abstract: ISPOR 21st Annual International Meeting Research, Washington, DC.
Authors: Patterson-Lomba O, Signorovitch J.

Rates of subsequent endometriosis-related surgeries following an initial laparoscopy or hysterectomy: A longitudinal analysis of commercially insured endometriosis patient in the united states.
Abstract: ISPOR 21st Annual International Meeting Research, Washington, DC.
Authors: Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

A systematic literature review of comorbidities and symptoms among uterine fibroids patients between 2000 and 2013.
Abstract: ISPOR 21st Annual International Meeting Research, Washington, DC.
Authors: Soliman AM, Yang H, Du EX, Kelkar S, Winkel C.

Epilepsy treatment patterns among patients with tuberous sclerosis complex.

Subependymal giant cell astrocytoma treatment patterns among patients with tuberous sclerosis complex.

Incremental direct and indirect costs of untreated vasomotor symptoms.
Publication: Menopause 2015 03; 22(3): 260-266
Authors: Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM.

Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Publication: Fertility and Sterility 2015 01; 103(1): 163-171
Authors: Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C.

The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.
Authors: Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C.

Using ClinicalTrials.gov to supplement information in ophthalmology conference abstracts about trial outcomes: A comparison study.
Publication: PloS One 2015 10 (6) (no pagination)(e0130619)
Authors: Scherer RW, Huynh L, Ervin AM, Dickersin K.

The Clinical Burden Associated with Zygomycosis-Related Hospitalizations in the U.S.

The Economic Burden Associated with Zygomycosis-Related Hospitalizations in the U.S.
Abstract: IDSA IDWeek Annual Meeting, San Diego, CA.
Cellular rejuvenation and ageing-proteome by Ginsenoside 20(S)-Rg3.

Abstract: 40th FEBS Congress: The Biochemical Basis of Life, Berlin, Germany.
Authors: Kim YR, Baek SJ, Kang YM, Oh KS, Kwon J, Choi JS.

Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.

Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

Out-of-pocket medical costs for parents with children with down syndrome in the united states.

Authors: Kageleiry A, Samuelsdon D, Duh MS, Lefebvre P, DerSarkissian M, Campbell JY, Skotko BG.

Treatment patterns of women diagnosed with uterine fibroids 5 years pre and post diagnosis: A longitudinal retrospective claims analysis of a commercially insured population in the US.

Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.

Publication: Journal of Medical Economics 2015 18(12): 1060-1070
Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.

Publication: Journal of Medical Economics 2015 18(12): 1060-1070
Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Comparison of Annual Treatment Costs for Patients Treated with Infusion /versus Injectable Biologics.

Abstract: AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA.
Authors: Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

Demographic and Clinical Characteristics of Patients with Tuberous Sclerosis Complex in a TSC Patient Database.

Abstract: International TSC Research Conference, Windsor, UK.

Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.

Publication: Current Medical Research and Opinion 2015 01; (0): 1-38
Authors: Fuldeore M, Yang H, Soliman AM, Winkel C.

Monitoring testing patterns among patients with tuberous sclerosis complex-related angiomyolipomas.

Abstract: International TSC Research Conference, Windsor, UK.

Burden of venous leg ulcers in the United States.

Publication: Journal of Medical Economics 2014 05; 17(5): 347-356
Authors: Rice JB, Desai U, Cummings AK, Bimbaum HG, Skornicki M, Parsons N.
Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.
Publication: Pain Medicine 2014 06; 15(6): 1015-1026
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Direct and indirect resource use and costs associated with non-infectious non-anterior uveitis.
Authors: Thorne JE, Tundia N, Skup M, Macaulay D, Revol C, Chao J, Mulani P, Dick AD.

Clinical and economic burden of vasomotor symptoms among untreated menopausal women.
Abstract: ICPE 30th Annual Meeting, Taipei, Taiwan.
Authors: Sarrel P, Lefebvre P, Lafaille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).
Abstract: 30th International Conference on Pharmacoeconomics and Therapeutic Risk Management Conference Taipei Taiwan (Republic of China).
Authors: Sarrel P, Lefebvre P, Lafaille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

A longitudinal retrospective claims analysis of healthcare costs incurred by uterine fibroids patients.
Abstract: 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI.
Authors: Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel C.

Treatment patterns among US women diagnosed with endometriosis: A retrospective claims analyses pre-and post-diagnosis.
Abstract: 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI.
Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Diagnosis and treatment patterns among patients with tuberous sclerosis complex-related angiomyolipomas.

Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis.
Abstract: Endocrine Society’s 96th Annual Meeting and Expo, Chicago, IL.
Authors: Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel CA.

Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.
Abstract: 51st ERA-EDTA Congress, Amsterdam Netherlands.
Authors: Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Risk of leaving the workforce in non-infectious uveitis.
Abstract: Association for Research in Vision and Ophthalmology (ARVO), May 4-8, 2014.
Authors: Tundia N, Skup M, Sorg R, Macaulay D, Chao J, Mulani P, Thorne JE.

Risk of ocular complications in non-infectious uveitis.
Abstract: Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL.
Authors: Skup M, Tundia N, Sorg R, Chao J, Mulani P, Dick A.

Clinical and economic burden of vasomotor symptoms among untreated menopausal women.
Abstract: AMCP 26th Annual Meeting, Tampa, FL.
Authors: Sarrel P, Lefebvre P, Lafaille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.
Medicaid spending on contraceptive coverage and pregnancy-related care.

*Publication:* Reprod Health 2014 03; 11(1): 20
*Authors:* Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P.

Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.

*Authors:* Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L.

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

*Publication:* Journal of Ophthalmic Inflammation and Infection 2013 11; 3(1): 64
*Authors:* Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS.

Systematic literature review of the costs of pregnancy in the US.

*Publication:* Pharmacoeconomics 2013 11; 31(11): 1005-1030
*Authors:* Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS.

Direct and indirect costs for women with vasomotor symptoms (VMS) receiving lower-versus higher-dose paroxetine.

*Abstract:* 24th Annual Meeting of the North American Menopause Society, NAMS 2013, Dallas, TX.
*Authors:* Portman D, Lafeuille MH, Lefebvre P, Gravel J, Duh MS, Aupperle PM, Sarrel P.

Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).

*Abstract:* 24th Annual Meeting of the North American Menopause Society, NAMS 2013, Dallas, TX.
*Authors:* Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

Actuarial analysis of Medicaid spending for contraception and pregnancy care.

*Abstract:* 1st Global Conference on Contraception, Reproductive and Sexual Health 2013, Copenhagen, Denmark.
*Authors:* Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

Medicaid spending for users of contraceptives and pregnancy-related care.

*Abstract:* 1st Global Conference on Contraception, Reproductive and Sexual Health 2013, Copenhagen, Denmark.
*Authors:* Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

Medical, drug, and work-loss costs of venous leg ulcers.

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA.
*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Actuarial analysis of Medicaid spending for contraception and pregnancy care.

*Abstract:* 21st Annual Women’s Health Congress: Women’s Health 2013, Washington, DC.
*Authors:* Laliberte F, Lefebvre P, Law A, Duh MS, Lynen R, Darney P.

Medical resource use and costs associated with chylomicronemia.

*Publication:* Journal of Medical Economics 2013 03; 16(5): 657-666
*Authors:* Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB.

Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.

*Publication:* Pain Medicine 2012 09; 13(9): 1110-1120
*Authors:* Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.
Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Publication: Pain Pract 2012 09; 12(7): 533-540
Authors: Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

Cost burden and treatment patterns associated with management of heavy menstrual bleeding.
Publication: J Womens Health (Larchmt) 2012 05; 21(5): 539-547
Authors: Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, Duh MS.

Economic burden and quality of life of vulvodynia in the United States.
Publication: Current Medical Research and Opinion 2012 04; 28(4): 601-608
Authors: Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C.

Effects of quinestrol and levonorgestrel on populations of plateau pikas, Ochotona curzoniae, in the Qinghai-Tibetan Plateau.

Comparisons of patient characteristics and health care costs by quartile among patients with allergic rhinitis.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.
Authors: Desai U, Ivanova JI, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

Health care costs and utilization for privately insured patients treated for non-infectious uveitis in the United States.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.
Authors: Johnson S, Duh MS, Mallya U, Diener M, Sorg R, Chu D.

Direct and indirect costs associated with Dupuytren’s contracture.
Publication: Journal of Medical Economics 2012 03; 15(4): 664-671
Authors: Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.
Publication: Osteoporosis International 2011 10; 22(10): 2611-2621
Authors: Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US.
Publication: Osteoporosis International 2011 01; 22(1): 47-56
Authors: Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

Analysis of genetic diversity of gemplasm of Pinellia ternata based on SRAP.
Authors: Yang M, Chen K.

Direct and indirect costs associated with dupuytren’s contracture.
Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD.
Authors: Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.
Health care resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer's perspective.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD.
Authors: Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, MS. D.

New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.

Abstract: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011, Baltimore, MD.
Authors: Delea TE, Duh MS, Wei LJ, Robins J.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.

Abstract: 30th Annual Scientific Meeting of the American Pain Society Conference, Austin, TX.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

A qualitative study on feasibility of a web-based Women’s Health Portal and Information System.

Publication: Patient 2011 07; 4(1): 67-68
Authors: Yang M, Kosinski M, Boulanger R.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

Publication: Journal of Medical Economics 2011 04; 14(3): 324-334
Authors: Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Real-world use of duloxetine for chronic low back pain: Treatment pattern and costs.

Abstract: ISPOR 13th Annual European Congress, Prague, Czech Republic.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle R.

Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.

Abstract: 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton United Kingdom.
Authors: Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoe-Streefland M, Jiang W, Zimetbaum PJ.

Real-world use of duloxetine for low back pain and chronic low back pain: Treatment pattern, direct and indirect costs.

Abstract: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2010, Atlanta, GA.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R.

Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.

Publication: Appl Health Econ Health Policy 2010 02; 8(2): 129-140
Authors: Rendas-Baum R, Yang M, Gricar J, Wallenstein GV.

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Publication: Pharmacoeconomics 2010 04; 28(5): 395-409
Authors: Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.

Publication: Journal of Pain 2009 09; 10(9): 976-983
Authors: White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG.
Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.

*Publication:* Current Medical Research and Opinion 2009 10; 25(10): 2487-2494
*Authors:* Yang M, Morin CM, Schaef er K, Wallenstein GV.

The costs of non-vertebral osteoporotic fractures in the United States.

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL.
*Authors:* Birnbaum HG, Pike C, Schiller M, Sharma H, Gu A, Burge RT, Edgell ET.

Real-world use of duloxetine for low back pain.

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL.
*Authors:* Ivanova J, Birnbaum HG, Schiller M, Kantor E, Waldman T, Johnstone BM, Faries D, Risser R, Swindle R.

Burden of premenstrual dysphoric disorder on health-related quality of life.

*Publication:* J Womens Health (Larchmt) 2008 01; 17(1): 113-121

Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.

*Authors:* White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.


*Abstract:* ISPOR 13th Annual International Meeting, Toronto, Canada.
*Authors:* Yu A, Wu EQ, Perrson B, Chang J, Costales C, Gricar J.

WH3 Clinical and economic outcomes among women using levonorgestrel-releasing intrauterine system (LNG-IUS).

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research.

Mapping MOS Sleep Scale scores to SF-6D utility index.

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2269-2282
*Authors:* Yang M, Dubois D, Kosinski M, Sun X, Gajria K.

Hemodynamic changes induced by positive pressure capnothorax during thoracoscopic thymectomy.

*Publication:* Chirurgia 2007 05; 102(3): 263-270
*Authors:* Tomescu D, Grigorescu B, Nitulescu R, Tomulescu V, Popescu I, Tulbure D.

The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.

*Authors:* Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA.

Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.

*Publication:* Current Medical Research and Opinion 2007 12; 23(12): 3215-3222
*Authors:* Meadows ES, Rousculp M, Sasser AC, Birnbaum HG, Moyneur E, Mallet D, Johnston JA.

Annual costs associated with diagnosis of uterine leiomyomata.

*Publication:* Obstetrics and Gynecology 2006 10; 108(4): 930-937
*Authors:* Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P.
Annual Costs Associated with Diagnosis of Uterine Fibroids.

Abstract: The American College of Obstetricians and Gynecologists (ACOG).

Authors: Hartmann KE, Birnbaum H, Wu EQ, Ben-Hamadi R, Spalding J, Stang P.

Lifetime Costs of Patients with Clinically Detected Uterine Fibroids: An Employer’s Perspective.

Publication: Drug Benefit Trends 2006 18(7): 405

Authors: Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective.

Abstract: The American College of Obstetricians and Gynecologists (ACOG).

Authors: Wu EQ, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE.

Assessing the economic impact of chronic conditions in postmenopausal women.


Authors: Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.


Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

POS1 Using a budget impact model to predict first-year use of a new osteoporosis therapy.

Abstract: International Society for Pharmacoeconomics and Outcomes Research.

Authors: Sasser A, Rousculp M, Birnbaum H, Moynier E, Wu E, Marcus R.

Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy.

Abstract: Academy of Managed Care Pharmacy (AMCP).

Authors: Rousculp MD, Sasser AC, Birnbaum HG, Moynier E, Wu EQ, Mallet D, Marcus R.

Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.

Publication: Journal of Rheumatology 2004 08; 31(8): 1621-1629

Authors: Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F.


Publication: Report Commissioned by Californians for Stem Cell Research and Cures 2004

Authors: Baker L, Deal B.

Economic cost and epidemiological characteristics of patients with fibromyalgia claims.

Publication: Journal of Rheumatology 2003 06; 30(6): 1318-1325

Authors: Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ.

The effects of chronic medical conditions on work loss and work cutback.

Publication: Journal of Occupational Environmental Medicine 2001 03; 43(3): 218-225

Authors: Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS.

Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.

Publication: Pharmacoepidemiology and Drug Safety 1999 07; 8(4): 275-283

Authors: Duh MS, Walker AM, Kronlund KH, Jr.

Calculating the workplace cost of chronic disease.

Publication: Business and Health 1995 09; 13(9): 27-28, 30

Authors: Greenberg PE, Finkelstein SN, Berndt ER.
**An alternative in terminal care: results of the National Hospice Study.**
*Publication:* Journal of Chronic Diseases 1986 01; 39(1): 9-26  
*Authors:* Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, H. B.

**An Alternative in Terminal Care: Results of the National Advice on Hospice Care for Benefits Design.**
*Publication:* Business and Health 1985  
*Authors:* Birnbaum H.

**Other (Health Policy, Market Access, and other topics)**

**Consider Value Vs. Budget Impact In Mass. Drug Prices.**
*Publication:* Law360 2017 09;  
*Authors:* Kirson N.

**Insurer And Provider Market Share.**
*Publication:* Health Affairs 2017 05; 36(5): 961  
*Authors:* Dyckman Z.

**Tracing the Path to Health Care Investigation Settlements.**
*Publication:* Law360 2017 04;  
*Authors:* Weinstein KA, Pike CT, Greenberg PE.

**Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?**
*Publication:* Cns Drugs 2017 08; 1-12  
*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**Health services utilization among fee-for-service Medicare and medicaid patients under age 65 with behavioral health illness at an urban safety net hospital.**
*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 07; 23(7): 781-788  
*Authors:* Cancino RS, Jack BW, Jarvis J, Cummings AK, Cooper E, Cremieux PY, Burgess JF.

**Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.**
*Publication:* Journal of Managed Care & Specialty Pharmacy 2017 10; 23(10)  

**Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-Generation Long-Acting Injectable Agents Versus Oral Atypical Antipsychotics.**
*Publication:* Clinical Therapeutics. 2017 09;  
*Authors:* Pilon D, Tandon N, Laveille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.

**Following Recent Trends in Affordable Care Act Insurance.**
*Publication:* Law360 2016 09;  
*Authors:* Chawla A, Cook K.

**Practical Uses For Machine Learning In Health Care Cases.**
*Publication:* Law360 2016 09;  
*Authors:* Yenikomshian M, Pinheiro LB, Royer J, Greenberg PE.
Updated trends in US brand-name and generic drug competition.  
Publication: Journal of Medical Economics 2016 04; 19(9): 836-844  
Authors: Grabowski H, Long G, Mortimer R, Boyo A.

Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing.  
Publication: BMJ Glob Health 2016 11; 1(3): e000134  

The Myth Of ’Price Disconnects’ In US Pharma Markets  
Publication: Law360 2016 05;  
Authors: Fink S, Lewis M.

Correlation Or Cause: Brand-Name Drug Prescription Rates  
Publication: Law360 2016 03;  
Authors: Greenbert P, Sisitsky T, R M.

Care pathways in US healthcare settings: current successes and limitations, and future challenges.  
Publication: American Journal of Managed Care 2016 01; 22(1): 53-62  
Authors: Chawla A, Westrich K, Matter S, Kaltenboeck A, Dubois R.

Reliable Analysis Is Key To Addressing Ascertainability.  
Publication: Law360 2016 12;  
Authors: Cacciola S, Fink S.

Can social media data lead to earlier detection of drug-related adverse events?  
Publication: Pharmacoepidemiology and Drug Safety 2016 12; 25(12): 1425-1433  
Authors: Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P.

Can The Life Sciences Industry Bank On Biosimilars?  
Publication: Law360 2016 04;  
Authors: Greenberg P, Sisitsky T, Mortimer R.

Retention of clinically stable art patients in a rapid model of care in Haiti.  
Authors: Moise CG, Bellot C, Hennessey KA, Rivera VR, Severe P, Aubin D, Homeus F, Saint-Vil A, Koenig SP, Pape JW.

Publication: Law360 2016 06;  
Authors: Pinheiro L, Royer J, Dadson N, Greenberg P.

Viewing Recent Opioid Regulations In Context.  
Publication: Law360 2016 04;  
Authors: Pike C, Weinstein K, Darling P, Greenberg P.

Publication: AHLA Connections 2015 09;  
Authors: Chipty T, Sendonaris A.
Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
*Publication:* Advances in Therapy 2015 03; 32(3): 270-283
*Authors:* Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P.

*Publication:* Pharmacoeconomics 2015 07; 33(7): 749-763
*Authors:* Chawla A, Carls G, Deng E, Tuttle E.

The roles of patents and research and development incentives in biopharmaceutical innovation.
*Publication:* Health Affairs 2015 02; 34(2): 302-310
*Authors:* Grabowski HG, DiMasi JA, Long G.

The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
*Publication:* Expert Opinion on Therapeutic Patents 2015 07; 25(7): 739-742
*Authors:* Cockburn I, Long G.

Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in the U.S. and EU-5: Payer and manufacturer experience and outlook.
*Abstract:* AMCP Nexus 2015, Orlando, FL.
*Authors:* Ko J, Nazareth T, Carpenter S, Demean S, Wu E, Sasane R, Navarro R.

*Publication:* Pharmacoeconomics 2015 07; 33(7): 629-641
*Authors:* Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: Payer and manufacturer experience and outlook.
*Abstract:* ISPOR 20th Annual International Meeting Research Conference, Philadelphia, PA.
*Authors:* Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, Sasane R, Navarro R.

Statistical identification of potential selection bias in retrospective chart reviews.
*Abstract:* ISPOR 20th Annual International Meeting Research Conference, Philadelphia, PA.
*Authors:* Signorovitch JE, Reichmann WM, Li N, Liu Z, Hao Y, Perez JR.

Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.
*Abstract:* AMCP 27th Annual Conference, San Diego, CA.
*Authors:* Macaulay D, Wei J, Terasawa E.

Comparison of Annual Treatment Costs for Patients Treated with Infusion /versus Injectable Biologics.
*Abstract:* AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA.
*Authors:* Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

Advanced Diagnostics: Innovation, Reimbursement, and Coverage Challenges.
*Publication:* In Vivo 2014 10;
*Authors:* Gorin B, Tuttle E.

Random Selection Is Best For MDL Bellwether Trials.
*Publication:* Law360 2014 10;
*Authors:* Brown L, Holian M, Rothman D.
Cost-effectiveness of health research study participant recruitment strategies: a systematic review.
*Authors:* Huynh L, Johns B, Liu SH, Vedula SS, Li T, Puhan MA.

Recent trends in brand-name and generic drug competition.
*Publication:* Journal of Medical Economics 2014 03; 17(3): 207-214
*Authors:* Grabowski H, Long G, Mortimer R.

The role of health economics and outcomes research in health care reform in China.
*Publication:* Pharmacoeconomics 2014 03; 32(3): 231-234
*Authors:* Liang W, Xie J, Fu H, Wu EQ.

What Attorneys Should Know about FDA’s MedWatch Data.
*Publication:* Law360 2014 01;
*Authors:* Duh MS CP, Greenberg P, Ellman B.

Cost of illness: an ongoing battle worth fighting.
*Publication:* Pharmacoeconomics 2014 12; 32(12): 1151-1152
*Authors:* Greenberg PE.

Evolving provider payment models and patient access to innovative medical technology.
*Publication:* Journal of Medical Economics 2014 12; 17(12): 883-893
*Authors:* Long G, Mortimer R, Sanzenbacher G.

Big Data Can Yield Big Insights on Promotional Practices.
*Publication:* Law360 2014 08;
*Authors:* Greenberg P, Sisitsky T.

The randomized blind start trial: Evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations.
*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands.
*Authors:* Signorovitch J, Ayyagari R, Kakkis E.

Evaluation of the value of webdata for detecting drug adverse events.
*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei Taiwan (Republic of China).

Identifying high-value treatment populations in clinical trials and real-world data.
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada.
*Authors:* Signorovitch J, Shaw J, Betts K, Wu EQ.

Outcomes-based contracting for pharmaceutical products in the United States: payer and manufacturer experience and outlook.
*Abstract:* AMCP’s 27th Annual Meeting & Expo, AMCP’s 27th Annual Meeting & Expo.
*Authors:* Frois C, Carpenter S, Demean S, Wu E, Navarro R.

Biosimilars
*Publication:* Encyclopedia of Health Economics 2014
*Authors:* Grabowski H, Long G, Mortimer R.
The impact of Brazil’s Bolsa Familia conditional cash transfer program on children’s health care utilization and health outcomes.

*Publication:* BMC International Health and Human Rights 2014 04; 14: 10  
*Authors:* Shei A, Costa F, Reis MG, Ko Al.

Effects of care management and telehealth: a longitudinal analysis using Medicare data.

*Publication:* Journal of the American Geriatrics Society 2013 09; 61(9): 1560-1567  
*Authors:* Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG.

On-Market Pricing Strategies.

*Publication:* Pharmaceutical Executive 2013 06;  
*Authors:* Works J, Parece A.

Brazil’s conditional cash transfer program associated with declines in infant mortality rates.

*Publication:* Health Affairs 2013 07; 32(7): 1274-1281  
*Authors:* Shei A.


*Publication:* 2013 01;  
*Authors:* Long G, Works J.

Cost utility of hub-and-spoke telestroke networks from societal perspective.

*Publication:* American Journal of Managed Care 2013 12; 19(12): 976-985  
*Authors:* Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, Wu EQ.


*Publication:* Today’s General Council 2013 08; 10(4)  
*Authors:* John L, Leckerman J, Greenberg P.

Estimating chronic disease prevalence from claims data: Reducing bias by accounting for diseased individuals who do not generate claims.

*Abstract:* ISPOR 16th Annual European Congress, Dublin Ireland.  
*Authors:* Signorovitch J, De G, Drabo E, Guerin A.

Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio.

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA.  
*Authors:* Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ.

Investigator-initiated approach to address an optimization problem in designing cost-efficient studies.

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA.  
*Authors:* Huynh L, Clark M, Frick KD.


*Abstract:* International Society for Pharmacoeconomics and Outcomes Research.  
*Authors:* Signorovitch J, Ayyagari R, Cheng D, Wu E.

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication.

*Publication:* JHEOR 2013: 54-61  
*Authors:* Frois CC, O’Connell Ti, Pesa J, Fasteneau J, Doshi P.
Recent Average Price Trends for Implantable Medical Devices, 2007-2011.
Publication: White Paper 2013 09;  
Authors: Long G, Mortimer R, Sanzenbalcher G.

Prioritizing Safety versus Budget: FDA and CMS Adopt Different Stances.
Publication: FDLI Update 2012 05;  
Authors: Sisitsky T, Greenberg P.

Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment.
Publication: Food and Drug Law Institute Update 2012 03: 19-21  
Authors: Long G, Mulhern C.

How to use Clinical-Trial Data in Court.
Publication: Law360 2012 07;  
Authors: Cremieux PY, Ghosh, A, Pinheiro L.

Duloxetine use in chronic low back pain: treatment patterns and costs.
Publication: Pharmacoeconomics 2012 07; 30(7): 595-609 
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Confounding factors in off-label drug use.
Publication: Health Affairs 2012 02; 31(2): 460; author reply 460  
Authors: Greenberg PE, Pike C, Sisitsky T.

Review of national institute for health and clinical excellence (NICE) recommendations for anti-cancer agents across multiple drug-indication combinations.

Publication: Value in Health 2012 05; 15(6): 940-947  
Authors: Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ.

Impact of Medicare part D coverage gap on beneficiaries’ adherence to prescription medications.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.  
Authors: Desai U, Carroll NV.

Modeling the progression of chronic diseases in a dynamic market: Implications for budget impact analysis.
Abstract: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2012, Washington, DC.  
Authors: Eldar-Lissai A, Banerjee R, McBride S, Leaf-Herrmann W.

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Publication: Journal of Medical Economics 2012 06; 15(6): 1078-1087  
Authors: Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings.
Publication: Health Affairs 2011 09; 30(9): 1689-1697  
Authors: Baker LC, Johnson SJ, Macaulay D, Birnbaum H.
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
Publication: Health Affairs 2011 11; 30(11): 2157-2166
Authors: Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.

Interprofessional education about decision support for patients across cultures.
Publication: J Interprof Care 2011 11; 25(6): 431-433
Authors: Hagoel L, Volz S, Palileo LM, Eldar-Lissai A, Kamath CC, Cox ED.

Publication: CPI Antitrust Chronicle 2011 05;
Authors: Chipty T.

President Reignites Biologics Exclusivity Battle with Proposal for Seven Years.
Publication: Specialty Pharmacy News 2011 03;
Authors: Long G.

Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.
Publication: Journal of Clinical Psychiatry 2011 06; 72(6): 787-794

Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.
Publication: Spine J 2011 07; 11(7): 622-632
Authors: Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW.

Data exclusivity for biologics.
Authors: Grabowski H, Long G, Mortimer R.

Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market.
Publication: Specialty Pharmacy News 2011 02; 8(2)
Authors: Long G.

Budget Proposals on Biosimilars, "Pay for Delay" Spark Controversy.
Publication: AIS’s Health Reform Week 2011 02; 2(6)
Authors: Long G.

The role of public-sector research in the discovery of drugs and vaccines.
Authors: Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML.

Publication: Journal of Health Politics, Policy and Law 2011 04; 36(2): 295-316
Authors: Danzon PM, Johnson SJ, Long G, Furukawa MF.

Comparative effectiveness research using matching-adjusted indirect comparison – A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data.
Abstract: 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Rockville, MD.
Authors: Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, Erder MH.

Utilizing rich data sources to identify patients’ subgroups that can benefit most from a treatment.
Abstract: The 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Rockville, MD.
Authors: Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, Erder MH.
Improved indirect treatment comparisons for comparative effectiveness research.

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD.
Authors: Signorovitch J, Navarro R, Betts K, Wu EQ.

An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are Low.

Publication: FDLI Update 2011 01; Jan/Feb
Authors: Wei E, Claggett B, Greenberg P, Wei LJ.

Implementation of the biosimilar pathway: economic and policy issues.

Publication: Seton Hall Law Rev 2011 07; 41(2): 511-557
Authors: Grabowski H, Long G, Mortimer R.

Introducing perspectives on comparative effectiveness research.

Publication: Pharmacoeconomics 2010 09; 28(10): 787-788
Authors: Birnbaum HG, Greenberg PE.

CER The Fruits of Comparative Effectiveness Sometimes it’s necessary to compare apples to oranges, as well as to other apples. New tools and a commitment to managing the impact of comparative effectiveness research grants payers the evidence they need to control drug costs.

Publication: Pharmaceutical Executive 2010 11: 78
Authors: Tuttle E, Chawla A, Nellesen D, Works J.

Methodological issues in a meta-analysis.

Publication: Hepatology 2010 07; 52(1): 395-396; author reply 396-397
Authors: Cremieux P.

Selecting the optimal target population for formulary coverage.

Authors: Wu EQ, Yu D, Xie J, Gu.

Comparative Effectiveness Research for Personalized Medicine.

Abstract: ISPOR 15th Annual International Meeting, Atlanta, GA.
Authors: Signorovitch J, Wu EQ, We LJ.

Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy.

Abstract: BIO International Convention, Chicago, IL.
Authors: Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T.

The role of compliance in telehealth adoption.

Authors: Newell D, Johnson S, Rutherford P, Welte I.

ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership-Measurement Model of Disease Management.

Publication: Healthc Q 2010 01; 13(4): 30-39
Authors: Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T.

Perspectives on comparative effectiveness research: views from diverse constituencies.

Publication: Pharmacoeconomics 2010 09; 28(10): 789-798
Authors: Nellesen D, Birnbaum HG, Greenberg PE.
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.

*Publication:* Current Medical Research and Opinion 2009 07; 25(7): 1793-1805

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

Economic Analysis in Off-Label Promotion Cases.

*Publication:* Law360 2009 02;

*Authors:* Greenberg P, Sisitsky T.

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.

*Publication:* Biostatistics 2009 04; 10(2): 275-281

*Authors:* Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.

*Abstract:* ISPOR 12th Annual European Congress, Paris France.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

The impact of drug vintage on patient survival: a patient-level analysis using Quebec’s provincial health plan data.


*Authors:* Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P.

Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data.

*Abstract:* ISPOR 14th Annual International Conference, Orlando, FL.

*Authors:* Wu EQ, Signorovitch J, Yu A.

Economic impact of generic entry of topiramate in the G4 European countries.

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL.

*Authors:* Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.

*Abstract:* ISPOR 14th Annual International Meeting Conference, Orlando, FL.

*Authors:* Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

Personalized Medicine: Trends in Clinical Studies Based on National Registry Data.

*Abstract:* ISPOR 14th Annual International Meeting Conference, Orlando, FL.

*Authors:* Nellesen D, Person A, Yee K, Chawla A.

Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees.

*Publication:* Health Economics 2009 05; 18(3): 275-290

*Authors:* Rice JB, Kasper JD, Pezzin LE.
The Growing Role of Economic Analysis in Off-Label Promotion Cases
Publication: Rx Compliance Report 2009 11; VIII(8): 7-8
Authors: Greenberg P, Sisitsky T.

Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
Publication: Pharmacoeconomics 2009 27(8): 623-625
Authors: Kalb PE, Greenberg PE.

Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.
Publication: Bariatric Times 2008 11;
Authors: Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.

Does generic substitution always make sense?
Publication: Journal of Medical Economics 2008 11(3): 547-553
Authors: Greenberg PE.

Publication: FDLI Update 2008 05; (3)
Authors: Duh MS, Greenberg P, Antras L.

The Role of Epidemiology in Drug Safety Litigations.
Authors: Duh MS, Greenberg PE, Weiner JR.

Authorized generic drugs, price competition, and consumers' welfare.
Publication: Health Affairs 2007 05; 26(3): 790-799
Authors: Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E.

The value of antihypertensive drugs: a perspective on medical innovation.
Publication: Health Affairs 2007 01; 26(1): 97-110

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Publication: Disease Management 2007 08; 10(4): 216-225
Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

Abstract: Congressional Budget Office, Washington DC.
Authors: Wu EQ, Greenberg P, Erder MH.

Competition between Generic and Branded Drugs.
Authors: Grabowski H.

Do drugs reduce utilization of other healthcare resources?
Publication: Pharmacoeconomics 2007 03; 25(3): 209-221
Authors: Cremieux PY, Ouellette P, Petit P.
The Drug Delivery Dilemma
Publication: SCRIP Supplement, Informa Health Care 2007
Authors: Gorin B, Tuttle E.

The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions.
Publication: White Paper 2007 08;
Authors: Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S.

Pharmaceutical spending and health outcomes.
Authors: Cremieux P-Y, Jarvinen D, Long G, Merrigan P.

Retrospective economic and outcomes analyses using non-US databases: a review.
Authors: Shi L, Wu EQ, Hodges M, Yu A, Birnbaum H.

The market for follow-on biologics: how will it evolve?
Publication: Health Affairs 2006 09; 25(5): 1291-1301
Authors: Grabowski H, Cockburn I, Long G.

A Roundtable Discussion: The Importance of Causation Analysis in Mass Tort Cases.
Publication: Food and Drug Law Institute Update 2006 11;
Authors: Greenberg PE, Lykos G, Gourley S, Davies C.

Generic competition in the US pharmaceutical industry.
Authors: Saha A, Grabowski H, Birnbaum H, Greenberg P, Bizan O.

Retirement patterns from career employment.
Publication: Gerontologist 2006 08; 46(4): 514-523
Authors: Cahill KE, Giandrea MD, Quinn JF.

A Regulatory Perspective on Productivity Claims: Implications for Future Productivity Research.
Publication: Health and Work Productivity: Emerging Issues in Research and Policy. 2006 04; (Spring)
Authors: Greenberg PE, Birnbaum HG.

Publication: Analysis Group Forum 2006 11;
Authors: Greenberg P, Sisitsky T.

Hospital cost flexibility in the presence of many outputs: a public-private comparison.
Publication: Health Care Manag Sci 2005 05; 8(2): 111-120
Authors: Cremieux PY, Ouellette P, Rimbaud F, Vigeant S.

Public and private pharmaceutical spending as determinants of health outcomes in Canada.
Publication: Health Economics 2005 02; 14(2); 107-116
Authors: Cremieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K.

Systematic Differences in Subjective vs. Societal Preferences.
Abstract: International Society for Quality of Life Research (ISOQOL).
Authors: Sullivan PW, Ghushchyan V, Wu EQ.
Treatment and Comorbidities in an Employed Population.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Parece A, Kang Y, Mareva MN, Taitel H.

Your patent is about to expire: what now.
Authors: Parece A, Tuttle E, Hector A.

Publication: Update (National Minority AIDS Council) 2004 03;
Authors: Cremieux P, Greenberg PE.

Administrative Claims Data: A Valuable Tool in Pharmaceutical Litigation.
Publication: FDLI Update 2004 01;
Authors: Birnbaum HG, Greenberg PE.

Money can’t buy happiness.
Publication: Business & Health 2004 04; 2004
Authors: Greenberg PE BH, Kessler RC.

Publication: Report Commissioned by Californians for Stem Cell Research and Cures 2004
Authors: Baker L, Deal B.

Measuring hospital performance in the presence of quasi-fixed inputs: an analysis of Québec hospitals.
Publication: Journal of Productivity Analysis 2004 21(2): 183-199
Authors: Bilodeau D, Crémieux P-Y, Jaumard B, Ouellette P, Vovor T.

The relationship between technology availability and health care spending.
Publication: Health Affairs 2003 07; Suppl Web Exclusives: W3-537-551
Authors: Baker L, Birnbaum H, Geppert J, Mishol D, Moyneur E.

PMD3: Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ate).
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Johnson K, Nichol M.

PMD4: Performance of two conditional expectation methods under unobserved selection bias.
Abstract: International Society for Pharmacoeconomics and Outcomes Research.
Authors: Wu E, Nichol M, Johnson K.

Provision of pharmacy services in community health centers and migrant health centers.
Authors: Barner JC, Brown CM, Shepherd MD, Chou JY, Yang M.

Switching costs, price sensitivity and health plan choice.
Publication: Journal of Health Economics 2002 01; 21(1): 89-116
Authors: Strombom BA, Buchmueller TC, Feldstein PJ.

Hospital technology in a nonmarket health care system.
Publication: Southern Economic Journal 2002: 511-529
Authors: Bilodeau D, Cremieux P-Y, Ouellette P.
**Actual and perceived impacts of tobacco regulation on restaurants and firms.**
*Publication:* Tobacco Control 2001 03; 10(1): 33-37  
*Authors:* Cremieux PY, Ouellette P.

**Omitted variable bias and hospital costs.**
*Authors:* Cremieux PY, Ouellette P.

**Impact of illness and its treatment on workplace costs: regulatory and measurement issues.**
*Authors:* Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P.

**Évaluation de l’efficience budgétaire des CLSC au Québec à partir de la méthode DEA.**
*Publication:* L’Actualité économique 2001 77(3): 409-424  
*Authors:* Crémieux P-Y, Gadbois D, Jaumard B, Ouellette P, Vovor T.

**Modeling for health care and other policy decisions: uses, roles, and validity.**
*Abstract:* International Society for Pharmacoeconomics and Outcomes Research.  
*Authors:* Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammit JK.

**Pharmaceutical spending and health outcomes in the United States.**
*Publication:* RESEARCH IN HUMAN CAPITAL AND DEVELOPMENT 2001: 59-76  
*Authors:* Cremieux P-Y, Ouellette P, Meilleur M-C, Leong S, Greenberg P, Birnbaum H.

**Comparative Econometric Models of Medical Costs.**
*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).  
*Authors:* Wu EQ, Hay JW.

**Diagnosing the illness.**
*Authors:* Cremieux P-Y, Ouellette P.

**Hospital cost function in a non-market health care system.**
*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

**Health care spending as determinants of health outcomes.**
*Publication:* Health Economics 1999 11; 8(7): 627-639  
*Authors:* Cremieux PY, Ouellette P, Pilon C.

**Pharmacoeconomics and health policy. Current applications and prospects for the future.**
*Publication:* Pharmacoeconomics 1999 11; 16(5 Pt 1): 425-432  
*Authors:* Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, LeLorier J, Ouellette P, Slavin MB.

**Tackling costs one disease at a time.**
*Publication:* Business and Health 1999 05; 17(5): 31-32, 37  
*Authors:* Greenberg P.

**Using healthcare claims data for outcomes research and pharmacoeconomic analyses.**
*Publication:* Pharmacoeconomics 1999 07; 16(1): 1-8  
*Authors:* Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L.
The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data.
Publication: Medical Care 1998 05; 36(5): 757-765
Authors: Birnbaum HG, Tang M.

Calculating Return on Investment from Reducing Workplace Costs of Illness.
Publication: Drug Benefit Trends 1998 03;
Authors: Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J.

Epidemiologic interpretation of artificial neural networks.
Publication: American Journal of Epidemiology 1998 06; 147(12): 1112-1122
Authors: Duh MS, Walker AM, Ayanian JZ.

Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example.
Publication: American Journal of Epidemiology 1998 02; 147(4): 407-413
Authors: Duh M, Walker A, Pagano M, Kronlund K.

Interpretation of the Weight Matrix in an Artificial Neural Network
Authors: Duh MS, Walker Am, Ayanian JZ.

Prediction and cross-validation in modeling incident cases of hepatic disorders using automated medical data.
Authors: Duh M, Walker A, Pagano M, Kronlund K.

Une analyse de la performance des CLSC au Québec.
Authors: Crémieux PY, Gadbois D, Ouellette P.

The Next Phase of Managed Care: Targeting Investments in Employee Health.
Publication: On Managed Care 1997 09;
Authors: Greenberg PE, Berndt E, Finkelstein S.

Une analyse du contexte budgétaire de l'activité médicale au Québec (An analysis of the budgetary context of medical activity in Quebec).
Publication: Le Medicin du Quebec 1997 08;
Authors: Cremieux PY, Ouellette, P.

Etude d’impact du projet de loi sur le tabac (IMpact report on the proposed tobacco law).
Publication: Ministry of Health and Social Services 1997
Authors: Cremieux PY, Fortin P, Lavoie F, Ouellette P, St Pierre Y.

Hospital Consolidation: Optimal Strategy for a Two-Hospital Town.
Publication: Ambulatory Health Care 1996
Authors: Deal B, Tiscornia JF.

Price Growth of prescription pharmaceutical preparations: an update and extension.
Publication: Competitive Strategies in the Pharmaceutical Industry 1996
Authors: Berndt E, Greenberg P.

Economic consequences of illness in the workplace.
Authors: Greenberg PE, Finkelstein SN, Berndt ER.
Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an Industry.
Publication: The National Law Journal 1995 09;
Authors: Danzon P, Stamm L, Greenberg P.

Consolidation and restructuring: the next step in managed care.
Publication: Health Care Management 1995 10; 2(1): 221-235
Authors: Danzon PM, Boothman LG, Greenberg PE.

The Health Care System in Canada.
Publication: Financing Health Care 1994
Authors: Mulhern C, Rozek R.

Navigating the Changing Tides of Managed Care and Health Reform.
Publication: American Medical Association Monograph 1994
Authors: Sherwin R.

When can a Medicare Insured Group (MIG) Succeed?
Publication: Inquiry 1994
Authors: Birnbaum HG CN, Lang K.

Savings estimate for a Medicare insured group.
Authors: Birnbaum H, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP.

Impacts of the New York long-term home health care program.
Publication: Medical Care 1986 24(7)
Authors: Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellingon-Otto K.

What does hospice cost?
Publication: American Journal of Public Health 1984 07; 74(7): 689-697
Authors: Birnbaum HG, Kidder D.

Publication: Gerontologist 1984 08; 24(4): 380-386
Authors: Birnbaum H, Burke R, Swearingen C, Dunlop B.

Implementing community based long-term care: Experience of the long-term home health care program.
Publication: The Gerontologist 1984 24(4)
Authors: Birnbaum HG, Burke R, Swearingen C, Dunlop B.

Managing programs for the elderly: design of a social information systems.
Publication: Health Care Financing Review 1983 02; 5(2): 11-23
Authors: Birnbaum H, Burke R, Pratter F.

The determinants of nursing home operating costs in New York State.
Publication: Health Services Research 1983 08; 18(2 Pt 2): 285-308
Authors: Lee AJ, Birnbaum H.

Medicare legislation for hospice care: implications of national hospice study data.
Publication: Health Affairs 1983 08; 2(2): 80-90
Authors: Mor V, Birnbaum H.
Home care in hospices.
Publication: Caring 1983 06; 2(6): 40-44
Authors: Birnbaum H, Mor V, Greer DS.

How does the nursing home sector behave: A multi-equation model of nursing home behavior.
Publication: Social Science and Medicine 1983 17(23): 1897-1906
Authors: Birnbaum HG, Lee AJ, Bishop C.

How nursing homes behave: a multi-equation model of nursing home behavior.
Publication: Social Science and Medicine 1983 17(23): 1897-1906
Authors: Lee AJ, Birnbaum H, Bishop C.

National hospice study analysis plan.
Publication: Journal of Chronic Diseases 1983 01; 36(11): 737-780
Authors: Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum H.

Why do nursing home costs vary? The determinants of nursing home costs.
Publication: Medical Care 1981 11; 19(11): 1095-1107
Authors: Birnbaum H, Bishop C, Lee AJ, Jensen G.
About Analysis Group’s HEOR Practice

Founded in 1981, Analysis Group is one of the largest private economics consulting firms, with more than 800 professionals across 13 offices. Analysis Group’s health care experts apply analytical expertise to health economics and outcomes research, clinical research, market access and commercial strategy, and health care policy engagements, as well as drug-safety related engagements in epidemiology. Analysis Group’s internal experts, together with its network of affiliated experts from academia, industry, and government, provide our clients with exceptional depth of expertise and end-to-end consulting services globally.

www.analysisgroup.com